[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 840
1. Ishihara H, Takoh M, Nishibayashi R, Sato A: Distribution and variation of bacitracin synthetase gene sequences in laboratory stock strains of Bacillus licheniformis. Curr Microbiol; 2002 Jul;45(1):18-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Distribution and variation of bacitracin synthetase gene (bac) sequences in 22 laboratory stock strains of Bacillus licheniformis were studied by Southern hybridization of bac gene probes from B. licheniformis ATCC 10716 to genomic PstI or HindIII restriction fragments.
  • None of the remaining 11 strains, including ATCC 14580 (type strain), gave any hybridization signals.
  • All strains carrying bac gene sequences were erythromycin resistant.
  • With one exception, all strains without bac gene sequences were erythromycin sensitive.
  • These results show that B. licheniformis strains are divided into two groups with respect to presence of bac gene sequences and erythromycin resistance.
  • [MeSH-major] Bacillus / classification. Bacillus / enzymology. Multienzyme Complexes / genetics. Peptide Synthases / genetics
  • [MeSH-minor] Anti-Bacterial Agents / metabolism. Bacitracin / isolation & purification. Blotting, Southern. Culture Media. DNA, Bacterial / analysis. Drug Resistance. Erythromycin / metabolism. Genes, Bacterial. Genetic Variation. Nucleic Acid Hybridization. Sequence Analysis, DNA / methods

  • Hazardous Substances Data Bank. Erythromycin .
  • Hazardous Substances Data Bank. BACITRACIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12029522.001).
  • [ISSN] 0343-8651
  • [Journal-full-title] Current microbiology
  • [ISO-abbreviation] Curr. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Culture Media; 0 / DNA, Bacterial; 0 / Multienzyme Complexes; 1405-87-4 / Bacitracin; 63937KV33D / Erythromycin; EC 6.3.2.- / Peptide Synthases; EC 6.3.2.- / bacitracin synthetase
  •  go-up   go-down


2. Roldán S, Herrera D, Sanz M: Biofilms and the tongue: therapeutical approaches for the control of halitosis. Clin Oral Investig; 2003 Dec;7(4):189-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, knowledge in regards to its role and implications in oral health and disease is scarce.
  • Moreover, although the dorsum of the tongue seems to harbour one of the most complex microbiological niches in human ecology, the knowledge of the role of tongue flora in health and disease is also very limited.
  • The structure of the tongue favours a unique and complex bacterial biofilm, in which periodontal pathogens are frequently found.
  • However, little is known about how to control this bacterial niche, and factors affecting tongue coating composition and aspect are not fully understood.
  • Different antimicrobials agents have been evaluated: chlorhexidine, chlorine dioxide, metal ions, triclosan, formulations containing essential oils, and hydrogen peroxide.
  • [MeSH-major] Biofilms / drug effects. Halitosis / drug therapy. Halitosis / microbiology. Tongue / microbiology
  • [MeSH-minor] Anti-Infective Agents, Local / pharmacology. Anti-Infective Agents, Local / therapeutic use. Chlorhexidine / pharmacology. Chlorhexidine / therapeutic use. Ecosystem. Humans. Mouthwashes / pharmacology. Oils, Volatile / pharmacology. Oils, Volatile / therapeutic use. Triclosan / pharmacology. Triclosan / therapeutic use

  • MedlinePlus Health Information. consumer health - Bad Breath.
  • Hazardous Substances Data Bank. TRICLOSAN .
  • Hazardous Substances Data Bank. CHLORHEXIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Periodontol. 2001 Jul;28(7):634-41 [11422584.001]
  • [Cites] J Periodontol. 1996 May;67(5):478-85 [8724705.001]
  • [Cites] J Periodontol. 1994 Jan;65(1):37-46 [8133414.001]
  • [Cites] Gerodontics. 1987 Aug;3(4):169-70 [3481604.001]
  • [Cites] Oral Microbiol Immunol. 1989 Jun;4(2):71-6 [2762017.001]
  • [Cites] J Can Dent Assoc. 2000 May;66(5):257-61 [10833869.001]
  • [Cites] Acta Odontol Scand. 1997 Aug;55(4):261-4 [9298169.001]
  • [Cites] J Clin Dent. 1999;10(4):131-4 [10825862.001]
  • [Cites] J Periodontal Res. 1986 Jul;21(4):434-9 [2942671.001]
  • [Cites] J Clin Periodontol. 1999 Dec;26(12):822-32 [10599911.001]
  • [Cites] J Periodontal Res. 1992 Jul;27(4 Pt 1):233-8 [1640345.001]
  • [Cites] J Clin Periodontol. 1998 Mar;25(3):215-24 [9543192.001]
  • [Cites] J Dent Res. 1992 Jul;71(7):1431-8 [1629460.001]
  • [Cites] J Am Dent Assoc. 1995 Oct;126(10):1384-93 [7594010.001]
  • [Cites] J Clin Dent. 1999;10(4):135-8 [10825863.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1976 Aug;42(2):172-81 [1066599.001]
  • [Cites] J Periodontol. 2002 Jul;73(7):797-812 [12146540.001]
  • [Cites] J Periodontol. 1991 Mar;62(3):203-6 [2027072.001]
  • [Cites] Compend Contin Educ Dent. 2000 Mar;21(3):241-4, 246, 248 passim; quiz 256 [11199703.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1978 Jun;45(6):876-83 [277852.001]
  • [Cites] Periodontol 2000. 2002;28:256-79 [12013345.001]
  • [Cites] J Clin Periodontol. 2003 May;30(5):427-34 [12716335.001]
  • [Cites] J Dent Res. 2000 Oct;79(10):1773-7 [11077993.001]
  • [Cites] J Clin Periodontol. 1995 Nov;22(11):854-9 [8550862.001]
  • [Cites] J Clin Periodontol. 2001 Oct;28(10):970-8 [11686816.001]
  • [Cites] J Am Dent Assoc. 2001 Sep;132(9):1263-7; quiz 1318 [11665351.001]
  • [Cites] J Clin Dent. 1998;9(2):39-42 [10518851.001]
  • [Cites] J Periodontol. 1995 Aug;66(8):679-84 [7473010.001]
  • [Cites] J Periodontol. 2001 Sep;72(9):1183-91 [11577950.001]
  • [Cites] J Clin Dent. 1998;9(3):76-82 [10518867.001]
  • [Cites] J Periodontol. 1992 Sep;63(9):783-9 [1474480.001]
  • [Cites] Am J Dent. 2000 Sep;13(Spec No):18C-22C [11763909.001]
  • [Cites] J Prosthet Dent. 1980 Mar;43(3):247-50 [6928191.001]
  • [Cites] J Clin Periodontol. 2003 Apr;30(4):300-6 [12694427.001]
  • [Cites] Bull Tokyo Dent Coll. 1978 Feb;19(1):43-52 [292525.001]
  • [Cites] J Clin Dent. 1998;9(4):83-8 [10518855.001]
  • [Cites] Chin Med J (Engl). 1987 Jan;100(1):38-44 [3109823.001]
  • [Cites] J Clin Periodontol. 2001 Aug;28(8):776-81 [11442738.001]
  • [Cites] Acta Odontol Scand. 1984 Jun;42(3):157-63 [6591677.001]
  • [Cites] J Dent Res. 1983 Jun;62(6):738-42 [6574156.001]
  • [Cites] J Dent Res. 1981 Nov;60(11):1891-6 [6945328.001]
  • [Cites] J Periodontol. 1992 Jan;63(1):39-43 [1552460.001]
  • [Cites] J Dent Res. 1997 Nov;76(11):1770-5 [9372794.001]
  • [Cites] J Periodontol. 1998 Mar;69(3):374-82 [9579625.001]
  • [Cites] J Periodontol. 1996 Jun;67(6):577-82 [8794967.001]
  • [Cites] J Clin Periodontol. 2001 Jun;28(6):499-507 [11350516.001]
  • [Cites] J Clin Periodontol. 1994 Aug;21(7):484-9 [7929861.001]
  • (PMID = 14513303.001).
  • [ISSN] 1432-6981
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Mouthwashes; 0 / Oils, Volatile; 4NM5039Y5X / Triclosan; R4KO0DY52L / Chlorhexidine
  • [Number-of-references] 54
  •  go-up   go-down


3. Dragin N, Uno S, Wang B, Dalton TP, Nebert DW: Generation of 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-) mouse line. Biochem Biophys Res Commun; 2007 Aug 3;359(3):635-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This lab previously characterized a BAC-transgenic mouse carrying the human CYP1A1_CYP1A2 locus; in this line, human dioxin-inducible CYP1A1 and basal vs dioxin-inducible CYP1A2 have been shown to be expressed normally (with regard to mRNAs, proteins and three enzyme activities) in every one of nine mouse tissues studied.
  • The Cyp1a1/1a2(-) double-knockout allele was bred with the "humanized" line; the final product is the hCYP1A1_1A2_Cyp1a1/1a2(-/-) line on a theoretically >99.8% C57BL/6J genetic background-having both human genes replacing the mouse orthologs.
  • This line will be valuable for human risk assessment studies involving any environmental toxicant or drug that is a substrate for CYP1A1 or CYP1A2.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - STOCK Del(9Cyp1a2-Cyp1a1)1Dwn Tg(CYP1A1,CYP1A2)1Dwn/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2006 Apr;26(8):2999-3007 [16581775.001]
  • [Cites] Mol Pharmacol. 2006 Apr;69(4):1103-14 [16377763.001]
  • [Cites] Genomics. 2000 Mar 1;64(2):127-31 [10729219.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 20;279(2):324-9 [11118286.001]
  • [Cites] EMBO Rep. 2000 Aug;1(2):133-9 [11265752.001]
  • [Cites] Nat Rev Genet. 2001 Oct;2(10):780-90 [11584294.001]
  • [Cites] Biochem Pharmacol. 2003 Feb 15;65(4):545-50 [12566081.001]
  • [Cites] Cancer Cell. 2003 May;3(5):449-58 [12781363.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 12;312(2):494-9 [14637164.001]
  • [Cites] Mol Pharmacol. 2004 May;65(5):1225-37 [15102951.001]
  • [Cites] Pharmacogenetics. 2004 Jan;14(1):1-18 [15128046.001]
  • [Cites] PLoS Comput Biol. 2006 Jul 7;2(7):e74 [16839196.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):947-60 [17128211.001]
  • [Cites] Hepatology. 2007 May;45(5):1118-28 [17464988.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):23847-50 [15028720.001]
  • [Cites] Mol Pharmacol. 1975 Nov;11(6):850-65 [54870.001]
  • [Cites] Mol Carcinog. 1989;2(4):192-8 [2803520.001]
  • [Cites] Methods Enzymol. 1991;206:587-94 [1664481.001]
  • [Cites] Science. 1994 Jul 1;265(5168):103-6 [8016642.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):160-4 [7816809.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7376-80 [7638200.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1671-6 [8643688.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6158-62 [8650236.001]
  • [Cites] Pharmacogenetics. 1996 Feb;6(1):1-42 [8845856.001]
  • [Cites] Mol Reprod Dev. 1997 Feb;46(2):109-13 [9021742.001]
  • [Cites] Biochem Pharmacol. 1997 Feb 7;53(3):249-54 [9065727.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jul;7(3):505-36 [9624215.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):1977-82 [10051580.001]
  • [Cites] Hum Mutat. 2005 Feb;25(2):196-206 [15643613.001]
  • [Cites] Mol Nutr Food Res. 2005 Feb;49(2):101-17 [15617087.001]
  • [Cites] Cell. 2005 May 6;121(3):479-92 [15882628.001]
  • [Cites] Pharmacogenet Genomics. 2005 Jul;15(7):503-11 [15970798.001]
  • [Cites] Chem Res Toxicol. 2005 Sep;18(9):1471-8 [16167840.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 7;267(1):184-9 [10623596.001]
  • (PMID = 17560947.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES008147-09; United States / NIEHS NIH HHS / ES / P30 ES006096-149007; United States / NIEHS NIH HHS / ES / R01 ES014403-01; United States / NIEHS NIH HHS / ES / P30 ES006096-139007; United States / NIEHS NIH HHS / ES / R01 ES014403-02; United States / NIEHS NIH HHS / ES / ES006096-159007; United States / NIEHS NIH HHS / ES / ES014403-02; United States / NIEHS NIH HHS / ES / ES006096-149007; United States / NIEHS NIH HHS / ES / R01 ES014403; United States / NIEHS NIH HHS / ES / R01 ES008147-09; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NIEHS NIH HHS / ES / ES014403-01; United States / NIEHS NIH HHS / ES / R01 ES08147; United States / NIEHS NIH HHS / ES / R01 ES008147-08; United States / NIEHS NIH HHS / ES / P30 ES006096-159007; United States / NIEHS NIH HHS / ES / R01 ES008147; United States / NIEHS NIH HHS / ES / ES006096-139007; United States / NIEHS NIH HHS / ES / ES008147-08; United States / NIEHS NIH HHS / ES / P30 ES06096
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 3417WMA06D / Benzo(a)pyrene; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1A2
  • [Other-IDs] NLM/ NIHMS26898; NLM/ PMC1994648
  •  go-up   go-down


Advertisement
4. Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, Schiller J, Johnson DH: Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol; 2010 Sep;5(9):1416-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer.
  • INTRODUCTION: The combination of paclitaxel/carboplatin (PC) and bevacizumab (B) was previously shown to extend overall survival (OS) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
  • A total of 68.8% of patients had adenocarcinoma histology; 18.9% had "not otherwise specified"; 5.5% had large cell undifferentiated; 2.6% had bronchoalveolar carcinoma; and 3.9% "other."
  • For adenocarcinoma, median OS was 10.3 months for PC treatment (n = 302) and 14.2 months for PCB (n = 300), HR 0.69 (95%CI: 0.58-0.83).
  • Adenocarcinoma was associated with an increased survival benefit of PCB treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 Feb;6(2):405 [21252724.001]
  • (PMID = 20686429.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / U10 CA066636
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Zou Y, Tornos C, Qiu X, Lia M, Perez-Soler R: p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment. Clin Cancer Res; 2007 Aug 15;13(16):4900-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment.
  • PURPOSE: To develop an optimal nonviral aerosol formulation for locoregional treatment of early lung cancer.
  • EXPERIMENTAL DESIGN: The formulation was made of polylysine/protamine combination (AND) as the carrier and p53 gene (p53sm) as therapeutic agent.
  • The preclinical safety and efficacy of AND-p53sm were studied in healthy mice and mice bearing orthotopic human non-small-cell lung cancer (NSCLC) xenograft.
  • CONCLUSIONS: This optimal formulation is suitable for delivering biological materials to human lung with aerosol administration.
  • This therapeutic strategy is an option for patients with early lung cancer and bronchoalveolar carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Genes, p53. Genetic Therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Aerosols. Animals. Chemistry, Pharmaceutical. Female. Gene Transfer Techniques. Humans. Male. Mice. Mice, Inbred ICR. Plasmids. Polylysine / administration & dosage. Protamines / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17699870.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Protamines; 25104-18-1 / Polylysine
  •  go-up   go-down


6. Nemtsov A: Suicides and alcohol consumption in Russia, 1965-1999. Drug Alcohol Depend; 2003 Aug 20;71(2):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in the level of BAC-positive suicides are closely correlated with changes in the alcohol consumption level (r=0.98), whereas changes in the number of BAC-negative suicides were not related to changes in consumption.

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Suicide.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12927654.001).
  • [ISSN] 0376-8716
  • [Journal-full-title] Drug and alcohol dependence
  • [ISO-abbreviation] Drug Alcohol Depend
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


7. Schweizer TA, Vogel-Sprott M, Danckert J, Roy EA, Skakum A, Broderick CE: Neuropsychological profile of acute alcohol intoxication during ascending and descending blood alcohol concentrations. Neuropsychopharmacology; 2006 Jun;31(6):1301-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Numerous studies have investigated the effects of alcohol on motor processes during rising and declining blood alcohol concentrations (BAC), however, relatively little research has examined the alcohol-induced impairment of cognitive performance on the two limbs of the BAC curve.
  • This experiment administered a neuropsychological test battery to assess the degree to which rising and declining BACs during an acute dose of alcohol impair nine cognitive processes within an individual.
  • In all, 20 healthy male social drinkers (university students) were assigned to one of two groups (n = 10) who received a beverage containing either 0.0 g/kg (placebo) or 0.65 g/kg alcohol and performed the test battery when BAC was increasing and was decreasing.
  • However, some processes were impaired only during rising BACs whereas the impairment of others during declining BACs was evident only by an increase in errors.
  • These results show cognitive tasks performed by an individual are not similarly affected by rising and declining BACs, and call attention to the importance of assessing both speed and accuracy on both limbs of the BAC curve.
  • The particular cognitive processes differentially affected by rising vs declining BACs raised the possibility that acute alcohol intoxication may impair one cerebral hemisphere to a greater degree than the other, and this could be explored by neuroimaging techniques.
  • [MeSH-minor] Adult. Analysis of Variance. Cognition / physiology. Humans. Male. Memory / drug effects. Memory / physiology. Mental Processes / drug effects. Mental Processes / physiology. Psychomotor Performance / drug effects. Reaction Time / drug effects. Reaction Time / physiology. Verbal Learning / physiology. Visual Perception / drug effects

  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251993.001).
  • [ISSN] 0893-133X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


8. Tan JS, File TM Jr, DiPersio JR, DiPersio LP, Hamor R, Saravolatz LD, Stout JE: Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila. Clin Infect Dis; 2001 Jun 1;32(11):1562-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This patient was found to have bronchoalveolar carcinoma of the lung by means of cytologic testing in 1 of 2 bronchoalveolar lavage samples, but no lesions were visible on bronchoscopy.
  • The poor outcome may have been partially due to the suspected underlying lung malignancy, as shown by cytologic examination, and by a delay in seeking medical attention.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Azithromycin / therapeutic use. Community-Acquired Infections / drug therapy. Legionnaires' Disease / drug therapy. Pneumonia, Bacterial / drug therapy
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Legionella pneumophila / drug effects. Legionella pneumophila / genetics. Legionella pneumophila / isolation & purification. Microbial Sensitivity Tests. Treatment Failure

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Legionnaires' Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZITHROMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11340527.001).
  • [ISSN] 1058-4838
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 83905-01-5 / Azithromycin
  •  go-up   go-down


9. Lee SO, Lee HW, Lee IS, Im HG: The pharmacological potential of Sorbus commixta cortex on blood alcohol concentration and hepatic lipid peroxidation in acute alcohol-treated rats. J Pharm Pharmacol; 2006 May;58(5):685-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pharmacological potential of Sorbus commixta cortex on blood alcohol concentration and hepatic lipid peroxidation in acute alcohol-treated rats.
  • The effect of Sorbus commixta cortex, a traditional herbal medicine used for the treatment of bronchitis, gastritis and dropsy, on blood alcohol concentration (BAC) and hepatic lipid peroxidation was examined in acute alcohol-treated rats.
  • A 30-min pretreatment with a methanol extract of S. commixta cortex (SC) at concentrations higher than 200 mg kg(-1) resulted in a significant decrease in BAC and the ethyl acetate fraction (SE) of the extract showed the highest potency, with a maximum of a 46% decrease at 150 mg kg(-1) 2 h after alcohol administration (3.0 g kg(-1)) compared with the control group (P < 0.005).
  • The rapid reduction in BAC did not appear to be due to the protection or activation of hepatic alcohol dehydrogenase (ADH) activity by SE.
  • [MeSH-major] Antioxidants / pharmacology. Drug-Induced Liver Injury / prevention & control. Ethanol. Lipid Peroxidation / drug effects. Liver / drug effects. Plant Extracts / pharmacology. Sorbus
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Catalase / antagonists & inhibitors. Catalase / metabolism. Dose-Response Relationship, Drug. Glutathione / metabolism. Male. Phenols / analysis. Rats. Rats, Sprague-Dawley. Superoxide Dismutase / antagonists & inhibitors. Superoxide Dismutase / metabolism. Time Factors

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640838.001).
  • [ISSN] 0022-3573
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Phenols; 0 / Plant Extracts; 3K9958V90M / Ethanol; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; GAN16C9B8O / Glutathione
  •  go-up   go-down


10. Pasqualini ME, Mohn CE, Petiti JP, Manzo P, Eynard AR: COX and LOX eicosanoids modulate platelet activation and procoagulation induced by two murine cancer cells. Prostaglandins Leukot Essent Fatty Acids; 2000 Dec;63(6):377-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX and LOX eicosanoids modulate platelet activation and procoagulation induced by two murine cancer cells.
  • Involvement of arachidonic acid cyclooxygenase (COX) and lipoxygenase (LOX) metabolites in platelet aggregation and coagulation induced by two varieties of cancer cells of murine transplantable tumors was studied.
  • A lung alveolar carcinoma (LAC) and a fibrosarcoma (FS), induced platelet aggregation and plasma coagulation (P<0.05).
  • Pretreatment of both tumor lines with a COX inhibitor did not block the tumor cell induced platelet aggregation (TCIPA).
  • With both neoplastic cell (NC) lines prothrombin time (PT) was shortened.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Blood Coagulation / drug effects. Cysteine Endopeptidases / secretion. Eicosanoids / physiology. Fibrosarcoma / pathology. Lipoxygenase / metabolism. Lung Neoplasms / pathology. Neoplasm Proteins. Platelet Activation / drug effects. Prostaglandin-Endoperoxide Synthases / metabolism
  • [MeSH-minor] Animals. Arachidonic Acids / metabolism. Coculture Techniques. Factor X / physiology. Iodoacetic Acid / pharmacology. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Thrombophilia / etiology. Thrombophilia / physiopathology. Trypsin Inhibitor, Kunitz Soybean / pharmacology. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / secretion

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. IODOACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11133175.001).
  • [ISSN] 0952-3278
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Arachidonic Acids; 0 / Eicosanoids; 0 / Neoplasm Proteins; 9001-29-0 / Factor X; 9088-41-9 / Trypsin Inhibitor, Kunitz Soybean; EC 1.13.11.12 / Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.26 / cancer procoagulant; WF5188V710 / Iodoacetic Acid
  •  go-up   go-down


11. Zhang XH, Guo XN, Zhong L, Luo XM, Jiang HL, Lin LP, Ding J: Establishment of the active catalytic domain of human PDGFRbeta tyrosine kinase-based ELISA assay for inhibitor screening. Biochim Biophys Acta; 2007 Oct;1770(10):1490-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In an effort towards therapeutic PDGFR inactivation, we expressed the catalytic domain of PDGFRbeta as a soluble active kinase using Bac-to-Bac expression system, and studied the correlations between PDGFRbeta activity and enzyme concentration, ATP concentration, substrate concentration and divalent cation type.
  • Our data collectively indicated that PDGFRbeta-based ELISA assay is a new method available for screening inhibitors targeting PDGFRbeta kinase and TKI-30 is a potential novel anti-cancer agent worthy of being further investigated.
  • [MeSH-minor] Animals. Cell Line. Drug Evaluation, Preclinical. Endothelial Cells / drug effects. Humans. Magnesium / pharmacology. Manganese / pharmacology. Moths. Recombinant Fusion Proteins / antagonists & inhibitors. Recombinant Fusion Proteins / metabolism

  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17719179.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrimidines; 0 / Recombinant Fusion Proteins; 0 / TKI-30; 42Z2K6ZL8P / Manganese; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; I38ZP9992A / Magnesium
  •  go-up   go-down


12. Roche AM, Freeman T, Skinner N: From data to evidence, to action: findings from a systematic review of hospital screening studies for high risk alcohol consumption. Drug Alcohol Depend; 2006 Jun 9;83(1):1-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: Sixty-five studies (N=100,980) of alcohol problem prevalence amongst hospital patients were reviewed.
  • BAC measures (26%) were nearly twice as likely (OR=1.92, p<.001) to reveal positive screens in the ED than self-reports (16%).
  • Males were two to four times more likely than females to screen positive (BAC: OR=2.37, p<.001, ED self-report: OR=3.07, p<.001, ward self-report: OR=4.30, p<.001).
  • For optimum return on resources, it is recommended to screen males in the ED using BAC measures.
  • [MeSH-major] Alcoholism / diagnosis. Evidence-Based Medicine. Mass Screening / statistics & numerical data. Patient Admission / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • Hazardous Substances Data Bank. ETHANOL .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310323.001).
  • [ISSN] 0376-8716
  • [Journal-full-title] Drug and alcohol dependence
  • [ISO-abbreviation] Drug Alcohol Depend
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  • [Number-of-references] 110
  •  go-up   go-down


13. Nemunaitis J, Sterman D, Jablons D, Smith JW 2nd, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, Hege K: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst; 2004 Feb 18;96(4):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
  • To evaluate the feasibility, safety, and efficacy of vaccination with autologous tumor cells genetically modified with an adenoviral vector (Ad-GM) to secrete human granulocyte-macrophage colony-stimulating factor (GM-CSF), we conducted a phase I/II multicenter trial in patients with early and advanced stage non-small-cell lung cancer (NSCLC).
  • Vaccines were generated from autologous tumor harvests.
  • Intradermal injections were given every 2 weeks for a total of three to six vaccinations.
  • Tumors were harvested from 83 patients, 20 with early-stage NSCLC and 63 with advanced- stage NSCLC; vaccines were successfully manufactured for 67 patients, and 43 patients were vaccinated.
  • Three of 33 advanced-stage patients, two with bronchioloalveolar carcinoma, had durable complete tumor responses (lasting 6, 18, and >or=22 months).
  • Longer survival was observed in patients receiving vaccines secreting GM-CSF at more than 40 ng/24 h per 10(6) cells (median survival = 17 months, 95% confidence interval [CI] = 6 to 23 months) than in patients receiving vaccines secreting less GM-CSF (median survival = 7 months, 95% CI = 4 to 10 months) (P =.028), suggesting a vaccine dose-related survival advantage.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Cancer Vaccines / genetics. Carcinoma, Non-Small-Cell Lung / drug therapy. Granulocyte-Macrophage Colony-Stimulating Factor / genetics. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Autoantigens / administration & dosage. Autoantigens / genetics. Dose-Response Relationship, Drug. Feasibility Studies. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2004 Apr 7;96(7):558-9 [15069124.001]
  • (PMID = 14970281.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Cancer Vaccines; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


14. Bidwell GL 3rd, Davis AN, Raucher D: Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release; 2009 Apr 2;135(1):2-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides.
  • The therapeutic index of current anti-cancer chemotherapeutics can be improved by two major mechanisms:.
  • 1) developing drugs which are specifically toxic to the cancer cells and 2) developing methods to deliver drugs to the tumor site.
  • In an attempt to combine these approaches, we developed a thermally responsive polypeptide inhibitor of c-Myc.
  • When injected systemically, ELP-fused drugs will aggregate and accumulate at the tumor site where local hyperthermia is applied.
  • In this study, the cellular uptake, intracellular distribution, and potency of the Pen, Tat and Bac cell penetrating peptides fused to ELP-H1 were evaluated.
  • While Pen-ELP-H1 and Tat-ELP-H1 were localized in the cytoplasm, Bac-ELP-H1 localized to the nucleus in a subset of the cells and was the most potent inhibitor of MCF-7 cell proliferation.
  • This data demonstrates that ELP can be targeted to the desired cellular compartment simply by choice of the CPP used, resulting in a more potent nuclear targeted c-Myc inhibitory polypeptide which may be beneficial in cancer therapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Carriers / chemistry. Peptide Fragments / chemistry. Peptides / chemistry. Proto-Oncogene Proteins c-myc / antagonists & inhibitors. Recombinant Fusion Proteins / chemistry
  • [MeSH-minor] Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cell Proliferation / drug effects. Cytoplasm / drug effects. Cytoplasm / metabolism. Dose-Response Relationship, Drug. Female. Humans. Hyperthermia, Induced. Microscopy, Fluorescence. Neoplasms / drug therapy. Neoplasms / metabolism. Phase Transition. Temperature. Time Factors

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095020.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA 113813-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / MYC protein, human; 0 / Peptide Fragments; 0 / Peptides; 0 / Proto-Oncogene Proteins c-myc; 0 / Recombinant Fusion Proteins; 81857-53-6 / elastin polypentapeptide
  •  go-up   go-down


15. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F: In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci; 2005 Dec;46(12):4594-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: In a previous study, it was demonstrated that in vitro in a human conjunctiva-derived cell line, latanoprost in its commercial presentation appeared to be less toxic than the benzalkonium chloride (BAC) it contains as a preservative.
  • Through a microplate cytometry technique, the investigation was furthered by study of whether the three commercially available antiglaucoma prostaglandin analogs could protect the same cell line in vitro against BAC toxicity and whether an antioxidative mechanism could be involved in such prostaglandin effects.
  • METHODS: Human conjunctiva-derived epithelial cells from the Chang cell line were exposed to three prostaglandins in their commercial presentation (latanoprost, travoprost, and bimatoprost) and to three concentrations of BAC (0.02%, 0.015%, and 0.005%), corresponding to the concentrations contained in the three prostaglandin eyedrops.
  • RESULTS: Cellular viability decreased as BAC concentration increased, but it was accompanied by concentration-dependent toxicity.
  • Toxicity of latanoprost and travoprost commercial solutions was statistically significantly lower than their respective BAC concentrations (P < 0.01), whereas bimatoprost induced no significant effects.
  • There was a statistically significant decrease in H2O2 detection with cells exposed to latanoprost (P < 0.01) and travoprost (P < 0.01) and a lower detection of O2*- with cells exposed to latanoprost (P < 0.01) compared with the corresponding BAC concentration alone.
  • The Yopro-1 test showed a BAC-induced apoptotic effect that increased with its concentration.
  • CONCLUSIONS: Latanoprost and travoprost were responsible for significant protective effects against BAC toxicity on conjunctiva-derived epithelial cells in vitro, probably related to their antioxidative properties.
  • Reduced reactive oxygen species production could be the main mechanism by which prostaglandin analogs protect epithelial cells from the proapoptotic effects of BAC.
  • [MeSH-major] Antihypertensive Agents / pharmacology. Antioxidants / pharmacology. Cloprostenol / analogs & derivatives. Conjunctiva / drug effects. Epithelial Cells / drug effects. Lipids / pharmacology. Prostaglandins F, Synthetic / pharmacology
  • [MeSH-minor] Amides. Apoptosis / drug effects. Benzalkonium Compounds / toxicity. Bimatoprost. Cell Line. Cell Survival. Cytoprotection. Fluorometry. Humans. Hydrogen Peroxide / metabolism. Preservatives, Pharmaceutical / toxicity. Reactive Oxygen Species / metabolism. Superoxides / metabolism. Travoprost

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303954.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amides; 0 / Antihypertensive Agents; 0 / Antioxidants; 0 / Benzalkonium Compounds; 0 / Lipids; 0 / Preservatives, Pharmaceutical; 0 / Prostaglandins F, Synthetic; 0 / Reactive Oxygen Species; 11062-77-4 / Superoxides; 4208238832 / Cloprostenol; 6Z5B6HVF6O / latanoprost; BBX060AN9V / Hydrogen Peroxide; QXS94885MZ / Bimatoprost; WJ68R08KX9 / Travoprost
  •  go-up   go-down


16. Knief P, Clarke C, Herzog E, Davoren M, Lyng FM, Meade AD, Byrne HJ: Raman spectroscopy--a potential platform for the rapid measurement of carbon nanotube-induced cytotoxicity. Analyst; 2009 Jun;134(6):1182-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study the suitability of Raman spectroscopy for the determination of carbon nanotube mediated toxicity on human alveolar carcinoma epithelial cells (A549) is explored.
  • The exposure of this cell line represents the primary pathway of exposure in humans, that of inhalation.
  • [MeSH-minor] Algorithms. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans. Inhalation. Least-Squares Analysis. Multivariate Analysis. Principal Component Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475146.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nanotubes, Carbon
  •  go-up   go-down


17. Antonijoan R, García-Gea C, Puntes M, Pérez J, Esbrí R, Serra C, Fortea J, Barbanoj MJ: Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults. Clin Ther; 2007 May;29(5):814-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A fast-dissolving tablet formulation of ebastine has been developed at 10- and 20-mg doses, with the intention of facilitating administration to patients experiencing problems with swallowing, including those confined to bed and elderly people, as well as those who may need to use ebastine when they do not have easy access to water to aid swallowing a tablet.
  • METHODS: This double-blind, double-dummy, randomized, placebo-controlled, 3-period crossover study was conducted at the Drug Research Centre, Department of Clinical Pharmacology, the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Healthy, nonatopic, white adults aged 18 to 40 years were randomly assigned to 1 of 6 study sequences: ABC, ACB, BAC, BCA, CBA, or CAB, where A was the ebastine fast-dissolving 20-mg tablet, B was the desloratadine 5-mg capsule, and C was placebo.
  • All study drugs were given orally once daily (8-9 AM) on days 1 to 5 of each study period.
  • Histamine skin-prick test (SPT) challenge was performed before study drug administration on day 1 of each period (baseline), and then every 20 minutes for 2 hours after administration and again after 24 hours.
  • The primary end point was inhibition o f the histamine response, defined as the percentage reduction from baseline wheal area 24 hours after 5 days of administration.
  • Mean itching, flare, and pain ratings were not significantly different between study drugs.
  • The relationship with the study drugs was considered unlikely in 6 cases and possible in the remaining 8 cases.
  • All study drugs were well tolerated.

  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. LORATADINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Ther. 2007 Dec;29(12):2774-5, author reply 2775-6 [18201596.001]
  • (PMID = 17697901.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Butyrophenones; 0 / Histamine H1 Antagonists; 0 / Piperidines; 7AJO3BO7QN / Loratadine; 820484N8I3 / Histamine; FVF865388R / desloratadine; TQD7Q784P1 / ebastine
  •  go-up   go-down


18. Shimizu M, Okuzumi K, Yoneyama A, Kunisada T, Araake M, Ogawa H, Kimura S: In vitro antiseptic susceptibility of clinical isolates from nosocomial infections. Dermatology; 2002;204 Suppl 1:21-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the susceptibility of a large number of strains to various antiseptics, we elaborated a simple, qualitative broth turbidity method in which we could quickly judge the efficacy visually.
  • The susceptibilities of Serratia marcescens No. 26 to 4 antiseptics obtained from the turbidity method showed a good agreement with those obtained from the colony-counting method; the 4 antiseptics tested were povidone-iodine (PVP-I), chlorhexidine gluconate (CHG), benzalkonium chloride (BAC) and alkyldiaminoethylglycine hydrochloride (AEG).
  • Both PVP-I and BAC had complete efficacy in 0.5 min against all isolates tested [100 isolates of S. marcescens, 103 of Klebsiella pneumoniae, 99 of Pseudomonas aeruginosa, 19 of Alcaligenes faecalis and 30 of A. xylosoxidans subsp. xylosoxydans (A. xylosoxydans)].
  • In contrast, the effectiveness of CHG was weak compared with PVP-I, BAC and AEG.
  • Strong resistance against AEG was noted even after 3-min exposure in 1 isolate each of A. faecalis and A. xylosoxydans.
  • It is concluded that the turbidity test is a simple and accurate method to evaluate susceptibility to various antiseptics and that it is suitable for a screening of a large number of strains.
  • Among the 4 antiseptics tested, PVP-I and BAC showed a consistently high activity against all isolates, confirming PVP-I and BAC to be clinically useful antiseptics.
  • [MeSH-major] Anti-Infective Agents, Local / pharmacology. Chlorhexidine / analogs & derivatives. Cross Infection / microbiology
  • [MeSH-minor] Benzalkonium Compounds / pharmacology. Colony Count, Microbial. Drug Resistance, Microbial. Humans. Klebsiella pneumoniae / drug effects. Microbial Sensitivity Tests. Povidone-Iodine / pharmacology. Pseudomonas aeruginosa / drug effects. Serratia marcescens / drug effects. Time Factors

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Povidone-iodine .
  • Hazardous Substances Data Bank. CHLORHEXIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12011516.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Benzalkonium Compounds; 25655-41-8 / Povidone-Iodine; MOR84MUD8E / chlorhexidine gluconate; R4KO0DY52L / Chlorhexidine
  •  go-up   go-down


19. Ohnishi H, Miyahara N, Dakhama A, Takeda K, Mathis S, Haribabu B, Gelfand EW: Corticosteroids enhance CD8+ T cell-mediated airway hyperresponsiveness and allergic inflammation by upregulating leukotriene B4 receptor 1. J Allergy Clin Immunol; 2008 Apr;121(4):864-71.e4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corticosteroids enhance CD8+ T cell-mediated airway hyperresponsiveness and allergic inflammation by upregulating leukotriene B4 receptor 1.
  • OBJECTIVES: The effects of the corticosteroid dexamethasone (DEX) on BLT1-expressing effector memory CD8+ T cells and effector memory CD8+ T cell-mediated airway hyperresponsiveness (AHR) and allergic inflammation were determined.
  • The effects of DEX on BLT1 expression, LTB4-induced Ca2+ influx, phosphorylation of extracellular signal-regulated kinase 1/2, chemotaxis, and effector memory CD8+ T cell-mediated AHR were examined.
  • Adoptive transfer of DEX-treated effector memory CD8+ T cells into ovalbumin-sensitized and ovalbumin-challenged CD8-/- mice resulted in significant increases in AHR, allergic inflammation, goblet cell metaplasia, and numbers of both CD8+ and CD4+ T cells in the bronchoalveolar lavage fluid and lungs.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395551.001).
  • [ISSN] 1097-6825
  • [Journal-full-title] The Journal of allergy and clinical immunology
  • [ISO-abbreviation] J. Allergy Clin. Immunol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL036577; United States / NHLBI NIH HHS / HL / HL-61005; United States / PHS HHS / / A1-52381; United States / NHLBI NIH HHS / HL / P01 HL036577-21A15977; United States / NHLBI NIH HHS / HL / HL036577-21A15977; United States / NHLBI NIH HHS / HL / HL-36577
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Allergens; 0 / Egg Proteins; 0 / Inflammation Mediators; 0 / Ltb4r1 protein, mouse; 0 / OVA-8; 0 / Peptide Fragments; 0 / Receptors, Leukotriene B4; 7S5I7G3JQL / Dexamethasone; 9006-59-1 / Ovalbumin
  •  go-up   go-down


20. Inoue K, Wakakura M, Miyanaga Y, Tomita G: [Microbial contamination of nipradiol with and without benzalkonium chloride]. Nippon Ganka Gakkai Zasshi; 2010 Jul;114(7):604-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To compare microbial contamination of nipradiol both with and without benzalkonium chloride (BAC).
  • SUBJECTS AND METHODS: Twenty primary open angle glaucoma patients treated with nipradiol with BAC were studied.
  • The nipradiol with BAC was switched to nipradiol without BAC.
  • Four weeks after switching, the nipradiol without BAC was once again switched to nipradiol with BAC.
  • RESULTS: In nipradiol without BAC microorganisms were isolated from caps (30%), nozzles (50%), solutions (0%), and filters (15%), whereas in nipradiol with BAC they were isolated from caps (35%), nozzles (40%), and solutions (25%).
  • The microorganisms in the nipradiol without BAC were coagulase-negative Staphylococci (38.2%) and Propionibacterium acnes (29.4%), and in the nipradiol with BAC they were coagulase-negative Staphylococci (20.5%), Alcaligenes xylosoxidans (12.8%).
  • CONCLUSIONS: In nipradiol without BAC, the bacteria were detected outside the filters, but not in the solution.
  • The rate of microbial contamination of the nipradiol without BAC was similar to that of the nipradiol with BAC.
  • Both the bacteria detected from the nipradiol with and those detected in the solution without BAC consisted only of bacterial flora of the cul-de-sac and skin.
  • [MeSH-major] Anti-Infective Agents, Local / pharmacology. Benzalkonium Compounds / pharmacology. Drug Contamination / prevention & control. Ophthalmic Solutions. Propanolamines
  • [MeSH-minor] Bacteria / isolation & purification. Female. Glaucoma, Open-Angle / drug therapy. Humans. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20681256.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Benzalkonium Compounds; 0 / Ophthalmic Solutions; 0 / Propanolamines; FVM336I71Y / nipradilol
  •  go-up   go-down


21. Epstein AM, Sher TG, Young MA, King AC: Tobacco chippers show robust increases in smoking urge after alcohol consumption. Psychopharmacology (Berl); 2007 Feb;190(3):321-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the high alcohol dose, craving was heightened during the rising portion of the blood alcohol curve (BAC).
  • There was a strong relationship between BAC and craving for positive reinforcement and this relationship was partially mediated by BAES stimulation, but not sedation.
  • [MeSH-major] Alcohol Drinking / psychology. Cues. Smoking / psychology. Tobacco Use Disorder / psychology
  • [MeSH-minor] Adult. Behavior / drug effects. Behavior / physiology. Dose-Response Relationship, Drug. Ethanol / administration & dosage. Ethanol / blood. Ethanol / pharmacokinetics. Female. Humans. Male. Models, Psychological. Psychopharmacology / methods. Reinforcement (Psychology). Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Anal Behav. 1976 May;25(3):279-92 [1270971.001]
  • [Cites] Exp Clin Psychopharmacol. 1997 May;5(2):137-42 [9234050.001]
  • [Cites] Behav Pharmacol. 1996 Mar;7(2):144-154 [11224406.001]
  • [Cites] J Abnorm Psychol. 1997 Feb;106(1):104-16 [9103722.001]
  • [Cites] Addiction. 2001 Oct;96(10):1419-32 [11571061.001]
  • [Cites] Nicotine Tob Res. 2001 Feb;3(1):7-16 [11260806.001]
  • [Cites] Psychopharmacology (Berl). 2000 Oct;152(3):334-42 [11105944.001]
  • [Cites] Behav Res Ther. 1979;17(2):157-60 [426744.001]
  • [Cites] Addict Behav. 1996 Mar-Apr;21(2):233-8 [8730526.001]
  • [Cites] N Engl J Med. 1990 Jan 11;322(2):95-9 [2248624.001]
  • [Cites] J Stud Alcohol. 1990 Mar;51(2):130-5 [2308350.001]
  • [Cites] Clin Pharmacol Ther. 1983 Jun;33(6):806-12 [6851412.001]
  • [Cites] JAMA. 1996 Apr 10;275(14):1097-103 [8601929.001]
  • [Cites] Psychol Addict Behav. 2005 Sep;19(3):263-70 [16187804.001]
  • [Cites] Health Psychol. 1995 Jul;14(4):301-9 [7556033.001]
  • [Cites] Health Psychol. 2002 Jul;21(4):384-92 [12090681.001]
  • [Cites] Alcohol Clin Exp Res. 2005 Apr;29(4):547-52 [15834219.001]
  • [Cites] J Stud Alcohol. 1993 Nov;54(6):750-61 [8271813.001]
  • [Cites] Br J Addict. 1991 Sep;86(9):1119-27 [1932883.001]
  • [Cites] Alcohol Clin Exp Res. 2002 Jun;26(6):827-35 [12068251.001]
  • [Cites] Addiction. 1997 Jan;92(1):15-26 [9060194.001]
  • [Cites] Arch Gen Psychiatry. 1961 Jun;4:561-71 [13688369.001]
  • [Cites] Pharmacol Biochem Behav. 1983;18 Suppl 1:349-54 [6634848.001]
  • [Cites] Behav Pharmacol. 1995 Jun;6(4):359-365 [11224344.001]
  • [Cites] Arch Gen Psychiatry. 1990 Apr;47(4):333-6 [2322084.001]
  • [Cites] J Stud Alcohol. 1975 Jan;36(1):117-26 [238068.001]
  • [Cites] Drug Alcohol Depend. 2004 Jul 15;75(1):55-65 [15225889.001]
  • [Cites] Addict Behav. 1985;10(3):203-7 [4083099.001]
  • [Cites] J Stud Alcohol. 2004 Jan;65(1):27-36 [15000501.001]
  • [Cites] Psychopharmacology (Berl). 1992;109(4):449-56 [1365861.001]
  • [Cites] Alcohol Clin Exp Res. 1993 Feb;17(1):140-6 [8452195.001]
  • [Cites] Psychopharmacology (Berl). 1989;97(4):539-47 [2498951.001]
  • [Cites] Br J Addict. 1990 Feb;85(2):271-8 [2180510.001]
  • [Cites] J Pers Soc Psychol. 1986 Dec;51(6):1173-82 [3806354.001]
  • [Cites] Psychol Methods. 2002 Mar;7(1):83-104 [11928892.001]
  • [Cites] Tob Control. 2005 Oct;14(5):315-20 [16183982.001]
  • (PMID = 16804691.001).
  • [ISSN] 0033-3158
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / F31-AA15017; United States / NCRR NIH HHS / RR / M01-RR00055; United States / NIAAA NIH HHS / AA / R01-AA013746; United States / NIAAA NIH HHS / AA / R03-AA015337
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


22. Rajakumar P, Sekar K, Shanmugaiah V, Mathivanan N: Synthesis of some novel imidazole-based dicationic carbazolophanes as potential antibacterials. Bioorg Med Chem Lett; 2008 Aug 1;18(15):4416-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, the cyclophanes 2a and 5a incorporating a pyridine moiety exhibited superior antibacterial activity against most of the pathogenic bacteria in the tested concentrations as compared to the other cyclophanes as well as the test control, benzalkonium chloride (BAC), cetylpyridinium chloride (CPC) and tetracycline.
  • [MeSH-major] Anti-Bacterial Agents / chemical synthesis. Anti-Bacterial Agents / pharmacology. Carbazoles / chemical synthesis. Carbazoles / pharmacology. Imidazoles / chemical synthesis. Imidazoles / pharmacology
  • [MeSH-minor] Benzalkonium Compounds / pharmacology. Cetylpyridinium / pharmacology. Microbial Sensitivity Tests. Molecular Structure. Proteus mirabilis / drug effects. Proteus vulgaris / drug effects. Pseudomonas aeruginosa / drug effects. Quaternary Ammonium Compounds / chemistry. Salmonella typhi / drug effects. Staphylococcus aureus / drug effects. Tetracycline / pharmacology

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. TETRACYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620857.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Benzalkonium Compounds; 0 / Carbazoles; 0 / Imidazoles; 0 / Quaternary Ammonium Compounds; CUB7JI0JV3 / Cetylpyridinium; F8VB5M810T / Tetracycline
  •  go-up   go-down


23. Senna MC, Augsburger M, Aebi B, Briellmann TA, Donzé N, Dubugnon JL, Iten PX, Staub C, Sturm W, Sutter K: First nationwide study on driving under the influence of drugs in Switzerland. Forensic Sci Int; 2010 May 20;198(1-3):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First nationwide study on driving under the influence of drugs in Switzerland.
  • In Switzerland, a two-tier system based on impairment by any psychoactive substances which affect the capacity to drive safely and zero tolerance for certain illicit drugs came into force on 1 January 2005.
  • At the same time the legal blood alcohol concentration (BAC) limit for driving was lowered from 0.80 to 0.50g/kg.
  • The purpose of this study was to analyze the prevalence of drugs in the first year after the introduction of the revision of the Swiss Traffic Law in the population of drivers suspected of driving under the influence of drugs (DUID).
  • Data collected were anonymous and included the age, gender, date and time of the event, the type of vehicle, the circumstances, the sampling time and the results of all the performed toxicological analyses.
  • One or more psychoactive drugs were detected in 89% of all analyzed blood samples.
  • In 11% (N=530) of the samples, neither alcohol nor drugs were present.
  • The most frequently encountered drugs in whole blood were cannabinoids (48% of total number of cases), ethanol (35%), cocaine (25%), opiates (10%), amphetamines (7%), benzodiazepines (6%) and methadone (5%).
  • Other medicinal drugs such as antidepressants and benzodiazepine-like were detected less frequently.
  • Poly-drug use was prevalent but it may be underestimated because the laboratories do not always analyze all drugs in a blood sample.
  • This first Swiss study points out that DUID is a serious problem on the roads in Switzerland.
  • [MeSH-major] Automobile Driving / legislation & jurisprudence. Substance-Related Disorders / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Amphetamines / analysis. Antidepressive Agents / analysis. Benzodiazepines / analysis. Cannabinoids / analysis. Central Nervous System Depressants / analysis. Cocaine / analysis. Ethanol / analysis. Female. Forensic Toxicology. Gas Chromatography-Mass Spectrometry. Humans. Male. Methadone / analysis. Middle Aged. Narcotics / analysis. Prevalence. Sex Distribution. Substance Abuse Detection. Switzerland / epidemiology

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Drugs and Young People.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • Hazardous Substances Data Bank. COCAINE .
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. METHADONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211534.001).
  • [ISSN] 1872-6283
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Amphetamines; 0 / Antidepressive Agents; 0 / Cannabinoids; 0 / Central Nervous System Depressants; 0 / Narcotics; 12794-10-4 / Benzodiazepines; 3K9958V90M / Ethanol; I5Y540LHVR / Cocaine; UC6VBE7V1Z / Methadone
  •  go-up   go-down


24. Coutinho JM, Singaraja RR, Kang M, Arenillas DJ, Bertram LN, Bissada N, Staels B, Fruchart JC, Fievet C, Joseph-George AM, Wasserman WW, Hayden MR: Complete functional rescue of the ABCA1-/- mouse by human BAC transgenesis. J Lipid Res; 2005 Jun;46(6):1113-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete functional rescue of the ABCA1-/- mouse by human BAC transgenesis.
  • The effect of these differences was assessed in vivo, using a bacterial artificial chromosome transgenic humanized ABCA1 mouse model that expresses the human gene in the absence of mouse ABCA1.
  • Humanized mice expressed human ABCA1 protein at levels similar to wild-type mice and fully compensated for cholesterol efflux activity and lipid levels seen in ABCA1-deficient mice.
  • Liver X receptor agonist administration resulted in significant increases in HDL values associated with parallel increases in the hepatic ABCA1 protein and mRNA levels in the humanized ABCA1 mice, as seen in the wild-type animals.
  • [MeSH-minor] ATP Binding Cassette Transporter 1. Animals. Binding Sites. Blotting, Southern. Cholesterol / metabolism. Chromosomes, Artificial, Bacterial. Computational Biology. DNA-Binding Proteins / agonists. Dose-Response Relationship, Drug. Exons. Gene Expression Regulation. Humans. In Situ Hybridization, Fluorescence. Lipid Metabolism. Lipoproteins, HDL / metabolism. Liver X Receptors. Mice. Mice, Knockout. Mice, Transgenic. Models, Genetic. Orphan Nuclear Receptors. Phylogeny. RNA / metabolism. RNA, Messenger / metabolism. Receptors, Cytoplasmic and Nuclear / agonists. Software. Species Specificity. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772424.001).
  • [ISSN] 0022-2275
  • [Journal-full-title] Journal of lipid research
  • [ISO-abbreviation] J. Lipid Res.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / 69153
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCA1 protein, human; 0 / ATP Binding Cassette Transporter 1; 0 / ATP-Binding Cassette Transporters; 0 / DNA-Binding Proteins; 0 / Lipoproteins, HDL; 0 / Liver X Receptors; 0 / Orphan Nuclear Receptors; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 63231-63-0 / RNA; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


25. Khiabani HZ, Opdal MS, Mørland J: Blood alcohol concentrations in apprehended drivers of cars and boats suspected to be impaired by the police. Traffic Inj Prev; 2008 Mar;9(1):31-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: According to the Norwegian Road Traffic Act, car drivers are not allowed to operate a vehicle with a blood alcohol concentration (BAC) above 0.2 g/kg.
  • Depending on the size of the boat or ship, boat drivers/captains/first mates are not allowed to conduct the boat with a BAC above 0.8 g/kg when driving small boats (length less than 15 m) and above 1.5 g/kg when running larger vessels/ships.
  • The new Sea Act of June 2005 states that captains/first mates cannot conduct a ship if he/she has a BAC above 0.2 g/kg.
  • Our aim was to determine the current median BAC in a large population of car and boat drivers in Norway.
  • Our other aim was to study if median BAC was higher in boat drivers than in car drivers who were suspected by the police to be impaired.
  • Furthermore, we wanted to investigate if the BAC levels were differently distributed by gender or age within and between these two groups.
  • METHODS: The Norwegian Institute of Public Health analyzes blood samples from all car/boat drivers suspected of driving under the influence of alcohol and non-alcoholic drugs.
  • Drivers, who in addition tested positive for drugs or abuse substances other than ethanol were excluded.
  • The median BAC in boat drivers (1.76 g/kg [range 0.02-3.54]) was significantly higher compared to that in car drivers (1.54 g/kg [range 0.00-4.27]).
  • In the car driver group, the mean BAC did not differ significantly between men and women.
  • The median level of BAC was significantly higher in men than in women in the boat driver group (1.77 g/kg with CI 1.69-1.85 vs. 1.27 g/kg with CI 0.78-1.76).
  • The median BAC in apprehended boat drivers was considerably high in the present study.
  • The median BAC was also high in car drivers despite strict legislation.

  • MedlinePlus Health Information. consumer health - Alcohol.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338292.001).
  • [ISSN] 1538-957X
  • [Journal-full-title] Traffic injury prevention
  • [ISO-abbreviation] Traffic Inj Prev
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


26. Macfarlane GT, Macfarlane LE: Acquisition, evolution and maintenance of the normal gut microbiota. Dig Dis; 2009;27 Suppl 1:90-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the succeeding weeks, months and years, a complex microbiota develops that plays a major role in host physiology.
  • While the digestive tract is colonised to varying degrees by micro-organisms throughout its length, due to acid pH and the short retention time of gastric contents, bacterial numbers in the stomach are usually low.
  • The rapid passage of digestive materials through the upper gut does not provide time for significant bacterial growth to occur, but cell numbers increase considerably in the distal ileum.
  • The rate of movement of intestinal contents slows in the colon, which facilitates the development of complex bacterial communities.
  • The large intestine is an intricate ecosystem that contains a complex microbiota composed of several hundred different types of bacteria.
  • The growth and metabolism of microbial communities in the large intestine are determined by many factors, such as diet, environment and host physiological processes, as well as the anatomic structure of the digestive tract, disease, immunity, host genetics, drugs and ageing.
  • Increased antibiotic use in older people and simply going into hospital have been shown to change bacterial community structure in the colonic microbiota, although the metabolic significance of this is unclear.
  • [MeSH-major] Biological Evolution. Gastrointestinal Tract / microbiology. Metagenome / physiology
  • [MeSH-minor] Aging / pathology. Animals. Colony Count, Microbial. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20203503.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


27. Girard TA, Wainwright PE: Testing the spatial- versus object-learning distinction: water-maze performance of male rats exposed to ethanol during the brain growth spurt. Behav Brain Res; 2002 Aug 21;134(1-2):493-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Artificially reared male Long-Evans rats were exposed to ethanol (ET) in a binge pattern from postnatal days 6-9 (6.5 g kg(-1) x day(-1); BAC approximately 330 mg/dl) or an isocaloric maltose-dextrin solution (gastrostomy control).
  • In experiment 2, the ET group was impaired in learning the spatial location of a submerged platform relative to intra-maze cues.
  • [MeSH-minor] Animals. Body Weight / physiology. Discrimination (Psychology) / drug effects. Discrimination (Psychology) / physiology. Female. Male. Motor Activity / physiology. Pregnancy. Rats. Rats, Long-Evans

  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science B.V.
  • (PMID = 12191836.001).
  • [ISSN] 0166-4328
  • [Journal-full-title] Behavioural brain research
  • [ISO-abbreviation] Behav. Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 3K9958V90M / Ethanol
  •  go-up   go-down


28. Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL Jr, Martin DH: Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis; 2004 Feb 13;4:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis.
  • BACKGROUND: Bacterial vaginosis (BV) is a polymicrobial syndrome characterized by a change in vaginal flora away from predominantly Lactobacillus species.
  • It is not readily identified by commercial diagnostic kits.
  • METHODS: Nucleotide sequencing of PCR amplified 16S rRNA gene segments, that were separated into bands within lanes on polyacrylamide gels by denaturing gradient gel electrophoresis (DGGE), was used to examine bacterial vaginal flora in 46 patients clinically described as having normal (Lactobacillus spp. predominant; Nugent score < or = 3) and abnormal flora (Nugent score > or = 4).
  • CONCLUSION: The results suggest that A. vaginae may be an important component of the complex bacterial ecology that constitutes abnormal vaginal flora.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Syst Bacteriol. 1999 Oct;49 Pt 4:1573-6 [10555338.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1737-42 [7491137.001]
  • [Cites] Mol Biol Evol. 1996 Mar;13(3):451-61 [8742634.001]
  • [Cites] J Bacteriol. 1996 Oct;178(19):5636-43 [8824607.001]
  • [Cites] Appl Environ Microbiol. 1997 Apr;63(4):1375-81 [9097434.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Clin Infect Dis. 1997 Sep;25 Suppl 2:S78-87 [9310640.001]
  • [Cites] Appl Environ Microbiol. 1998 Jul;64(7):2585-95 [9647834.001]
  • [Cites] J Bacteriol. 1998 Sep;180(18):4765-74 [9733676.001]
  • [Cites] Appl Environ Microbiol. 1996 Mar;62(3):1045-50 [11536748.001]
  • [Cites] Int J Syst Bacteriol. 1999 Apr;49 Pt 2:601-10 [10319482.001]
  • [Cites] J Microbiol Methods. 1999 Jun;36(3):167-79 [10379803.001]
  • [Cites] Curr Opin Microbiol. 1999 Jun;2(3):317-22 [10383868.001]
  • [Cites] Appl Environ Microbiol. 1999 Sep;65(9):3834-42 [10473383.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):492-8 [10655334.001]
  • [Cites] Lett Appl Microbiol. 2001 Apr;32(4):215-9 [11298928.001]
  • [Cites] Sex Transm Dis. 2001 May;28(5):292-7 [11354269.001]
  • [Cites] Appl Environ Microbiol. 2001 Aug;67(8):3557-63 [11472932.001]
  • [Cites] Clin Infect Dis. 2001 Sep 15;33(6):894-6 [11512096.001]
  • [Cites] Infect Dis Obstet Gynecol. 2001;9(3):133-41 [11516061.001]
  • [Cites] Syst Appl Microbiol. 2001 Jul;24(2):227-31 [11518325.001]
  • [Cites] Zh Mikrobiol Epidemiol Immunobiol. 2001 Jul-Aug;(4):78-84 [11569274.001]
  • [Cites] Obstet Gynecol. 2001 Oct;98(4):656-63 [11576584.001]
  • [Cites] Contraception. 2001 Sep;64(3):169-72 [11704096.001]
  • [Cites] J Infect Dis. 2002 Jan 1;185(1):69-73 [11756983.001]
  • [Cites] BJOG. 2002 Jan;109(1):34-43 [11845812.001]
  • [Cites] Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S17-21 [12173103.001]
  • [Cites] Br J Nutr. 2002 Sep;88 Suppl 1:S29-37 [12215179.001]
  • [Cites] J Infect Dis. 2002 Dec 15;186(12):1770-80 [12447763.001]
  • [Cites] Appl Environ Microbiol. 2003 Jan;69(1):97-101 [12513982.001]
  • [Cites] J Clin Microbiol. 2003 Feb;41(2):558-63 [12574246.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Apr;81(1):61-3 [12676400.001]
  • [Cites] J Dent Res. 2003 May;82(5):338-44 [12709498.001]
  • [Cites] Appl Environ Microbiol. 2003 May;69(5):2893-8 [12732563.001]
  • [Cites] J Microbiol Methods. 2003 Jul;54(1):13-20 [12732417.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2788-90 [12791933.001]
  • [Cites] J Clin Microbiol. 1991 Feb;29(2):297-301 [1706728.001]
  • [Cites] FEMS Microbiol Lett. 1992 Aug 15;74(2-3):235-40 [1382033.001]
  • [Cites] Appl Environ Microbiol. 1993 Mar;59(3):695-700 [7683183.001]
  • [Cites] Am J Obstet Gynecol. 1993 Aug;169(2 Pt 2):441-5 [8357040.001]
  • [Cites] Appl Environ Microbiol. 1996 Feb;62(2):340-6 [8593039.001]
  • (PMID = 15018635.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U19 AI43024
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / RNA, Ribosomal, 16S; 140QMO216E / Metronidazole
  • [Other-IDs] NLM/ PMC362875
  •  go-up   go-down


29. Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, Cassuto Y, Shinar D: Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev; 2008 May;40(3):926-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: We tested the subjective feelings and driving abilities after placebo, smoking two dosages of THC (13 mg and 17 mg), drinking (0.05% BAC) and 24 h after smoking the high dose THC cigarette, while monitoring physiological activity of the drugs by heart rate.
  • The moderate dose of alcohol and the low THC dose were equally detrimental to some of the driving abilities, with some differences between the two drugs.
  • [MeSH-minor] Adult. Female. Heart Rate / drug effects. Humans. Israel. Male. Reaction Time / drug effects. Task Performance and Analysis

  • MedlinePlus Health Information. consumer health - Alcohol.
  • Hazardous Substances Data Bank. delta 9-Tetrahydrocannabinol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460360.001).
  • [ISSN] 0001-4575
  • [Journal-full-title] Accident; analysis and prevention
  • [ISO-abbreviation] Accid Anal Prev
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7J8897W37S / Dronabinol
  •  go-up   go-down


30. Wang Y, Feinstein SI, Manevich Y, Ho YS, Fisher AB: Peroxiredoxin 6 gene-targeted mice show increased lung injury with paraquat-induced oxidative stress. Antioxid Redox Signal; 2006 Jan-Feb;8(1-2):229-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peroxiredoxin 6 gene-targeted mice show increased lung injury with paraquat-induced oxidative stress.
  • Mice with knock-out of peroxiredoxin 6 (Prdx6), a recently described antioxidant enzyme, were evaluated for susceptibility to lung injury with paraquat (PQ) administration.
  • ), all Prdx6-/- mice died (LT50 54 +/- 2.05 h, mean +/- SE) by 4 days, whereas 86% of the wild-type (WT) mice (C57BL/6) survived (n = 14).
  • At 2 days after PQ, lung wet/dry weight ratio increased significantly (p < 0.05) to 7.57 +/- 0.37 in Prdx6-/- mice vs. 5.42 +/- 0.25 in WT mice.
  • Total protein and nucleated cells in bronchoalveolar lavage fluid and TBARS and protein carbonyls in lung homogenate also showed more marked increases in Prdx6-/- mice.
  • At 2.5 days after PQ, light microscopy of WT lungs showed mild injury while Prdx6-/- lungs showed epithelial cell necrosis, perivascular edema, and inflammatory cells.
  • With low dose PQ (12.5 mg/kg), mortality and lung injury were less marked but were significantly greater with Prdx6-/- compared to WT mice.
  • These results show that Prdx6-/- mice have increased susceptibility to lung injury with PQ administration.
  • Thus, Prdx6 protects lungs against PQ toxicity as shown previously for hyperoxia, indicating that it functions as an important lung antioxidant enzyme.
  • [MeSH-major] Lung Injury. Oxidative Stress / drug effects. Paraquat / toxicity. Peroxidases / genetics
  • [MeSH-minor] Animals. Bronchoalveolar Lavage Fluid / chemistry. Lung / drug effects. Lung / pathology. Mice. Mice, Inbred C57BL. Mice, Knockout. Necrosis. Peroxiredoxin VI. Peroxiredoxins. Thiobarbituric Acid Reactive Substances / analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Paraquat .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487056.001).
  • [ISSN] 1523-0864
  • [Journal-full-title] Antioxidants & redox signaling
  • [ISO-abbreviation] Antioxid. Redox Signal.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES-06639; United States / NHLBI NIH HHS / HL / HL-65543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiobarbituric Acid Reactive Substances; EC 1.11.1.- / Peroxidases; EC 1.11.1.15 / Peroxiredoxin VI; EC 1.11.1.15 / Peroxiredoxins; EC 1.11.1.15 / Prdx6 protein, mouse; PLG39H7695 / Paraquat
  •  go-up   go-down


31. Huffman LJ, Judy DJ, Rao KM, Frazer DG, Goldsmith WT: Lung responses to hypothyroidism, hyperthyroidism, and lipopolysaccharide challenge in rats. J Toxicol Environ Health A; 2000 Dec 15;61(7):623-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung responses to hypothyroidism, hyperthyroidism, and lipopolysaccharide challenge in rats.
  • The objectives of this investigation were to study the effects of hypo- and hyperthyroidism on some factors involved in lung injury under basal conditions (air exposure) and during an inflammatory response induced by inhalation exposure to lipopolysaccharide (LPS; 100 microg/ml; 3 h) in adult rats.
  • Hyperthyroidism alone caused a greater degree of lung cell damage, an increase in the permeability of the alveolar-capillary barrier, a rise in the total number of phagocytic cells obtained by bronchoalveolar lavage (BAL), and enhanced nitric oxide (NO) release by phagocytic cells relative to that in euthyroid control animals.
  • Exposure of animals to LPS produced inflammatory responses, which included significant increases in lung cell damage, permeability of the alveolar-capillary barrier, number of phagocytic cells obtained by BAL, and NO production by the phagocytic cells.
  • In general, hyperthyroidism enhanced the effects of LPS, while hypothyroidism reduced LPS-induced responses.
  • These results suggest that thyroid status alone can affect some of the factors involved in lung injury and also modulate some of the inflammatory effects of LPS.
  • Hyperthyroidism tends to enhance lung injury, while hypothyroidism seems to reduce lung injury.
  • [MeSH-major] Hyperthyroidism / pathology. Hypothyroidism / pathology. Lipopolysaccharides / toxicity. Lung / pathology
  • [MeSH-minor] Albumins / metabolism. Animals. Body Weight / drug effects. Bronchoalveolar Lavage Fluid / cytology. Capillaries / pathology. Cell Count. Cell Membrane Permeability / drug effects. Endotoxins / pharmacology. L-Lactate Dehydrogenase / metabolism. Male. Nitric Oxide / metabolism. Phagocytes / drug effects. Rats. Rats, Sprague-Dawley. Thyroxine / toxicity

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127416.001).
  • [ISSN] 1528-7394
  • [Journal-full-title] Journal of toxicology and environmental health. Part A
  • [ISO-abbreviation] J. Toxicol. Environ. Health Part A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Albumins; 0 / Endotoxins; 0 / Lipopolysaccharides; 31C4KY9ESH / Nitric Oxide; 67924-63-4 / endotoxin, Escherichia coli; EC 1.1.1.27 / L-Lactate Dehydrogenase; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


32. Bertrand S, Nouel D, Morin F, Nagy F, Lacaille JC: Gabapentin actions on Kir3 currents and N-type Ca2+ channels via GABAB receptors in hippocampal pyramidal cells. Synapse; 2003 Nov;50(2):95-109
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gabapentin actions on Kir3 currents and N-type Ca2+ channels via GABAB receptors in hippocampal pyramidal cells.
  • These activities appeared controversial and we therefore sought to further clarify gabapentin actions in rat hippocampal slices by characterizing K(+) currents and Ca(2+) channels targeted by gabapentin using whole-cell recording and multiphoton Ca(2+) imaging.
  • 1) We found that gabapentin and baclofen induced inwardly rectifying K(+) currents (K(Gbp) and K(Bac), respectively), sensitive to Ba(2+) and Cs(+).
  • 3) K(Gbp), K(Bac), and K(IR) currents showed some differences in sensitivity to Ba(2+) and Cs(+), indicating the possible activation of distinct Kir3 currents, independent of K(IR), by gabapentin and baclofen.
  • 4) Gabapentin inhibition of Ca(2+) channels was abolished by omega-conotoxin GVIA, but not by omega-agatoxin IVA and nimodipine, indicating a predominant action of gabapentin on N-type Ca(2+) channels.
  • 5) Gabapentin actions were linked to activation of pertussis toxin-sensitive G-proteins since N-ethylmaleimide (NEM) blocked K(Gbp) activation and Ca(2+) channel inhibition by gabapentin.
  • The anticonvulsant actions of gabapentin in hippocampal cells may thus involve GABA(B) receptor coupling to G-proteins and modulation of Kir3 and N-type Ca(2+) channels.
  • [MeSH-major] Acetates / pharmacology. Amines. Anticonvulsants / pharmacology. Calcium Channels, N-Type / drug effects. Cyclohexanecarboxylic Acids. Hippocampus / drug effects. Potassium Channels / drug effects. Potassium Channels, Inwardly Rectifying. Pyramidal Cells / drug effects. Receptors, GABA-B / drug effects. gamma-Aminobutyric Acid
  • [MeSH-minor] Action Potentials / drug effects. Action Potentials / physiology. Animals. Baclofen / pharmacology. Barium / pharmacology. Calcium Channel Blockers / pharmacology. Cell Membrane / drug effects. Cell Membrane / metabolism. Cesium / pharmacology. Epilepsy / drug therapy. Epilepsy / metabolism. Epilepsy / physiopathology. Ethylmaleimide / pharmacology. G Protein-Coupled Inwardly-Rectifying Potassium Channels. GTP-Binding Proteins / drug effects. GTP-Binding Proteins / metabolism. Male. Organ Culture Techniques. Rats. Rats, Sprague-Dawley. omega-Conotoxin GVIA / pharmacology

  • Hazardous Substances Data Bank. GABAPENTIN .
  • Hazardous Substances Data Bank. Barium, Elemental .
  • Hazardous Substances Data Bank. CESIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12923812.001).
  • [ISSN] 0887-4476
  • [Journal-full-title] Synapse (New York, N.Y.)
  • [ISO-abbreviation] Synapse
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 0 / Amines; 0 / Anticonvulsants; 0 / Calcium Channel Blockers; 0 / Calcium Channels, N-Type; 0 / Cyclohexanecarboxylic Acids; 0 / G Protein-Coupled Inwardly-Rectifying Potassium Channels; 0 / Potassium Channels; 0 / Potassium Channels, Inwardly Rectifying; 0 / Receptors, GABA-B; 1KSV9V4Y4I / Cesium; 24GP945V5T / Barium; 56-12-2 / gamma-Aminobutyric Acid; 6CW7F3G59X / gabapentin; 92078-76-7 / omega-Conotoxin GVIA; EC 3.6.1.- / GTP-Binding Proteins; H789N3FKE8 / Baclofen; O3C74ACM9V / Ethylmaleimide
  •  go-up   go-down


33. Hattori N, Sakakibara T, Kajiyama N, Igarashi T, Maeda M, Murakami S: Enhanced microbial biomass assay using mutant luciferase resistant to benzalkonium chloride. Anal Biochem; 2003 Aug 15;319(2):287-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To provide a highly sensitive assay, the concentration of benzalkonium chloride (BAC) in the ATP extractant was optimized by using a mutant luciferase resistant to BAC.
  • The use of 0.2% BAC, which was acceptable for the luciferase, simultaneously achieved the maximum extraction of intracellular ATP from microorganisms and the inactivation of the ATP-eliminating enzymes for removal of extracellular ATP.
  • The yeast cell of Saccharomyces cerevisiae IFO 10217 could be detected at 1CFU/ml.
  • With 54 kinds of microorganisms, the average ATP extraction efficiency compared to the trichloroacetic acid extraction method was 81.0% in 24 strains among gram-negative bacteria, 99.4% in 13 strains among gram-positive bacteria, and 97.0% in 17 strains among yeast.
  • [MeSH-minor] Colony Count, Microbial. Drug Resistance, Bacterial. Gram-Negative Bacteria / growth & development. Gram-Negative Bacteria / metabolism. Gram-Positive Bacteria / growth & development. Gram-Positive Bacteria / metabolism. Kinetics. Luminescent Measurements. Trichloroacetic Acid / chemistry

  • Hazardous Substances Data Bank. TRICHLOROACETIC ACID .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12871724.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzalkonium Compounds; 5V2JDO056X / Trichloroacetic Acid; 8L70Q75FXE / Adenosine Triphosphate; EC 1.13.12.- / Luciferases
  •  go-up   go-down


34. Bergenstrom A, Go V, Nam LV, Thuy BT, Celentano DD, Frangakis C, Quan VM: Return to post-test counselling by out-of-treatment injecting drug users participating in a cross-sectional survey in north Vietnam. AIDS Care; 2007 Aug;19(7):935-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Return to post-test counselling by out-of-treatment injecting drug users participating in a cross-sectional survey in north Vietnam.
  • Our study assessed factors associated with return to post-test counselling among 309 out-of-treatment injecting drug users who underwent VCT as part of a cross-sectional survey in Bac Ninh, Vietnam during August and September 2003.
  • In a multivariate analysis, higher return rate was associated with residence in Bac Ninh town centre (adjusted OR=1.9; CI=1.1-3.1).
  • [MeSH-minor] AIDS Serodiagnosis. Adolescent. Adult. Cross-Sectional Studies. Female. Health Knowledge, Attitudes, Practice. Humans. Male. Middle Aged. Multivariate Analysis. Risk Factors. Substance Abuse, Intravenous. Vietnam. Voluntary Programs

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Counseling and Testing .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712699.001).
  • [ISSN] 0954-0121
  • [Journal-full-title] AIDS care
  • [ISO-abbreviation] AIDS Care
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 1R01 MH64895
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


35. Ronen A, Chassidim HS, Gershon P, Parmet Y, Rabinovich A, Bar-Hamburger R, Cassuto Y, Shinar D: The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. Accid Anal Prev; 2010 Nov;42(6):1855-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Driving under the influence of drugs (DUID) is one of the main causes of car accidents.
  • Alcohol and marijuana are the most popular drugs among recreational users.
  • Many classify these drugs as "Light" drugs and therefore allow themselves to drive after consuming them.
  • 1) to investigate the effect of alcohol (BAC=0.05%), THC (13 mg) and their combination on driving and non-driving tasks.
  • 2) to investigate the extent to which people are willing to drive based on their subjective sensations and their perceived effects of the drugs.
  • [MeSH-major] Accidents, Traffic / prevention & control. Accidents, Traffic / psychology. Alcoholic Intoxication / psychology. Attitude. Automobile Driving / psychology. Dronabinol / adverse effects. Marijuana Smoking / adverse effects. Marijuana Smoking / psychology. Psychomotor Performance / drug effects
  • [MeSH-minor] Adult. Arousal / drug effects. Attention / drug effects. Drug Synergism. Ethanol / blood. Female. Health Knowledge, Attitudes, Practice. Humans. Male. Pain Measurement. Problem Solving / drug effects

  • Hazardous Substances Data Bank. delta 9-Tetrahydrocannabinol .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20728636.001).
  • [ISSN] 1879-2057
  • [Journal-full-title] Accident; analysis and prevention
  • [ISO-abbreviation] Accid Anal Prev
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3K9958V90M / Ethanol; 7J8897W37S / Dronabinol
  •  go-up   go-down


36. Frère SG, Lüthi A: Pacemaker channels in mouse thalamocortical neurones are regulated by distinct pathways of cAMP synthesis. J Physiol; 2004 Jan 1;554(Pt 1):111-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activation of beta-adrenergic receptors with (-)-isoproterenol (Iso) led to a small steady enhancement of Ih amplitude, whereas activation of GABAB receptors with (+/-)-Baclofen (Bac) reduced Ih, consistent with an up- and down-regulation of basal cAMP levels, respectively.
  • In contrast, a transient (taudecay, approximately 200 s), supralinear up-regulation of Ih was observed upon coapplication of Iso and Bac that was larger than that observed with Iso alone.
  • GABA, in the presence of the GABAA antagonist picrotoxin, mimicked, whereas N-ethylmaleimide, an inhibitor of Gi-proteins, blocked the up-regulation, supporting a requirement for GABAB receptor activation in the potentiation.
  • [MeSH-major] Biological Clocks / physiology. Cerebral Cortex / cytology. Cyclic AMP / metabolism. Neurons / physiology. Thalamus / cytology
  • [MeSH-minor] Adenylyl Cyclases / metabolism. Adrenergic beta-Agonists / pharmacology. Animals. Baclofen / pharmacology. Drug Synergism. Female. GABA Agonists / pharmacology. GTP-Binding Protein alpha Subunits, Gi-Go / metabolism. GTP-Binding Protein alpha Subunits, Gs / metabolism. Isoproterenol / pharmacology. Male. Mice. Neural Pathways. Patch-Clamp Techniques. Receptors, Neurotransmitter / metabolism. Up-Regulation / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 1985 Jan;27(1):53-9 [2981401.001]
  • [Cites] J Physiol. 1986 Mar;372:245-59 [2425084.001]
  • [Cites] J Neurochem. 1986 Sep;47(3):800-10 [2874192.001]
  • [Cites] J Biol Chem. 1987 Apr 5;262(10):4501-7 [3104318.001]
  • [Cites] Brain Res. 1988 Apr 5;445(2):303-13 [3370465.001]
  • [Cites] J Neurochem. 1989 Sep;53(3):753-8 [2547900.001]
  • [Cites] J Neurochem. 1989 Sep;53(3):989-91 [2547912.001]
  • [Cites] Prog Biophys Mol Biol. 1988;52(3):165-247 [2477870.001]
  • [Cites] J Neurochem. 1989 Dec;53(6):1941-51 [2553869.001]
  • [Cites] Nature. 1991 May 9;351(6322):145-7 [1709448.001]
  • [Cites] J Neurosci. 2000 Dec 15;20(24):9187-94 [11124996.001]
  • [Cites] Cell Mol Life Sci. 1999 Nov 15;56(7-8):683-700 [11212315.001]
  • [Cites] Annu Rev Physiol. 2001;63:235-57 [11181956.001]
  • [Cites] Neuroreport. 2001 Mar 5;12(3):591-5 [11234770.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:145-74 [11264454.001]
  • [Cites] Biochem Pharmacol. 2001 Jul 15;62(2):183-90 [11389876.001]
  • [Cites] Nature. 2001 Jun 14;411(6839):805-10 [11459060.001]
  • [Cites] Pflugers Arch. 2001 Sep;442(6):928-42 [11680627.001]
  • [Cites] J Physiol. 2001 Nov 1;536(Pt 3):677-92 [11691864.001]
  • [Cites] Nat Neurosci. 2001 Dec;4(12):1207-16 [11704764.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Jan 31;133(1):69-75 [11850065.001]
  • [Cites] J Physiol. 1990 Dec;431:319-42 [1712844.001]
  • [Cites] Science. 1991 Dec 6;254(5037):1500-3 [1962211.001]
  • [Cites] J Physiol. 1992 Feb;447:729-53 [1593463.001]
  • [Cites] Neuron. 1992 Sep;9(3):441-8 [1326294.001]
  • [Cites] Cell. 1992 Sep 18;70(6):869-72 [1525824.001]
  • [Cites] Neuron. 1993 Jan;10(1):83-8 [8381289.001]
  • [Cites] Neuron. 1993 Mar;10(3):427-35 [8384857.001]
  • [Cites] Science. 1993 Apr 9;260(5105):222-6 [7682336.001]
  • [Cites] J Physiol. 1993 Mar;462:753-64 [8392580.001]
  • [Cites] Trends Neurosci. 1994 Jan;17(1):37-41 [7511849.001]
  • [Cites] Neuron. 1994 Jul;13(1):179-86 [7519024.001]
  • [Cites] J Neurosci. 1994 Nov;14(11 Pt 2):7109-16 [7525895.001]
  • [Cites] J Neurophysiol. 1994 Nov;72(5):2360-7 [7884464.001]
  • [Cites] Annu Rev Physiol. 1996;58:299-327 [8815797.001]
  • [Cites] Neuron. 1996 Aug;17(2):297-308 [8780653.001]
  • [Cites] Brain Res. 1996 May 13;720(1-2):220-4 [8782915.001]
  • [Cites] J Physiol. 1996 Jun 15;493 ( Pt 3):845-54 [8799904.001]
  • [Cites] J Neurosci. 1996 Oct 15;16(20):6374-85 [8815916.001]
  • [Cites] Neuropharmacology. 1996 Jun;35(6):703-12 [8887979.001]
  • [Cites] Science. 1996 Nov 15;274(5290):1211-5 [8895474.001]
  • [Cites] J Neurophysiol. 1996 Oct;76(4):2262-70 [8899601.001]
  • [Cites] Eur J Neurosci. 1996 Oct;8(10):2098-110 [8921301.001]
  • [Cites] J Neurochem. 1997 Feb;68(2):498-506 [9003034.001]
  • [Cites] Nature. 1979 Jul 19;280(5719):235-6 [450140.001]
  • [Cites] J Neurosci. 1981 Aug;1(8):876-86 [7346592.001]
  • [Cites] Mol Pharmacol. 1984 Jan;25(1):24-8 [6323949.001]
  • [Cites] Annu Rev Neurosci. 1997;20:185-215 [9056712.001]
  • [Cites] J Physiol. 1997 May 1;500 ( Pt 3):643-51 [9161982.001]
  • [Cites] Adv Second Messenger Phosphoprotein Res. 1998;32:1-21 [9421583.001]
  • [Cites] Neuropharmacology. 1997 Oct;36(10):1405-15 [9423928.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 18;241(2):476-80 [9425295.001]
  • [Cites] Trends Neurosci. 1998 Jan;21(1):28-32 [9464683.001]
  • [Cites] J Neurosci. 1998 Mar 1;18(5):1671-8 [9464992.001]
  • [Cites] Nature. 1998 Jun 11;393(6685):587-91 [9634236.001]
  • [Cites] J Sleep Res. 1998;7 Suppl 1:24-9 [9682190.001]
  • [Cites] Neuron. 1998 Jul;21(1):9-12 [9697847.001]
  • [Cites] J Neurosci. 1998 Sep 15;18(18):7084-98 [9736632.001]
  • [Cites] Biochem Pharmacol. 1999 Mar 15;57(6):649-52 [10037449.001]
  • [Cites] Nat Neurosci. 1999 Jul;2(7):634-41 [10404196.001]
  • [Cites] Ann N Y Acad Sci. 1999 Apr 30;868:741-64 [10414361.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9391-6 [10430953.001]
  • [Cites] Biol Chem. 1999 Jul-Aug;380(7-8):975-80 [10494850.001]
  • [Cites] J Neurosci. 2000 Jul 1;20(13):5153-62 [10864972.001]
  • [Cites] J Neurosci. 2000 Jul 15;20(14):5264-75 [10884310.001]
  • [Cites] Brain Res Mol Brain Res. 2000 Sep 30;81(1-2):129-39 [11000485.001]
  • [Cites] J Neurosci. 2000 Oct 1;20(19):7478-88 [11007907.001]
  • [Cites] Eur J Neurosci. 2002 Jan;15(2):291-307 [11849296.001]
  • [Cites] Annu Rev Physiol. 2003;65:453-80 [12471170.001]
  • [Cites] J Physiol. 2003 May 1;548(Pt 3):765-75 [12651920.001]
  • [Cites] J Pharmacol Exp Ther. 1973 May;185(2):371-8 [4350039.001]
  • [Cites] J Pharmacol Exp Ther. 1975 Jan;192(1):22-32 [235635.001]
  • [Cites] Adv Cyclic Nucleotide Res. 1975;5:603-18 [165689.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Mar;81(5):1585-9 [6324206.001]
  • (PMID = 14678496.001).
  • [ISSN] 0022-3751
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / GABA Agonists; 0 / Receptors, Neurotransmitter; E0399OZS9N / Cyclic AMP; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gi-Go; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs; EC 4.6.1.1 / Adenylyl Cyclases; H789N3FKE8 / Baclofen; L628TT009W / Isoproterenol
  • [Other-IDs] NLM/ PMC1664735
  •  go-up   go-down


37. Cisler RA, Hargarten SH: Public health strategies to reduce and prevent alcohol-related illness, injury and death in Wisconsin and Milwaukee County. WMJ; 2000 Jun;99(3):71-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper illustrates the application of a Public Health Model toward understanding the nature and extent of alcohol-related problems and, in turn, provides examples of strategies targeted at reducing or preventing alcohol-related illness, injury and death in Wisconsin and Milwaukee County.
  • More specifically, data are provided detailing the widespread use and misuse of alcohol as well as the medical, behavioral and social problems associated with its use.
  • In sum, the public health model specifies three interrelated factors--the host, the agent or vehicle, and the environment--that focus strategies to reduce and/or prevent illness, injury and death.
  • The paper concludes with specific examples of alcohol-related public health strategies targeting the host (e.g., youth and families, minority groups), the agent/vehicle (e.g., alcohol content, labeling of containers, large containers), and the environment (e.g., motor vehicle operation BAC limits, zero tolerance laws, alcohol advertising).

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10927987.001).
  • [ISSN] 1098-1861
  • [Journal-full-title] WMJ : official publication of the State Medical Society of Wisconsin
  • [ISO-abbreviation] WMJ
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 44
  •  go-up   go-down


38. Dziadziuszko R, Siemiatkowska A, Limon J, Rzyman W, Jassem J, Bunn PA Jr, Varella-Garcia M, Hirsch FR: Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. J Thorac Oncol; 2007 Jan;2(1):91-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.
  • Bronchioalveolar carcinoma of the lung represents increasingly recognized clinical entity with relatively high probability of response to epidermal growth factor receptor tyrosine kinase inhibitors.
  • Patients who respond to these agents eventually develop resistance.
  • In this case report, we describe a patient who relapsed after gefitinib treatment and achieved unusual response to vinflunine single-agent chemotherapy, despite earlier progression to a combination of another vinca alkaloid and cisplatin.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease Progression. Female. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410018.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


39. Yanochko GM, Khoh-Reiter S, Evans MG, Jessen BA: Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cells. Toxicol In Vitro; 2010 Jun;24(4):1324-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preservatives are used in ocular medications to prevent microbial contamination.
  • The use of benzalkonium chloride (BAC), the most widely used preservative in ocular medications, has been scrutinized with a number of studies indicating its toxicity to monolayer cultures of corneal and conjunctival epithelial cells.
  • The purpose of this study was to evaluate and compare the toxicity of BAC and other preservatives and common components of ocular formulations on monolayer and stratified air-lifted cultures of Chang conjunctival cells.
  • Unlike monolayer cultures in which ocular medications containing BAC caused near complete loss of cell viability, stratified, air-lifted cultures were not affected by the presence of BAC in ocular medications with up to 30-min exposures.
  • These results demonstrate that stratification significantly affects cell viability of Chang conjunctival cells in response to preservatives and additives of ophthalmic preparations.
  • [MeSH-major] Benzalkonium Compounds / toxicity. Conjunctiva / drug effects. Preservatives, Pharmaceutical / toxicity
  • [MeSH-minor] Cell Line. Cell Survival / drug effects. Chlorhexidine / analogs & derivatives. Chlorhexidine / toxicity. Dose-Response Relationship, Drug. Edetic Acid / toxicity. Ophthalmic Solutions. Sorbic Acid / toxicity. Thimerosal / toxicity. Toxicity Tests

  • Hazardous Substances Data Bank. SORBIC ACID .
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. THIMEROSAL .
  • Hazardous Substances Data Bank. CHLORHEXIDINE .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20144907.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzalkonium Compounds; 0 / Ophthalmic Solutions; 0 / Preservatives, Pharmaceutical; 2225PI3MOV / Thimerosal; 9G34HU7RV0 / Edetic Acid; MOR84MUD8E / chlorhexidine gluconate; R4KO0DY52L / Chlorhexidine; X045WJ989B / Sorbic Acid
  •  go-up   go-down


40. Behr J, Degenkolb B, Krombach F, Vogelmeier C: Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J; 2002 May;19(5):906-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine.
  • Intracellular total glutathione (GSHt) and activation of bronchoalveolar lavage cells (BAC) obtained from 18 FA patients (9 males, aged 52+/-2 yrs), before and after 12 weeks of oral NAC (600 mg t.i.d.
  • Intracellular GSHt was decreased in FA (1.57+/-0.20 nmol 1x10(6) BAC(-1) versus 2.78+/-0.43 nmol x 10(6) BAC(-1)).
  • After NAC treatment, the intracellular GSHt content increased (1.57+/-0.20 versus 1.87+/-0.19 nmol x 1 x 10(6) BAC(-1)).
  • The spontaneous oxidative activity of BAC decreased after NAC treatment (2.7+/-0.8 versus 1.0+/-0.2 nmol x 1 x 10(6) BAC(-1) x h(-1)).
  • Interleukin-8 concentration (82.1+/-31.5 versus 80.0+/-22.6 pg x mL bronchoalveolar fluid (BALF), nonsignificant (NS)) and myeloperoxidase activity (1.93+/-0.64 versus 1.55+/-0.47 mU x mL(-1) BALF, NS) did not change significantly, but were found to be inversely correlated to intracellular GSHt.
  • This increase is associated with a mild reduction of oxidative activity but not with a reduction of bronchoalveolar cell activation in these patients.
  • [MeSH-major] Acetylcysteine / pharmacology. Bronchoalveolar Lavage Fluid / chemistry. Free Radical Scavengers / pharmacology. Glutathione / analysis. Pulmonary Fibrosis / physiopathology. Pulmonary Fibrosis / therapy
  • [MeSH-minor] Administration, Oral. Adult. Female. Humans. Interleukin-8 / analysis. Male. Middle Aged. Oxidative Stress / drug effects. Peroxidase / analysis. Prospective Studies


41. Bade J, van Grinsven E, Custers J, Hoekstra S, Ponstein A: T-DNA tagging in Brassica napus as an efficient tool for the isolation of new promoters for selectable marker genes. Plant Mol Biol; 2003 May;52(1):53-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the promoters provided sufficient expression of the nptII gene to yield transgenic plants when using kanamycin as selective agent.
  • Database searching (BLASTN) revealed that the promoters have significant homology with three Arabidopsis BAC clones, one Arabidopsis cDNA and one Brassica napus cDNA.
  • [MeSH-major] Brassica napus / genetics. DNA, Bacterial / genetics. Genes, Plant / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Base Sequence. Culture Techniques. DNA, Plant / chemistry. DNA, Plant / genetics. DNA, Plant / isolation & purification. Genetic Vectors / genetics. Glucuronidase / genetics. Glucuronidase / metabolism. Indoleacetic Acids / pharmacology. Molecular Sequence Data. Plants, Genetically Modified. Recombinant Fusion Proteins / drug effects. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Sequence Analysis, DNA. Transformation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3867-71 [8171004.001]
  • [Cites] Transgenic Res. 1993 Jan;2(1):33-47 [8513337.001]
  • [Cites] Plant Cell Rep. 1996 Apr;15(8):572-7 [24178520.001]
  • [Cites] Plant Mol Biol. 1991 Oct;17(4):837-51 [1655114.001]
  • [Cites] Plant Mol Biol. 1992 Jan;18(2):235-45 [1731986.001]
  • [Cites] Nat Biotechnol. 1996 May;14 (5):643-6 [9630959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Nov;86(21):8467-71 [2554318.001]
  • [Cites] Biotechniques. 1995 Sep;19(3):394-7, 400 [7495552.001]
  • [Cites] Gene. 1982 Oct;19(3):259-68 [6295879.001]
  • [Cites] Plant Mol Biol. 1998 Jan;36(2):205-17 [9484433.001]
  • [Cites] Plant Mol Biol. 1999 Sep;41(1):45-55 [10561067.001]
  • [Cites] Plant Cell. 1997 Oct;9(10):1713-25 [9368412.001]
  • [Cites] Plant Mol Biol. 1994 Jul;25(4):721-33 [8061322.001]
  • [Cites] Plant Mol Biol. 1999 Mar;39(5):979-90 [10344203.001]
  • [Cites] Cell. 1999 Apr 16;97(2):157-60 [10219236.001]
  • [Cites] Theor Appl Genet. 1993 Jun;86(5):621-8 [24193712.001]
  • [Cites] Gene. 1991 May 30;101(2):239-46 [1647361.001]
  • [Cites] EMBO J. 1989 Feb;8(2):343-50 [2656253.001]
  • [Cites] Biotechnology (N Y). 1992 Feb;10(2):141-4 [1369373.001]
  • [Cites] Plant J. 1993 Nov;4(5):863-73 [8275103.001]
  • [Cites] Biotechnology (N Y). 1990 Mar;8(3):217-21 [1366404.001]
  • [Cites] Mol Gen Genet. 1990 Jan;220(2):245-50 [2325623.001]
  • [Cites] Plant Mol Biol. 1993 Apr;22(1):129-42 [8388747.001]
  • [Cites] Development. 1991 Aug;112(4):1009-19 [1935694.001]
  • [Cites] Gene. 1993 Dec 22;136(1-2):87-94 [8294045.001]
  • [Cites] Mol Gen Genet. 1990 Nov;224(2):248-56 [2177527.001]
  • [Cites] EMBO J. 1986 Aug;5(8):1755-60 [16453695.001]
  • [Cites] Plant J. 2000 Feb;21(4):329-39 [10758484.001]
  • [Cites] Science. 1992 Jul 3;257(5066):72-4 [1621095.001]
  • [Cites] Plant Mol Biol. 1998 Jul;37(4):715-27 [9687074.001]
  • [Cites] Plant Physiol. 1989 Oct;91(2):694-701 [16667089.001]
  • [Cites] Plant Cell. 1998 Jan;10(1):75-89 [9477573.001]
  • [Cites] Plant Cell. 1999 Mar;11(3):323-34 [10072394.001]
  • [Cites] Plant J. 1994 Oct;6(4):567-77 [7987415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5212-6 [2052601.001]
  • [Cites] Plant Cell Rep. 1993 Feb;12(4):189-93 [24197017.001]
  • (PMID = 12825689.001).
  • [ISSN] 0167-4412
  • [Journal-full-title] Plant molecular biology
  • [ISO-abbreviation] Plant Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Plant; 0 / Indoleacetic Acids; 0 / Recombinant Fusion Proteins; 0 / T-DNA; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


42. Hejna JA, Timmers CD, Reifsteck C, Bruun DA, Lucas LW, Jakobs PM, Toth-Fejel S, Unsworth N, Clemens SL, Garcia DK, Naylor SL, Thayer MJ, Olson SB, Grompe M, Moses RE: Localization of the Fanconi anemia complementation group D gene to a 200-kb region on chromosome 3p25.3. Am J Hum Genet; 2000 May;66(5):1540-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fanconi anemia (FA) is a rare autosomal recessive disease manifested by bone-marrow failure and an elevated incidence of cancer.
  • These breaks and rearrangements are greatly elevated by treatment of FA cells with the use of DNA cross-linking agents.
  • A 1.2-Mb bacterial-artificial-chromosome (BAC)/P1 contig was constructed, bounded by the marker D3S3691 distally and by the gene ATP2B2 proximally.
  • BACs were then used as probes for FISH analyses, to map the extent of the deletions in four of the noncomplemented microcell hybrid cell lines.

  • Genetic Alliance. consumer health - Fanconi Anemia.
  • Genetic Alliance. consumer health - Anemia.
  • COS Scholar Universe. author profiles.
  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1979 May;120(2):417-21 [436969.001]
  • [Cites] Mutat Res. 1999 Sep 13;435(1):103-9 [10526221.001]
  • [Cites] J Cell Physiol. 1979 Nov;101(2):311-23 [511954.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6349-53 [6947234.001]
  • [Cites] Am J Hum Genet. 1982 Sep;34(5):794-810 [6812413.001]
  • [Cites] Am J Med Genet. 1983 Apr;14(4):767-72 [6846406.001]
  • [Cites] Hum Genet. 1985;70(3):236-42 [4018790.001]
  • [Cites] Eur J Cell Biol. 1985 May;37:240-2 [4029168.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Am J Hum Genet. 1991 Jan;48(1):1-15 [1985451.001]
  • [Cites] Hum Genet. 1991 Jan;86(3):256-60 [1997377.001]
  • [Cites] Nature. 1992 Apr 30;356(6372):763-7 [1574115.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8794-7 [1528894.001]
  • [Cites] Genomics. 1992 Oct;14(2):484-7 [1427863.001]
  • [Cites] Hum Genet. 1993 Oct 1;92(3):282-8 [8406436.001]
  • [Cites] Mutat Res. 1993 Oct;294(3):255-62 [7692265.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Feb 15;198(3):1143-52 [7906940.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2629-33 [8146166.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2486-91 [8162598.001]
  • [Cites] Hum Mol Genet. 1994 Jun;3(6):903-8 [7951234.001]
  • [Cites] EMBO J. 1995 Aug 1;14(15):3679-86 [7641687.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Jul 15;82(2):123-7 [7664241.001]
  • [Cites] Nat Genet. 1995 Nov;11(3):341-3 [7581463.001]
  • [Cites] Genomics. 1996 Apr 1;33(1):151-2 [8617505.001]
  • [Cites] Blood. 1996 Jul 1;88(1):49-58 [8704201.001]
  • [Cites] Genomics. 1996 Jun 1;34(2):213-8 [8661051.001]
  • [Cites] Genome Res. 1996 May;6(5):454-62 [8743995.001]
  • [Cites] Somat Cell Mol Genet. 1996 Mar;22(2):151-7 [8782494.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):320-3 [8896563.001]
  • [Cites] J Med Genet. 1996 Oct;33(10):842-7 [8933338.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Dec;17(4):269-72 [8946209.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2151-6 [9187114.001]
  • [Cites] Curr Biol. 1997 Jun 1;7(6):397-407 [9197244.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8010-5 [9223305.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8016-20 [9223306.001]
  • [Cites] Am J Hum Genet. 1997 Oct;61(4):940-4 [9382107.001]
  • [Cites] Science. 1997 Nov 28;278(5343):1612-5 [9374458.001]
  • [Cites] Nucleic Acids Res. 1998 Feb 15;26(4):1124-5 [9461477.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):82-5 [9666798.001]
  • [Cites] J Biol Chem. 1998 Jul 24;273(30):18693-6 [9668038.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):390-4 [9697703.001]
  • [Cites] Mol Cell. 1998 Aug;2(2):259-65 [9734364.001]
  • [Cites] Science. 1998 Oct 23;282(5389):744-6 [9784132.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):281-3 [9806548.001]
  • [Cites] Am J Hum Genet. 1999 May;64(5):1400-5 [10205272.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4662-7 [10493522.001]
  • [Cites] J Mol Biol. 1975 Nov 5;98(3):503-17 [1195397.001]
  • (PMID = 10762542.001).
  • [ISSN] 0002-9297
  • [Journal-full-title] American journal of human genetics
  • [ISO-abbreviation] Am. J. Hum. Genet.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 1PO1HL48546; United States / NCI NIH HHS / CA / CA56626; United States / NHGRI NIH HHS / HG / HG00470
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Genetic Markers; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Interleukin-1 Receptor-Associated Kinases; EC 3.2.2.- / N-Glycosyl Hydrolases; EC 3.2.2.23 / DNA-Formamidopyrimidine Glycosylase
  • [Other-IDs] NLM/ PMC1378015
  •  go-up   go-down


43. Mirzapoiazova T, Kolosova IA, Moreno L, Sammani S, Garcia JG, Verin AD: Suppression of endotoxin-induced inflammation by taxol. Eur Respir J; 2007 Sep;30(3):429-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathogenesis of acute lung injury includes transendothelial diapedesis of leukocytes into lung tissues and disruption of endothelial/epithelial barriers leading to protein-rich oedema.
  • It was hypothesised that the microtubule-stabilising agent, taxol, might attenuate inflammation and vascular leak associated with acute lung injury in vivo.
  • The effect of intravenously delivered taxol was assessed using a model of murine lung injury induced by intratracheal lipopolysaccharide (LPS) administration.
  • Parameters of lung injury and inflammation were assessed 18 h after treatment.
  • Intravenously delivered taxol significantly reduced inflammatory histological changes in lung parenchyma and parameters of LPS-induced inflammation: infiltration of proteins and inflammatory cells into bronchoalveolar lavage fluid, lung myeloperoxidase activity, and extravasation of Evans blue-labelled albumin into lung tissue.
  • In addition to lung proteins, intravenous taxol reduced accumulation of leukocytes in ascitic fluid in a model of LPS-induced peritonitis.
  • [MeSH-minor] Animals. Bronchoalveolar Lavage Fluid / immunology. Capillary Leak Syndrome / immunology. Capillary Leak Syndrome / pathology. Extravasation of Diagnostic and Therapeutic Materials / immunology. Extravasation of Diagnostic and Therapeutic Materials / pathology. Leukocyte Count. Lung / immunology. Lung / pathology. Mice. Mice, Inbred C57BL. Peritonitis / immunology. Peritonitis / pathology. Peroxidase / metabolism. Pulmonary Edema / immunology. Pulmonary Edema / pathology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537765.001).
  • [ISSN] 0903-1936
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL 067307; United States / NHLBI NIH HHS / HL / HL 083327; United States / NHLBI NIH HHS / HL / HL 58064; United States / NHLBI NIH HHS / HL / HL 80675
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Lipopolysaccharides; 0 / Tubulin Modulators; EC 1.11.1.7 / Peroxidase; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


44. Pauly A, Labbe A, Baudouin C, Liang H, Warnet JM, Brignole-Baudouin F: In vivo confocal microscopic grading system for standardized corneal evaluation: application to toxic-induced damage in rat. Curr Eye Res; 2008 Oct;33(10):826-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Rat corneas were instilled with 0.01-0.5% benzalkonium chloride (BAC) and examined using high-resolution in vivo confocal microscopy (HRT-II) to measure corneal thickness and characterize corneal damage patterns.
  • RESULTS: The scoring system revealed a dose-dependent effect of BAC and discriminated between high- and low-dose treatments.
  • [MeSH-major] Benzalkonium Compounds / toxicity. Cornea / drug effects. Corneal Diseases / chemically induced. Corneal Diseases / classification. Detergents / toxicity. Microscopy, Confocal
  • [MeSH-minor] Animals. Cell Count. Cell Size. Dose-Response Relationship, Drug. Male. Rats. Rats, Inbred Lew

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853316.001).
  • [ISSN] 1460-2202
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzalkonium Compounds; 0 / Detergents
  •  go-up   go-down


45. Archer F, Jacquier E, Lyon M, Chastang J, Cottin V, Mornex JF, Leroux C: Alveolar type II cells isolated from pulmonary adenocarcinoma: a model for JSRV expression in vitro. Am J Respir Cell Mol Biol; 2007 May;36(5):534-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar type II cells isolated from pulmonary adenocarcinoma: a model for JSRV expression in vitro.
  • Ovine pulmonary adenocarcinoma (OPA) is a naturally occurring cancer in sheep, with clinical, radiologic, and histopathologic features similar to that of human pneumonic-type bronchioloalveolar carcinoma.
  • JSRV (Jaagsiekte Sheep RetroVirus) is the etiologic agent of this contagious lung cancer in sheep.
  • Cells involved in the tumor derive from alveolar type II cells and Clara cells, epithelial cells of the distal respiratory tract.
  • These cells are the major site for viral expression in JSRV-infected animals.
  • Interestingly, the cellular pathways involved in the transformation process seem to be dependent of the origin and type of the cell used.
  • In order to investigate the specific interactions between JSRV and alveolar type II cells, we developed an in vitro experimental model in which lung epithelial cells were isolated from OPA and control lungs.
  • Cells in culture expressed alveolar type II cell specific markers such as surfactant protein (SP)-A, SP-C, and a high alkaline phosphatase activity.
  • Alveolar Type II cells derived from tumoral lungs showed a proliferative advantage and expressed the JSRV virus.
  • We thus report on the first in vitro system whereby alveolar type II cells from OPA were efficiently maintained in culture and stably expressed JSRV.
  • This novel experimental model will set up the stage for elucidating lung epithelial transformation in the JSRV-induced tumor.
  • [MeSH-major] Jaagsiekte sheep retrovirus / genetics. Lung Neoplasms / veterinary. Pulmonary Adenomatosis, Ovine / virology. Pulmonary Alveoli / pathology. Pulmonary Alveoli / virology
  • [MeSH-minor] Animals. Biomarkers / metabolism. Cell Aging. Cell Separation. Cells, Cultured. DNA, Viral / analysis. DNA, Viral / genetics. Gene Expression Regulation, Viral. Models, Biological. Pulmonary Surfactant-Associated Protein A / metabolism. Pulmonary Surfactant-Associated Protein C / metabolism. RNA-Directed DNA Polymerase / metabolism. Serial Passage. Sheep, Domestic

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17158359.001).
  • [ISSN] 1044-1549
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral; 0 / Pulmonary Surfactant-Associated Protein A; 0 / Pulmonary Surfactant-Associated Protein C; EC 2.7.7.49 / RNA-Directed DNA Polymerase
  •  go-up   go-down


46. Glover KJ, Weerapana E, Chen MM, Imperiali B: Direct biochemical evidence for the utilization of UDP-bacillosamine by PglC, an essential glycosyl-1-phosphate transferase in the Campylobacter jejuni N-linked glycosylation pathway. Biochemistry; 2006 Apr 25;45(16):5343-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Campylobacter jejuni has a general N-linked glycosylation pathway, encoded by the pgl gene cluster.
  • In C. jejuni, a heptasaccharide is transferred from an undecaprenyl pyrophosphate donor [GalNAc-alpha1,4-GalNAc-alpha1,4-(Glcbeta1,3)-GalNAc-alpha1,4-GalNAc-alpha1,4-GalNAc-alpha1,3-Bac-alpha1-PP-undecaprenyl, where Bac is bacillosamine (2,4-diacetamido-2,4,6-trideoxyglucose)] to the asparagine side chain of target proteins at the Asn-X-Ser/Thr motif.
  • In addition, we revealed that PglC does not accept uridine 5'-diphospho-N-acetylglucosamine or uridine 5'-diphospho-N-acetylgalactosamine as substrates but will accept uridine 5'-diphospho-6-hydroxybacillosamine, an analogue of bacillosamine that retains the C-6 hydroxyl functionality from the biosynthetic precursor.
  • The in vitro characterization of PglC as a bacillosamine 1-phosphoryl transferase provides direct evidence for the early steps in the C. jejuni N-linked glycosylation pathway, and the coupling of PglC with the latter glycosyltransferases (PglA, PglJ, PglH, and PglI) allows for the "one-pot" chemoenzymatic synthesis of the undecaprenyl pyrophosphate heptasaccharide donor.
  • [MeSH-minor] Carbohydrate Conformation. Catalysis / drug effects. Cloning, Molecular. Detergents / pharmacology. Gene Expression. Glycosylation. Polysaccharides / chemistry. Polysaccharides / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618123.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM039334; United States / NIGMS NIH HHS / GM / GM65699
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Detergents; 0 / Polysaccharides; 0 / UDP-bacillosamine; 0 / Uridine Diphosphate Sugars; EC 2.7.- / Phosphotransferases
  •  go-up   go-down


47. Walton JT, Hill DJ, Protheroe RG, Nevill A, Gibson H: Investigation into the effect of detergents on disinfectant susceptibility of attached Escherichia coli and Listeria monocytogenes. J Appl Microbiol; 2008 Jul;105(1):309-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Plate counts show that E. coli attached to stainless steel surfaces became significantly more susceptible to benzalkonium chloride (BAC) after treatment with sodium alkyl sulfate (SAS) and fatty alcohol ethoxylate (FAE).
  • No change in susceptibility was observed with Sodium dodecyl sulfate (SDS). L. monocytogenes became significantly less susceptible to BAC after treatment with SAS and SDS yet no change in susceptibility was observed with FAE.
  • Flow cytometry using the fluoresceine propidium iodide revealed significant increases in cell membrane permeability of both organisms by SAS and FAE, although the effect was much greater in E. coli.
  • CONCLUSIONS: In E. coli, detergents that increase susceptibility to BAC increase membrane permeability.
  • In L. monocytogenes, detergents that reduce susceptibility to BAC lower cell surface hydrophobicity.
  • SIGNIFICANCE AND IMPACT OF THE STUDY: Detergents can influence the sensitivity of pathogenic food borne micro-organisms to BAC.
  • [MeSH-major] Benzalkonium Compounds / pharmacology. Detergents / pharmacology. Disinfectants / pharmacology. Equipment Contamination / prevention & control. Escherichia coli / drug effects. Listeria monocytogenes / drug effects
  • [MeSH-minor] Bacterial Adhesion / drug effects. Colony Count, Microbial. Flow Cytometry. Food Microbiology. Hydrophobic and Hydrophilic Interactions. Microbial Sensitivity Tests. Stainless Steel

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410344.001).
  • [ISSN] 1365-2672
  • [Journal-full-title] Journal of applied microbiology
  • [ISO-abbreviation] J. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzalkonium Compounds; 0 / Detergents; 0 / Disinfectants; 12597-68-1 / Stainless Steel
  •  go-up   go-down


48. Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR, Gonzalez FJ: The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos; 2007 Feb;35(2):194-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A.
  • The most common clinical implication for the activation of the human pregnane X receptor (PXR) is the occurrence of drug-drug interactions mediated by up-regulated cytochromes P450 3A (CYP3A) isozymes.
  • Typical rodent models do not predict drug-drug interactions mediated by human PXR because of species differences in response to PXR ligands.
  • In the current study, a PXR-humanized mouse model was generated by bacterial artificial chromosome (BAC) transgenesis in Pxr-null mice using a BAC clone containing the complete human PXR gene and 5'- and 3'-flanking sequences.
  • In rifampicin-pretreated PXR-humanized mice, an approximately 60% decrease was observed for both the maximal midazolam serum concentration (C(max)) and the area under the concentration-time curve, as a result of a 3-fold increase in midazolam 1'-hydroxylation.
  • These results illustrate the potential utility of the PXR-humanized mice in the investigation of drug-drug interactions mediated by CYP3A and suggest that the PXR-humanized mouse model would be an appropriate in vivo tool for evaluation of the overall pharmacokinetic consequences of human PXR activation by drugs.
  • [MeSH-major] Cytochrome P-450 Enzyme System / physiology. Drug Interactions. Receptors, Steroid / genetics
  • [MeSH-minor] Animals. Humans. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Midazolam / pharmacokinetics. Models, Animal

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Midazolam .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17093002.001).
  • [ISSN] 0090-9556
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U19 AI067773-02; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Steroid; 0 / pregnane X receptor; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / CYP3A protein, mouse; R60L0SM5BC / Midazolam
  •  go-up   go-down


49. Hahn C, Islamian AP, Renz H, Nockher WA: Airway epithelial cells produce neurotrophins and promote the survival of eosinophils during allergic airway inflammation. J Allergy Clin Immunol; 2006 Apr;117(4):787-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Eosinophil-epithelial cell interactions make a major contribution to asthmatic airway inflammation.
  • Neurotrophin levels are increased in bronchoalveolar lavage fluid during allergic asthma.
  • OBJECTIVE: We sought to investigate the role of neurotrophins as inflammatory mediators in eosinophil-epithelial cell interactions during the allergic immune response.
  • METHODS: Neurotrophin expression in the lung was investigated by means of immunohistochemistry and ELISA in a mouse model of chronic experimental asthma.
  • Coculture experiments were performed with airway epithelial cells and bronchoalveolar lavage fluid eosinophils.
  • RESULTS: Neurotrophin levels increased continuously during chronic allergic airway inflammation, and airway epithelial cells were the major source of NGF and BDNF within the inflamed lung.
  • Lung eosinophils expressed the BDNF and NGF receptors tropomyosin-related kinase (Trk) A and TrkB, and coculture with airway epithelial cells resulted in enhanced epithelial neurotrophin production, as well as in prolonged survival of eosinophils.
  • [MeSH-minor] Animals. Asthma / etiology. Asthma / pathology. Asthma / physiopathology. Base Sequence. Brain-Derived Neurotrophic Factor / biosynthesis. Cell Survival. Cytokines / pharmacology. Epithelial Cells / drug effects. Epithelial Cells / physiology. Female. Inflammation Mediators / metabolism. Mice. Mice, Inbred BALB C. Models, Biological. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, trkA / biosynthesis. Receptor, trkB / biosynthesis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630935.001).
  • [ISSN] 0091-6749
  • [Journal-full-title] The Journal of allergy and clinical immunology
  • [ISO-abbreviation] J. Allergy Clin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor; 0 / Cytokines; 0 / Inflammation Mediators; 0 / Nerve Growth Factors; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, trkA; EC 2.7.10.1 / Receptor, trkB
  •  go-up   go-down


50. Alberts MJ, Latchaw RE, Selman WR, Shephard T, Hadley MN, Brass LM, Koroshetz W, Marler JR, Booss J, Zorowitz RD, Croft JB, Magnis E, Mulligan D, Jagoda A, O'Connor R, Cawley CM, Connors JJ, Rose-DeRenzy JA, Emr M, Warren M, Walker MD, Brain Attack Coalition: Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke; 2005 Jul;36(7):1597-616
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: To develop recommendations for the establishment of comprehensive stroke centers capable of delivering the full spectrum of care to seriously ill patients with stroke and cerebrovascular disease.
  • Recommendations were developed by members of the Brain Attack Coalition (BAC), which is a multidisciplinary group of members from major professional organizations involved with the care of patients with stroke and cerebrovascular disease.
  • Articles with information about clinical trials, meta-analyses, care guidelines, scientific guidelines, and other relevant clinical and research reports were examined and graded using established evidence-based medicine approaches for therapeutic and diagnostic modalities.
  • Evidence was also obtained from a questionnaire survey sent to leaders in cerebrovascular disease.
  • Members of BAC reviewed literature related to their field and graded the scientific evidence on the various diagnostic and treatment modalities for stroke.
  • Input was obtained from the organizations represented by BAC.
  • BAC met on several occasions to review each specific recommendation and reach a consensus about its importance in light of other medical, logistical, and financial factors.
  • CONCLUSIONS: There are a number of key areas supported by evidence-based medicine that are important for a comprehensive stroke center and its ability to deliver the wide variety of specialized care needed by patients with serious cerebrovascular disease.
  • Integration of these elements into a coordinated hospital-based program or system is likely to improve outcomes of patients with strokes and complex cerebrovascular disease who require the services of a comprehensive stroke center.
  • [MeSH-major] Cerebrovascular Disorders / therapy. Hospital Departments / organization & administration. Hospitals, Special / organization & administration. Stroke / diagnosis. Stroke / therapy
  • [MeSH-minor] Academic Medical Centers. Cerebral Hemorrhage / therapy. Clinical Protocols. Critical Care. Delivery of Health Care. Diagnostic Imaging. Education, Medical, Continuing. Emergency Medical Services. Health Planning Guidelines. Humans. Patient Education as Topic. Practice Guidelines as Topic. Rehabilitation

  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Stroke. 2005 Jul;36(7):1616-8 [15961714.001]
  • [CommentIn] Stroke. 2005 Nov;36(11):2344-5 [16224092.001]
  • (PMID = 15961715.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Franchini J, Ranucci E, Ferruti P, Rossi M, Cavalli R: Synthesis, physicochemical properties, and preliminary biological characterizations of a novel amphoteric agmatine-based poly(amidoamine) with RGD-like repeating units. Biomacromolecules; 2006 Apr;7(4):1215-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis, physicochemical properties, and preliminary biological characterizations of a novel amphoteric agmatine-based poly(amidoamine) with RGD-like repeating units.
  • A linear, amphoteric poly(amidoamine) nicknamed AGMA1, based on 4-aminobutylguanidine, or agmatine, was successfully prepared by Michael-type polyaddition of monoprotonated agmatine and 2,2-bis(acrylamido)acetic acid (BAC).
  • Copolymers between AGMA1 and the biocompatible poly(amidoamine) ISA23 (deriving from the polyaddition of 2-methylpiperazine with BAC) were also prepared.
  • The lack of hemolytic activity of AGMA1 even at acidic pH values seems typical of the agmatine-BAC sequences and may be ascribed to their RGD-like structure.
  • [MeSH-minor] Animals. Cell Line. Cell Proliferation / drug effects. Chemistry, Physical. Humans. Hydrogen-Ion Concentration. In Vitro Techniques. Molecular Structure. Physicochemical Phenomena

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16602741.001).
  • [ISSN] 1525-7797
  • [Journal-full-title] Biomacromolecules
  • [ISO-abbreviation] Biomacromolecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligopeptides; 0 / Polyamines; 70J407ZL5Q / Agmatine; 99896-85-2 / arginyl-glycyl-aspartic acid
  •  go-up   go-down


52. Walters ST, Vader AM, Harris TR: A controlled trial of web-based feedback for heavy drinking college students. Prev Sci; 2007 Mar;8(1):83-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Alcohol consumption has been a growing concern at U.S. colleges, particularly among first-year students, who are at increased risk for problems.
  • RESULTS: At 8 weeks, the feedback group showed a significant decrease in drinks per week and peak BAC over control.

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Health. 2000 Mar;48(5):235-8 [10778024.001]
  • [Cites] Psychol Addict Behav. 2000 Dec;14(4):342-55 [11130153.001]
  • [Cites] J Stud Alcohol. 2005 Jul;66(4):470-8 [16240554.001]
  • [Cites] Psychol Addict Behav. 2002 Mar;16(1):56-63 [11934087.001]
  • [Cites] J Consult Clin Psychol. 2000 Aug;68(4):728-33 [10965648.001]
  • [Cites] Addict Behav. 2004 Feb;29(2):281-97 [14732417.001]
  • [Cites] J Consult Clin Psychol. 1998 Aug;66(4):604-15 [9735576.001]
  • [Cites] J Consult Clin Psychol. 2004 Jun;72(3):434-47 [15279527.001]
  • [Cites] J Stud Alcohol Suppl. 2002 Mar;(14):23-39 [12022728.001]
  • [Cites] J Stud Alcohol. 1985 May;46(3):223-7 [4010299.001]
  • [Cites] Int J Addict. 1990 May;25(5):495-513 [2258257.001]
  • [Cites] Addict Behav. 2005 Jul;30(6):1168-82 [15925126.001]
  • [Cites] J Stud Alcohol. 1994 Nov;55(6):739-42 [7861803.001]
  • [Cites] J Consult Clin Psychol. 2004 Apr;72(2):155-64 [15065951.001]
  • [Cites] J Drug Educ. 1995;25(1):31-40 [7776148.001]
  • [Cites] J Am Coll Health. 2002 Mar;50(5):203-17 [11990979.001]
  • [Cites] J Consult Clin Psychol. 1992 Dec;60(6):974-9 [1460160.001]
  • [Cites] J Stud Alcohol. 2001 May;62(3):370-80 [11414347.001]
  • [Cites] J Am Coll Health. 2006 Jan-Feb;54(4):213-8 [16450845.001]
  • [Cites] J Drug Educ. 2000;30(3):361-72 [11092154.001]
  • [Cites] J Stud Alcohol. 2002 Mar;63(2):136-44 [12033690.001]
  • [Cites] J Pers Soc Psychol. 1986 Dec;51(6):1173-82 [3806354.001]
  • [Cites] Prev Sci. 2003 Dec;4(4):287-94 [14599000.001]
  • [Cites] J Stud Alcohol. 2002 Sep;63(5):559-67 [12380852.001]
  • [Cites] J Consult Clin Psychol. 1985 Apr;53(2):189-200 [3998247.001]
  • [Cites] J Stud Alcohol. 1989 Jan;50(1):30-7 [2927120.001]
  • (PMID = 17136461.001).
  • [ISSN] 1389-4986
  • [Journal-full-title] Prevention science : the official journal of the Society for Prevention Research
  • [ISO-abbreviation] Prev Sci
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Kenemans JL, Hebly W, van den Heuvel EH, Grent-'T-Jong T: Moderate alcohol disrupts a mechanism for detection of rare events in human visual cortex. J Psychopharmacol; 2010 Jun;24(6):839-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moderate doses of alcohol (blood alcohol concentration [BAC] of about 0.05%) may result in acute impairments at various levels of information processing.
  • A number of reports have documented detrimental effects of moderate alcohol on the mismatch negativity (MMN), the electrocortical manifestation of a rapid (100 ms poststimulus) mechanism dedicated to the detection of unexpected auditory change (e.g., Jääskeläinen, et al., 1995).
  • [MeSH-major] Attention / drug effects. Ethanol / pharmacology. Reaction Time / drug effects. Visual Cortex / drug effects. Visual Perception / drug effects
  • [MeSH-minor] Acoustic Stimulation. Adolescent. Adult. Analysis of Variance. Auditory Perception / drug effects. Brain Mapping. Electroencephalography. Evoked Potentials, Auditory / drug effects. Evoked Potentials, Visual / drug effects. Female. Humans. Male. Photic Stimulation. Psychomotor Performance / drug effects. Signal Processing, Computer-Assisted

  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028837.001).
  • [ISSN] 1461-7285
  • [Journal-full-title] Journal of psychopharmacology (Oxford, England)
  • [ISO-abbreviation] J. Psychopharmacol. (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


54. Andela VB, Altuwaijri S, Wood J, Rosier RN: Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists. FEBS Lett; 2005 Mar 14;579(7):1765-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists.
  • We demonstrate expression and coordinate induction of PPARgamma and lipogenic enzymes (HMG-CoA synthase, HMG-CoA reductase and fatty acid synthase) in a murine lung alveolar carcinoma cell line (Line 1) treated with the PPARgamma agonist troglitazone (TRO) [0-100 microM].
  • These findings, suggest that inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Chromans / pharmacology. Fatty Acids / metabolism. Neoplasms, Experimental / metabolism. PPAR gamma / agonists. Thiazolidinediones / pharmacology. Trimetazidine / pharmacology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / prevention & control. Adenosine Triphosphate / metabolism. Animals. Apoptosis. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Respiration / drug effects. Coenzyme A Ligases / genetics. Coenzyme A Ligases / metabolism. Fatty Acid Synthases / genetics. Fatty Acid Synthases / metabolism. Gene Expression / drug effects. Glucose / metabolism. Hydroxymethylglutaryl CoA Reductases / genetics. Hydroxymethylglutaryl CoA Reductases / metabolism. Hydroxymethylglutaryl-CoA Synthase. Lung Neoplasms / metabolism. Lung Neoplasms / prevention & control. Mice. Oxidation-Reduction / drug effects. Oxygen Consumption / drug effects

  • Hazardous Substances Data Bank. GLUCOSE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757673.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromans; 0 / Fatty Acids; 0 / PPAR gamma; 0 / Thiazolidinediones; 8L70Q75FXE / Adenosine Triphosphate; EC 1.1.1.- / Hydroxymethylglutaryl CoA Reductases; EC 2.3.1.85 / Fatty Acid Synthases; EC 2.3.3.10 / Hydroxymethylglutaryl-CoA Synthase; EC 6.2.1.- / Coenzyme A Ligases; I66ZZ0ZN0E / troglitazone; IY9XDZ35W2 / Glucose; N9A0A0R9S8 / Trimetazidine
  •  go-up   go-down


55. National Toxicology Program: NTP toxicology and carcinogensis studies of vanadium pentoxide (CAS No. 1314-62-1) in F344/N rats and B6C3F1 mice (inhalation). Natl Toxicol Program Tech Rep Ser; 2002 Dec;(507):1-343
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vanadium pentoxide was nominated for study by the National Cancer Institute as a representative of the metals class study.
  • Relative lung weights of 4 mg/m(3) or greater males and 2 mg/m(3) or greater females were significantly greater than those of the chamber controls.
  • Lavage fluid analysis indicated an inflammatory response in the lung that was either directly mediated by vanadium pentoxide or was secondary to lung damage induced by vanadium pentoxide exposure.
  • Absolute and relative lung weights of 4 mg/m(3) or greater males and all exposed groups of females and liver weights of 16 mg/m(3) males were significantly greater than those of the chamber controls.
  • Lavage fluid analysis indicated an inflammatory response in the lung that was either directly mediated by vanadium pentoxide or was secondary to lung damage induced by vanadium pentoxide exposure.
  • Absolute and relative lung weights were significantly greater for 4 mg/m(3) or greater males and females than for the chamber controls as were the relative lung weights of 2 mg/m(3) males.
  • The incidences of several nonneoplastic lesions of the lung and nose were significantly increased in males and females exposed to 2 mg/m(3) or greater.
  • Data from pulmonary function analyses indicated that a restrictive lung disease was present in male and female rats exposed to 4 mg/m(3) or greater, while an obstructive lung disease was present only in the 16 mg/m(3) groups.
  • Absolute and relative lung weights of males and females exposed to 4 mg/m(3) or greater were significantly greater than those of the chamber controls.
  • Some mice exposed to 2 or 4 mg/m(3) had inflammation of the lung, and all mice exposed to 8 or 16 mg/m(3) had inflammation and epithelial hyperplasia of the lung.
  • Alveolar and bronchiolar epithelial hyperplasia was observed in most rats exposed to 2 or 4 mg/m(3) on days 6 and 13.
  • Cell turnover rates were increased in the terminal bronchioles on days 6 and 13 and in the alveoli in the 4 mg/m(3) group on day 6 and in all exposed groups on day 13.
  • Assessment of lung vanadium concentrations suggested deposition and clearance exhibited linear kinetics over the exposure range studied.
  • Lung clearance half-times ranged from 4.42 to 4.96 days.
  • Alveolar and bronchiolar epithelial hyperplasia occurred with similar incidences and severities among the exposed groups on days 6 and 13, and time- and concentration-related increases in the incidences of interstitial inflammation and histiocytic infiltration also occurred in these groups.
  • Cell turnover rates were increased in the terminal bronchioles on day 6 and remained greater than those of the chamber controls on day 13.
  • In the alveoli, cell turnover rates were increased in an exposure concentration-related manner on day 13; cell turnover rates were increased only in the 8 mg/m(3) group on day 6.
  • Assessment of lung vanadium concentrations suggested deposition and clearance exhibited linear kinetics over the exposure range studied.
  • Lung clearance half-times ranged from 2.40 to 2.55 days.
  • Alveolar/bronchiolar neoplasms were present in exposed groups of male rats, and the incidences often exceeded the historical control ranges.
  • Alveolar/bronchiolar adenomas were present in 0.5 and 1 mg/m(3) females; one 2 mg/m(3) female also had an alveolar/bronchiolar carcinoma.
  • The incidence of alveolar/bronchiolar adenoma in the 0.5 mg/m(3) group was at the upper end of the historical control ranges.
  • Nonneoplastic lesions related to vanadium pentoxide exposure occurred in the respiratory system (lung, larynx, and nose) of male and female rats, and the severities of these lesions generally increased with increasing exposure concentration.
  • The incidences of alveolar/bronchiolar neoplasms were significantly increased in all groups of exposed males and females.
  • Nonneoplastic lesions related to vanadium pentoxide exposure occurred in the respiratory system (lung, larynx, and nose) of male and female mice, and the severities of these lesions generally increased with increasing exposure concentration.
  • MOLECULAR ONCOLOGY STUDIES: K-ras codon 12 mutation and loss of heterozygosity on chromosome 6 were detected in vanadium pentoxide-induced alveolar/bronchiolar carcinomas from mice.
  • CONCLUSIONS: Under the conditions of this 2-year inhalation study, there was some evidence of carcinogenic activity of vanadium pentoxide in male F344/N rats and equivocal evidence of carcinogenic activity of vanadium pentoxide in female F344/Nrats based on the occurrence of alveolar/bronchiolar neoplasms.
  • There was clear evidence of carcinogenic activity of vanadium pentoxide in male and female B6C3F1 mice based on increased incidences of alveolar/bronchiolar neoplasms. (ABSTRACT TRUNCATED)
  • [MeSH-major] Lung Neoplasms / chemically induced. Vanadium Compounds / toxicity
  • [MeSH-minor] Animals. Body Burden. Body Weight / drug effects. Dose-Response Relationship, Drug. Female. Humans. Inhalation Exposure. Lung / drug effects. Lung / pathology. Lung / physiology. Male. Mice. Pulmonary Alveoli / drug effects. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VANADIUM COMPOUNDS .
  • Hazardous Substances Data Bank. VANADIUM PENTOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12533744.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vanadium Compounds; BVG363OH7A / vanadium pentoxide
  •  go-up   go-down


56. Deng Z, Li Y, Xia R, Wang W, Huang X, Zhang L, Zhang S, Yang C, Zhang Y, Chen M, Xie Q: Structural analysis of 83-kb genomic DNA from Thellungiella halophila: sequence features and microcolinearity between salt cress and Arabidopsis thaliana. Genomics; 2009 Nov;94(5):324-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we determined a continuous sequence approximately 83 kb from a salt cress BAC clone, providing the first insight into the genomic feature for this species.
  • [MeSH-major] Brassicaceae / genetics. DNA, Plant / genetics. Genome, Plant / drug effects. Salt-Tolerance. Sequence Analysis, DNA
  • [MeSH-minor] Arabidopsis / drug effects. Arabidopsis / genetics. Arabidopsis / metabolism. Chromosomes, Artificial, Bacterial / genetics. Computational Biology / methods. DNA Transposable Elements. Gene Expression Profiling. Gene Expression Regulation, Plant. Molecular Sequence Data. Salt-Tolerant Plants / drug effects. Salt-Tolerant Plants / genetics. Sequence Inversion. Sodium Chloride / pharmacology. Terminal Repeat Sequences / genetics

  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646522.001).
  • [ISSN] 1089-8646
  • [Journal-full-title] Genomics
  • [ISO-abbreviation] Genomics
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ226510
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Transposable Elements; 0 / DNA, Plant; 451W47IQ8X / Sodium Chloride
  •  go-up   go-down


57. Tang B, Dutt K, Papale L, Rusconi R, Shankar A, Hunter J, Tufik S, Yu FH, Catterall WA, Mantegazza M, Goldin AL, Escayg A: A BAC transgenic mouse model reveals neuron subtype-specific effects of a Generalized Epilepsy with Febrile Seizures Plus (GEFS+) mutation. Neurobiol Dis; 2009 Jul;35(1):91-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A BAC transgenic mouse model reveals neuron subtype-specific effects of a Generalized Epilepsy with Febrile Seizures Plus (GEFS+) mutation.
  • Mutations in the voltage-gated sodium channel SCN1A are responsible for a number of seizure disorders including Generalized Epilepsy with Febrile Seizures Plus (GEFS+) and Severe Myoclonic Epilepsy of Infancy (SMEI).
  • To determine the effects of SCN1A mutations on channel function in vivo, we generated a bacterial artificial chromosome (BAC) transgenic mouse model that expresses the human SCN1A GEFS+ mutation, R1648H.
  • These results demonstrate that the effects of SCN1A mutations are cell type-dependent and that the R1648H mutation specifically leads to a reduction in interneuron excitability.
  • [MeSH-major] Chromosomes, Artificial, Bacterial / physiology. Disease Models, Animal. Epilepsy, Generalized / genetics. Mutation / genetics. Nerve Tissue Proteins / genetics. Seizures, Febrile / genetics. Sodium Channels / genetics
  • [MeSH-minor] Animals. Animals, Newborn. Arginine / genetics. Biophysical Phenomena. Cells, Cultured. Dose-Response Relationship, Drug. Electroencephalography / methods. Electromyography / methods. Histidine / genetics. Kainic Acid. Membrane Potentials / drug effects. Membrane Potentials / genetics. Membrane Potentials / physiology. Mice. Mice, Inbred C57BL. Mice, Transgenic. NAV1.1 Voltage-Gated Sodium Channel. Neurons / physiology. Patch-Clamp Techniques. RNA, Messenger / metabolism. Sodium Channel Blockers / pharmacology. Tetrodotoxin / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TETRODOTOXIN .
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2006 Mar 29;26(13):3465-73 [16571753.001]
  • [Cites] J Neurosci. 2006 Mar 8;26(10):2714-23 [16525050.001]
  • [Cites] J Neurosci. 2007 May 30;27(22):5903-14 [17537961.001]
  • [Cites] Genomics. 2007 Aug;90(2):225-35 [17544618.001]
  • [Cites] J Neurosci. 2007 Oct 10;27(41):11065-74 [17928448.001]
  • [Cites] Nat Genet. 2000 Apr;24(4):343-5 [10742094.001]
  • [Cites] J Comp Neurol. 2000 Jun 19;422(1):123-39 [10842222.001]
  • [Cites] J Physiol. 2000 Dec 15;529 Pt 3:533-9 [11118488.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):859-65 [11254444.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):866-73 [11254445.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Mar 31;88(1-2):37-53 [11295230.001]
  • [Cites] Genomics. 2001 Apr 1;73(1):56-65 [11352566.001]
  • [Cites] Am J Hum Genet. 2001 Jun;68(6):1327-32 [11359211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6384-9 [11371648.001]
  • [Cites] J Neurosci. 2001 Oct 1;21(19):7481-90 [11567038.001]
  • [Cites] Neuroscience. 2001;106(2):275-85 [11566500.001]
  • [Cites] Neuron. 2002 Jun 13;34(6):877-84 [12086636.001]
  • [Cites] Neuroscience. 2003;116(1):37-48 [12535936.001]
  • [Cites] Brain. 2003 Mar;126(Pt 3):531-46 [12566275.001]
  • [Cites] Epilepsia. 2003 Sep;44(9):1257-8 [12919402.001]
  • [Cites] Brain Dev. 2003 Oct;25(7):488-93 [13129592.001]
  • [Cites] Neurology. 2003 Sep 23;61(6):765-9 [14504318.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11147-52 [15263074.001]
  • [Cites] EMBO J. 1989 Dec 1;8(12):3611-6 [2555170.001]
  • [Cites] Neuron. 1989 Dec;3(6):695-704 [2561976.001]
  • [Cites] Mol Pharmacol. 1993 Apr;43(4):635-44 [8386312.001]
  • [Cites] J Biol Chem. 1995 Feb 17;270(7):3306-12 [7852416.001]
  • [Cites] J Neurosci. 1997 Oct 1;17(19):7330-8 [9295379.001]
  • [Cites] J Neurophysiol. 1998 Sep;80(3):1547-51 [9744958.001]
  • [Cites] J Neurobiol. 1999 Jun 15;39(4):547-57 [10380076.001]
  • [Cites] J Comp Neurol. 1999 Sep 20;412(2):342-52 [10441760.001]
  • [Cites] J Neurosci. 1999 Sep 1;19(17):7384-93 [10460245.001]
  • [Cites] Cell. 2004 Dec 29;119(7):1013-26 [15620359.001]
  • [Cites] J Neurosci. 2005 Jan 12;25(2):507-13 [15647496.001]
  • [Cites] Epilepsy Res. 2005 Feb;63(2-3):151-6 [15715999.001]
  • [Cites] J Comp Neurol. 2005 Dec 12;493(2):274-90 [16255028.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18177-82 [16326807.001]
  • [Cites] J Gen Physiol. 2006 Jan;127(1):1-14 [16380441.001]
  • [Cites] Nat Neurosci. 2006 Sep;9(9):1142-9 [16921370.001]
  • (PMID = 19409490.001).
  • [ISSN] 1095-953X
  • [Journal-full-title] Neurobiology of disease
  • [ISO-abbreviation] Neurobiol. Dis.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS046484-04; United States / NINDS NIH HHS / NS / R01 NS051834; United States / NINDS NIH HHS / NS / R01 NS051834-04; United States / NINDS NIH HHS / NS / NS 48336; United States / NINDS NIH HHS / NS / NS 051834; United States / NINDS NIH HHS / NS / R01 NS048336; Italy / Telethon / / GGP07277; United States / NINDS NIH HHS / NS / R01 NS046484; United States / NINDS NIH HHS / NS / NS 046484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NAV1.1 Voltage-Gated Sodium Channel; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / SCN1A protein, human; 0 / Scn1a protein, mouse; 0 / Sodium Channel Blockers; 0 / Sodium Channels; 4368-28-9 / Tetrodotoxin; 4QD397987E / Histidine; 94ZLA3W45F / Arginine; SIV03811UC / Kainic Acid
  • [Other-IDs] NLM/ NIHMS114716; NLM/ PMC2735447
  •  go-up   go-down


58. Scagliotti GV, Smit E, Bosquee L, O'Brien M, Ardizzoni A, Zatloukal P, Eberhardt W, Smid-Geirnaerdt M, de Bruin HG, Dussenne S, Legrand C, Giaccone G, European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG): A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer; 2005 Oct;50(1):91-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956).
  • PURPOSE: The incidence of bronchioloalveolar carcinoma (BAC) has risen steadily over the last decades along with the increasing frequency of adenocarcinomas.
  • BAC is relatively resistant to commonly used chemotherapy regimens.
  • A phase II study with single agent paclitaxel in patients with stages IIIB, IV or recurrent BAC was performed.
  • EXPERIMENTAL DESIGN: Patients with BAC with at least one target bidimensionally measurable lesion staged as unresectable stages IIIB, IV or recurrent disease, not previously irradiated; ECOG performance status 0-2; life expectancy greater than 3 months; age range between 18 and 75, received paclitaxel at a dose of 200 mg/m2 i.v. as 3h continuous infusion on day 1 every 21 days.
  • Only one partial response (PR) was observed among the 18 eligible patients who started protocol treatment, with a response rate of 5.6% (95% CI: 0.1-27.3%).
  • After an independent review, two PR were confirmed, for a response rate of 11.1% (95% CI: 1.4-34.7%); nine patients had stable disease (50.0%), three patients had progressive disease (11.1%) and four patients were not assessable (22.2%).
  • CONCLUSIONS: Paclitaxel as single agent in stages IIIB-IV BAC was well tolerated and manageable but of limited efficacy.
  • BAC should not be excluded from trials of new forms of chemotherapy.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019107.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


59. Ubels JL, Clousing DP, Van Haitsma TA, Hong BS, Stauffer P, Asgharian B, Meadows D: Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar as a gelling agent. Curr Eye Res; 2004 Jun;28(6):437-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar as a gelling agent.
  • PURPOSE: Pre-clinical studies of a new artificial tear product (Systane Lubricating Eye Drops Alcon Laboratories, Inc., Fort Worth, TX) containing the novel gelling agent hydroxypropyl-guar (HP-guar) and two demulcents, polyethylene glycol 400 (PEG) and propylene glycol (PG) were conducted to determine the ability of the product to protect ocular surface epithelial cells from desiccation in vivo and in vitro, and to promote recovery of the damaged corneal epithelial barrier in vivo.
  • Other leading artificial tear products were also evaluated as comparators to determine the relative effectiveness of different polymer systems.
  • Corneas of anesthetized rabbits were treated with the new artificial tear product and subjected to desiccation by holding the eyelids open for 2 hours with a speculum.
  • Control eyes were subjected to desiccation without application of a tear formulation.
  • To measure recovery of the corneal epithelium from damage, corneas of anethesthetized rabbits were exposed to 0.01% benzalkonium chloride (BAC) for 5 minutes to increase epithelial permeability.
  • In the desiccation and CF uptake experiments, the new tear product was also compared to a tear product formulation without HP-guar and to a commercially available artificial tear containing carboxymethyl cellulose (CMC) and Purite.
  • In a third set of experiments, immortalized human corneal epithelial cells and Chang conjunctival cells in culture were exposed to the PEG/PG/HP-guar tear product, the control formulation without HP-guar, a tear formulation preserved with BAC, or the artificial tear containing CMC/Purite for 15min.
  • Cell viability was determined using the MTT assay.
  • RESULTS: The in vivo desiccation model, showed that the new tear product, Systane, offered complete protection of the cornea from desiccation (methylene blue uptake not different than naïve control).
  • Following exposure to 0.01% BAC, the new artificial tear product also provided an environment in which the corneal epithelium recovered completely from damage (CF uptake not different than normal, untreated cornea).
  • Results from the in vitro desiccation procedure indicated that viability of corneal epithelial and Chang cells treated with the PEG/PG/HP-guar product was significantly greater than viability of cells treated with the tear product without HP-guar or the tear products containing BAC or CMC/Purite.
  • CONCLUSIONS: The tear product containing HP-guar, PEG 400 and propylene glycol satisfies several pre-clinical criteria for an appropriate artificial tear formulation.
  • The combination of ingredients in the formulation appears to provide an effective mucomimetic artificial tear product.
  • These pre-clinical data suggest that the product will be effective in providing superior relief for the dry eye sufferer.
  • [MeSH-major] Cellulose / analogs & derivatives. Cellulose / pharmacology. Cornea / drug effects. Dry Eye Syndromes / prevention & control. Galactans / pharmacology. Mannans / pharmacology. Ophthalmic Solutions / pharmacology. Polyethylene Glycols / pharmacology
  • [MeSH-minor] Animals. Cell Line. Cell Survival. Desiccation. Drug Evaluation, Preclinical. Drug Therapy, Combination. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Fluoresceins / metabolism. Humans. Humidity. Methylene Blue / metabolism. Plant Gums. Rabbits

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • Hazardous Substances Data Bank. GUAR GUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15512952.001).
  • [ISSN] 0271-3683
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fluoresceins; 0 / Galactans; 0 / Mannans; 0 / Ophthalmic Solutions; 0 / Plant Gums; 30IQX730WE / Polyethylene Glycols; 3301-79-9 / 6-carboxyfluorescein; 9004-34-6 / Cellulose; E89I1637KE / guar gum; RFW2ET671P / hydroxypropylcellulose; T42P99266K / Methylene Blue
  •  go-up   go-down


60. Lü JX, Peng Y, Meng ZF: [Eukaryotic expression and tumor-targeting modification of human mutated-IL-18 fusion gene]. Yi Chuan; 2005 Jul;27(4):557-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidermal growth factor (EGF) is an important growth factor that plays a central role in the regulation of cell cycle and differentiation.
  • In the present study, a fusion protein, consisting of EGFR binding domain fused to human IL18 mature peptide via a linker peptide of (Gly4ser) 3, was constructed and expressed in the insect cell line Sf9 using Bac-to-Bac baculovirus expression system.
  • Furthermore, EGF Receptor competitive test in human epithelial cancer A431 cell line showed that EGF- IL18 fusion protein can specifically bind with EGFR by competing with native EGF protein.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16120577.001).
  • [ISSN] 0253-9772
  • [Journal-full-title] Yi chuan = Hereditas
  • [ISO-abbreviation] Yi Chuan
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-18; 0 / Recombinant Fusion Proteins; 62229-50-9 / Epidermal Growth Factor; 82115-62-6 / Interferon-gamma; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


61. Straube F, Grenet O, Bruegger P, Ulrich P: Contact allergens and irritants show discrete differences in the activation of human monocyte-derived dendritic cells: consequences for in vitro detection of contact allergens. Arch Toxicol; 2005 Jan;79(1):37-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using human monocyte-derived dendritic cells (MoDC), this study was designed to refine the settings of a potential routine screening protocol for contact allergens and to investigate the so far poorly defined concentration dependency of contact allergen-specific effects.
  • MoDC were generated by 6 days of culture in the presence of IL-4 and GM-CSF and were then cultured for 24 or 48 h in medium with lipopolysaccharide (LPS), contact allergens [picrylsulphonic acid (TNBS), 1-chloro-2,4-dinitrobenzene (DNCB)] or irritants [sodium dodecyl sulphate (SDS), benzalkonium chloride (BAC)] that were free of detectable endotoxin contamination.
  • However, at partially cytotoxic concentrations, irritants also induced CD86 and HLA-DR expression, as confirmed by flow cytometry and quantitative RT-PCR.
  • Both SDS and BAC induced activation marker expression on surviving MoDC, when more than 50% of the MoDC population had been killed by the treatment.
  • [MeSH-major] Allergens / toxicity. Dendritic Cells / drug effects. Irritants / toxicity. Monocytes / cytology
  • [MeSH-minor] Antigens, CD / biosynthesis. Antigens, CD / immunology. Antigens, CD86. Cell Survival / drug effects. Cells, Cultured. Dermatitis, Allergic Contact / immunology. Dose-Response Relationship, Drug. Flow Cytometry. HLA-DR Antigens / biosynthesis. HLA-DR Antigens / immunology. Humans. Inhibitory Concentration 50. Lipopolysaccharides / immunology. Lipopolysaccharides / pharmacology. Membrane Glycoproteins / biosynthesis. Membrane Glycoproteins / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15372140.001).
  • [ISSN] 0340-5761
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Allergens; 0 / Antigens, CD; 0 / Antigens, CD86; 0 / CD86 protein, human; 0 / HLA-DR Antigens; 0 / Irritants; 0 / Lipopolysaccharides; 0 / Membrane Glycoproteins
  •  go-up   go-down


62. Monti D, Giannelli R, Chetoni P, Burgalassi S: Comparison of the effect of ultrasound and of chemical enhancers on transdermal permeation of caffeine and morphine through hairless mouse skin in vitro. Int J Pharm; 2001 Oct 23;229(1-2):131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effect of ultrasound (US) on permeation of two model drugs, caffeine (CAF) and morphine (MOR), through hairless mouse skin in vitro was compared with that of three chemical enhancers.
  • The chemical enhancers, tested in combination with propylene glycol (PG), were benzalkonium chloride (BAC) oleyl alcohol (OA) and alpha-terpineol (TER).
  • [MeSH-minor] Administration, Cutaneous. Animals. Buffers. Chromatography, High Pressure Liquid. Excipients. In Vitro Techniques. Male. Mice. Mice, Hairless. Propylene Glycols. Stimulation, Chemical. Surface-Active Agents. Ultrasonics

  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. CAFFEINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11604265.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Buffers; 0 / Central Nervous System Stimulants; 0 / Excipients; 0 / Narcotics; 0 / Propylene Glycols; 0 / Surface-Active Agents; 3G6A5W338E / Caffeine; 76I7G6D29C / Morphine
  •  go-up   go-down


63. MacNeil IA, Tiong CL, Minor C, August PR, Grossman TH, Loiacono KA, Lynch BA, Phillips T, Narula S, Sundaramoorthi R, Tyler A, Aldredge T, Long H, Gilman M, Holt D, Osburne MS: Expression and isolation of antimicrobial small molecules from soil DNA libraries. J Mol Microbiol Biotechnol; 2001 Apr;3(2):301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Natural products have been a critically important source of clinically relevant small molecule therapeutics.
  • Recently, increasing evidence has shown that the number of species cultivated from soil represents less than 1% of the total population, opening up the exciting possibility that these uncultured species may provide a large untapped pool from which novel natural products can be discovered.
  • We have constructed and expressed in E. coli a BAC (bacterial artificial chromosome) library containing genomic fragments of DNA (5-120kb) isolated directly from soil organisms (S-DNA).
  • These results show that genes involved in natural product synthesis can be cloned directly from S-DNA and expressed in a heterologous host, supporting the idea that this technology has the potential to provide novel natural products from the wealth of environmental microbial diversity and is a potentially important new tool for drug discovery.
  • [MeSH-major] Anti-Bacterial Agents / biosynthesis. DNA, Bacterial / genetics. Escherichia coli / genetics. Gene Library. Phylogeny. Soil Microbiology
  • [MeSH-minor] Amino Acid Sequence. Chromosomes, Artificial, Bacterial. DNA, Ribosomal / genetics. Enzymes / genetics. Molecular Sequence Data. Mutagenesis, Insertional. Open Reading Frames. Polymerase Chain Reaction. RNA, Ribosomal, 16S / genetics

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11321587.001).
  • [ISSN] 1464-1801
  • [Journal-full-title] Journal of molecular microbiology and biotechnology
  • [ISO-abbreviation] J. Mol. Microbiol. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / Enzymes; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


64. Johal BS, Laskin J: A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy. Expert Rev Anticancer Ther; 2006 Oct;6(10):1411-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy.
  • Bronchioloalveolar carcinoma is a fascinating and unusual variant of nonsmall-cell lung cancer that has a tendency towards an indolent course and to metastasize to the lung rather than distant organs.
  • Chemotherapy has shown activity in advanced bronchioloalveolar carcinoma but response rates remain low.
  • Epidermal growth factor receptor tyrosine kinase inhibitors have shown impressive activity against bronchioloalveolar carcinoma in trials.
  • New data suggest that epidermal growth factor receptor mutations and gene copy number may predict subsets of patients who could most benefit from these novel agents.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / administration & dosage. Drug Delivery Systems / trends. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069526.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 56
  •  go-up   go-down


65. Verster JC, Volkerts ER, Schreuder AH, Eijken EJ, van Heuckelum JH, Veldhuijzen DS, Verbaten MN, Paty I, Darwish M, Danjou P, Patat A: Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol; 2002 Dec;22(6):576-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Part 1 was a single-blind, two-period crossover design to determine the effects of a single dose of ethanol (0.03% < BAC < 0.05%) or ethanol-placebo on driving ability, memory, and psychomotor performance.
  • Part 2 was a double-blind, five-period crossover design to measure the effects of a middle-of-the-night administration of zaleplon 10 or 20 mg, zolpidem 10 or 20 mg, or placebo on driving ability 4 hours after administration and memory and psychomotor performance 6 hours after administration.
  • [MeSH-major] Acetamides / adverse effects. Automobile Driving. Hypnotics and Sedatives / pharmacology. Memory / drug effects. Psychomotor Performance / drug effects. Pyridines / adverse effects. Pyrimidines / adverse effects
  • [MeSH-minor] Adult. Cross-Over Studies. Dose-Response Relationship, Drug. Double-Blind Method. Ethanol / adverse effects. Ethanol / pharmacology. Female. Humans. Male. Single-Blind Method. Task Performance and Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12454557.001).
  • [ISSN] 0271-0749
  • [Journal-full-title] Journal of clinical psychopharmacology
  • [ISO-abbreviation] J Clin Psychopharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetamides; 0 / Hypnotics and Sedatives; 0 / Pyridines; 0 / Pyrimidines; 151319-34-5 / zaleplon; 3K9958V90M / Ethanol; 7K383OQI23 / zolpidem
  •  go-up   go-down


66. Ferk F, Misík M, Hoelzl C, Uhl M, Fuerhacker M, Grillitsch B, Parzefall W, Nersesyan A, Micieta K, Grummt T, Ehrlich V, Knasmüller S: Benzalkonium chloride (BAC) and dimethyldioctadecyl-ammonium bromide (DDAB), two common quaternary ammonium compounds, cause genotoxic effects in mammalian and plant cells at environmentally relevant concentrations. Mutagenesis; 2007 Nov;22(6):363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benzalkonium chloride (BAC) and dimethyldioctadecyl-ammonium bromide (DDAB), two common quaternary ammonium compounds, cause genotoxic effects in mammalian and plant cells at environmentally relevant concentrations.
  • In the present study, we tested two important representatives, namely, benzalkonium chloride (BAC) and dimethyldioctadecyl-ammonium bromide (DDAB) in four genotoxicity tests, namely, in the Salmonella/microsome assay with strains TA 98, TA 100 and TA 102, in the single-cell gel electrophoresis (SCGE) assay with primary rat hepatocytes and in micronucleus (MN) assays with peripheral human lymphocytes and with root tip cells of Vicia faba.
  • In the bacterial experiments, consistently negative results were obtained in the dose range between 0.001 and 110 microg per plate in the presence and absence of metabolic activation while significant induction of DNA migration was detected in the liver cells.
  • With BAC, a moderate but significant effect was found with an exposure concentration of 1.0 mg/l while DDAB caused damage at lower doses (0.3 mg/l).
  • The MN assays with blood cells were carried out under identical conditions to the SCGE experiments and a significant increase was seen at the highest dose levels (BAC: 1.0 and 3.0 mg/l; DDAB: 1 mg/l).
  • Both compounds also caused significant induction of MN as well as inhibition of cell division in plant cells, the lowest effective levels were 1.0 and 10 mg/l for DDAB and BAC, respectively.
  • Furthermore, the direct contact of humans to QAC-containing detergents and pharmaceuticals that contain substantially higher concentrations than those which were required to cause effects in eukaryotic cells in the present study should be studied further in regard to potential DNA-damaging effects in man.
  • [MeSH-major] Anti-Infective Agents, Local / toxicity. Benzalkonium Compounds / toxicity. Hepatocytes / drug effects. Lymphocytes / drug effects. Quaternary Ammonium Compounds / toxicity. Salmonella typhimurium / drug effects. Vicia faba / drug effects
  • [MeSH-minor] Adult. Animals. Cells, Cultured. Humans. Male. Micronucleus Tests. Mutagenicity Tests. Rats. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DIMETHYLDIOCTADECYLAMMONIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656635.001).
  • [ISSN] 0267-8357
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents, Local; 0 / Benzalkonium Compounds; 0 / Quaternary Ammonium Compounds; 251IW5I21C / dimethyldioctadecylammonium
  •  go-up   go-down


67. George WH, Davis KC, Norris J, Heiman JR, Schacht RL, Stoner SA, Kajumulo KF: Alcohol and erectile response: the effects of high dosage in the context of demands to maximize sexual arousal. Exp Clin Psychopharmacol; 2006 Nov;14(4):461-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address unresolved questions about alcohol and erectile functioning, the authors evaluated the effects of high blood alcohol concentrations (BACs) and arousal instructional demands on indices of penile circumference change and self-reported sexual arousal.
  • In Study 1, a target BAC of .10% (vs. .00%) attenuated peak circumference change from a neutral baseline but did not affect mean change, latency to arousal onset (a 5% increase in circumference from baseline), latency to peak achieved arousal, or subjective arousal, which correlated moderately with physiological indices.
  • In Study 2, instructions to maximize (vs. suppress) arousal increased peak and mean circumference change and interacted with a target BAC of .08% (vs. .00%) to influence latency to arousal onset.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychophysiology. 1977 May;14(3):266-74 [854556.001]
  • [Cites] J Abnorm Psychol. 1976 Dec;85(6):587-94 [993455.001]
  • [Cites] J Abnorm Psychol. 1978 Aug;87(4):418-30 [681614.001]
  • [Cites] J Abnorm Psychol. 1978 Dec;87(6):609-16 [739084.001]
  • [Cites] Biofeedback Self Regul. 1981 Jun;6(2):191-205 [7260188.001]
  • [Cites] J Abnorm Psychol. 1981 Feb;90(1):35-45 [7264053.001]
  • [Cites] Behav Res Ther. 1983;21(1):1-8 [6681954.001]
  • [Cites] J Psychosom Res. 1983;27(2):105-16 [6683315.001]
  • [Cites] J Pers Soc Psychol. 1983 Jul;45(1):188-98 [6886965.001]
  • [Cites] Behav Res Ther. 1983;21(4):365-73 [6626108.001]
  • [Cites] J Stud Alcohol. 1984 May;45(3):219-24 [6748663.001]
  • [Cites] J Stud Alcohol. 1985 Mar;46(2):107-15 [3990295.001]
  • [Cites] J Consult Clin Psychol. 1986 Apr;54(2):140-8 [3700800.001]
  • [Cites] Psychiatry Res. 1988 Jun;24(3):231-50 [3406241.001]
  • [Cites] Can J Psychiatry. 1988 Dec;33(9):800-8 [3214828.001]
  • [Cites] Psychol Bull. 1989 May;105(3):374-86 [2660179.001]
  • [Cites] Urology. 1990 May;35(5):399-404 [2336768.001]
  • [Cites] Arch Sex Behav. 1991 Feb;20(1):1-16 [2003767.001]
  • [Cites] Arch Sex Behav. 1992 Feb;21(1):17-31 [1546933.001]
  • [Cites] J Sex Marital Ther. 1994 Spring;20(1):14-23 [8169962.001]
  • [Cites] Arch Sex Behav. 1994 Dec;23(6):665-84 [7872861.001]
  • [Cites] Arch Sex Behav. 1995 Aug;24(4):369-82 [7661653.001]
  • [Cites] J Abnorm Psychol. 1997 Nov;106(4):598-607 [9358690.001]
  • [Cites] Annu Rev Sex Res. 2000;11:92-124 [11351836.001]
  • [Cites] Arch Sex Behav. 2004 Feb;33(1):43-53 [14739689.001]
  • [Cites] J Abnorm Psychol. 1976 Apr;85(2):225-34 [1254783.001]
  • [Cites] J Stud Alcohol. 1976 Mar;37(3):265-72 [4660.001]
  • [Cites] Psychopharmacologia. 1976 May 28;47(2):123-34 [1273207.001]
  • [Cites] Behav Res Ther. 1977;15(3):239-52 [339894.001]
  • (PMID = 17115874.001).
  • [ISSN] 1064-1297
  • [Journal-full-title] Experimental and clinical psychopharmacology
  • [ISO-abbreviation] Exp Clin Psychopharmacol
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA013565; United States / NIAAA NIH HHS / AA / R01 AA013565-03; United States / NIAAA NIH HHS / AA / AA13565
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 3K9958V90M / Ethanol
  • [Other-IDs] NLM/ NIHMS320179; NLM/ PMC3164266
  •  go-up   go-down


68. Wargo MJ, Hogan DA: Examination of Pseudomonas aeruginosa lasI regulation and 3-oxo-C12-homoserine lactone production using a heterologous Escherichia coli system. FEMS Microbiol Lett; 2007 Aug;273(1):38-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Escherichia coli pAHL-BAC cultures produced LasI-synthesized acylhomoserine lactones (AHLs) at levels and with kinetics similar to what is observed in cultures of P. aeruginosa strain PAO1.
  • Analysis of the lasI transcript also showed similar induction profiles in both the E. coli pAHL-BAC strain and P. aeruginosa.
  • Transposon mutagenesis of pAHL-BAC confirmed that transcriptional regulation by LasR is necessary for 3OC12HSL production, and showed that artificially increasing lasI transcript levels leads to higher levels of 3OC12HSL.
  • Previous studies have shown that P. aeruginosa 3OC12HSL inhibits hypha formation, but not growth, in Candida albicans, and the E. coli pAHL-BAC similarly inhibited filamentation when grown in coculture with the fungus.
  • It is proposed that this system will be useful for the study of factors that impact lasI regulation and 3OC12HSL production, and for the examination of the role of LasI-produced AHLs in bacterial interactions with other organisms.
  • [MeSH-major] 4-Butyrolactone / analogs & derivatives. Bacterial Proteins / genetics. Gene Expression Regulation, Bacterial. Pseudomonas aeruginosa / genetics
  • [MeSH-minor] Candida albicans / drug effects. Candida albicans / growth & development. Cloning, Molecular. Coculture Techniques. DNA Transposable Elements. DNA-Binding Proteins / physiology. Escherichia coli / genetics. Hyphae / drug effects. Kinetics. Mutagenesis, Insertional. RNA, Bacterial / biosynthesis. RNA, Messenger / biosynthesis. Trans-Activators / physiology. Transcription, Genetic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BUTYROLACTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559399.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20-RR018787; United States / NIAID NIH HHS / AI / T32 AI07519
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA Transposable Elements; 0 / DNA-Binding Proteins; 0 / LasI protein, Pseudomonas aeruginosa; 0 / LasR protein, Pseudomonas aeruginosa; 0 / RNA, Bacterial; 0 / RNA, Messenger; 0 / Trans-Activators; 1192-20-7 / homoserine lactone; OL659KIY4X / 4-Butyrolactone
  •  go-up   go-down


69. Zheng J, Zhang G, Lu Y, Fang F, He J, Li N, Talbi A, Zhang Y, Tang Y, Zhu J, Chen X: Effect of pulmonary surfactant and phospholipid hexadecanol tyloxapol on recombinant human-insulin absorption from intratracheally administered dry powders in diabetic rats. Chem Pharm Bull (Tokyo); 2010 Dec;58(12):1612-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hypoglycemic effect caused by PS or PHT containing rh-insulin was analyzed and the area above the curves (AAC) of serum glucose levels versus time, the minimum glucose concentration (C(min)), the time to C(min) (T(min)) and the pharmacological availability (PA%) were derived from the serum glucose profiles.
  • In addition, PHT as well as PS did not change the lactate dehydrogenase (LDH) activity, alkaline phosphatase (AKP) activity and N-acetyl-β-D-glucoaminidase (NAG) activity in bronch fluid which are sensitive indicators of acute toxicity to lung cells in bronchoalveolar lavage (BAL).
  • It is concluded that PS and PHT is a promising absorption enhancer for pulmonary delivery systems of large molecule drugs as rh-insulin.
  • [MeSH-major] Hypoglycemic Agents / pharmacokinetics. Insulin / pharmacokinetics. Phospholipids / chemistry. Polyethylene Glycols / chemistry. Pulmonary Surfactants / chemistry. Surface-Active Agents / chemistry
  • [MeSH-minor] Absorption. Acetylglucosaminidase / metabolism. Alkaline Phosphatase / metabolism. Animals. Blood Glucose / analysis. Chemistry, Pharmaceutical. Diabetes Mellitus, Experimental / drug therapy. Drug Administration Routes. Humans. Hydro-Lyases / metabolism. Lung Injury / metabolism. Powders / chemistry. Rats. Recombinant Proteins / metabolism. Recombinant Proteins / pharmacokinetics. Recombinant Proteins / therapeutic use. Time Factors. Trachea

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139264.001).
  • [ISSN] 1347-5223
  • [Journal-full-title] Chemical & pharmaceutical bulletin
  • [ISO-abbreviation] Chem. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Phospholipids; 0 / Powders; 0 / Pulmonary Surfactants; 0 / Recombinant Proteins; 0 / Surface-Active Agents; 30IQX730WE / Polyethylene Glycols; EC 3.1.3.1 / Alkaline Phosphatase; EC 3.2.1.52 / Acetylglucosaminidase; EC 4.2.1.- / Hydro-Lyases; EC 4.2.1.54 / lactate dehydratase; Y27PUL9H56 / tyloxapol
  •  go-up   go-down


70. Zhang W, Li H, Li Y, Zeng Z, Li S, Zhang X, Zou Y, Zhou T: Effective inhibition of HCMV UL49 gene expression and viral replication by oligonucleotide external guide sequences and RNase P. Virol J; 2010;7:100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The emergence of drug-resistant strains of HCMV has posed a need for the development of new drugs and treatment strategies.
  • Antisense molecules are promising gene-targeting agents for specific regulation of gene expression.
  • External guide sequences (EGSs) are oligonucleotides that consist of a sequence complementary to a target mRNA and recruit intracellular RNase P for specific degradation of the target RNA.
  • The UL49-deletion BAC of HCMV was significantly defective in growth in human foreskin fibroblasts.
  • Therefore, UL49 gene may serve as a potential target for novel drug development to combat HCMV infection.
  • Moreover, our study provides evidence that exogenous administration of a DNA-based EGS can be used as a potential therapeutic approach for inhibiting gene expression and replication of a human virus.
  • [MeSH-major] Cytomegalovirus / physiology. Cytomegalovirus Infections / virology. Down-Regulation / drug effects. Gene Expression Regulation, Viral / drug effects. Oligonucleotides / pharmacology. Ribonuclease P / metabolism. Viral Structural Proteins / genetics. Virus Replication / drug effects
  • [MeSH-minor] Cell Line. Humans

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2000 Jan;18(1):58-61 [10625392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5812-7 [10811889.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1425-8 [11563036.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6759-62 [11741968.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14223-8 [14623981.001]
  • [Cites] Cell Microbiol. 2004 Jun;6(6):499-508 [15104592.001]
  • [Cites] Hum Immunol. 2004 May;65(5):403-9 [15172438.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1269-73 [8122108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11115-9 [7479948.001]
  • [Cites] Nucleic Acids Res. 1996 Jul 15;24(14):2690-6 [8758997.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7327-32 [9636148.001]
  • [Cites] RNA. 1998 Jul;4(7):847-55 [9671057.001]
  • [Cites] Annu Rev Biochem. 1998;67:99-134 [9759484.001]
  • [Cites] Annu Rev Biochem. 1998;67:153-80 [9759486.001]
  • [Cites] RNA. 1998 Nov;4(11):1397-406 [9814760.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2005 Mar;37(3):210-4 [15756425.001]
  • [Cites] Yi Chuan Xue Bao. 2005 Nov;32(11):1205-12 [16318287.001]
  • [Cites] RNA. 2006 Jan;12(1):63-72 [16301604.001]
  • [Cites] Nucleic Acids Res. 2006;34(2):575-83 [16432261.001]
  • [Cites] J Virol. 2007 Oct;81(20):11267-81 [17686857.001]
  • [Cites] Biochim Biophys Acta. 2007 Nov-Dec;1769(11-12):603-12 [17976837.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2009 May;41(5):389-98 [19430703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9073-8 [15184661.001]
  • [Cites] Science. 1990 Aug 17;249(4970):783-6 [1697102.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8006-10 [1381505.001]
  • [Cites] Science. 1993 Aug 20;261(5124):1004-12 [8351515.001]
  • (PMID = 20482805.001).
  • [ISSN] 1743-422X
  • [Journal-full-title] Virology journal
  • [ISO-abbreviation] Virol. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oligonucleotides; 0 / Viral Structural Proteins; EC 3.1.26.5 / Ribonuclease P
  • [Other-IDs] NLM/ PMC2885339
  •  go-up   go-down


71. Patel JD: Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma. Clin Lung Cancer; 2004 Dec;6 Suppl 1:S43-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.
  • Bronchoalveolar carcinoma (BAC) is a previously uncommon subset of non-small-cell lung cancer (NSCLC) with unique epidemiology, pathology, clinical features, and natural history compared with other NSCLC subtypes.
  • Recent data indicate that the incidence of BAC is increasing.
  • Although many studies have reported that patients with BAC have prolonged survival, advanced BAC remains incurable, with most patients eventually dying of respiratory failure from progressive pulmonary involvement or intercurrent illness.
  • Previous limited data suggest that chemotherapy for BAC provides modest benefit; however, anecdotal reports of swift and durable responses after treatment with tyrosine kinase (TK) inhibitors of the epidermal growth factor receptor (EGFR) in patients with BAC have prompted further investigation in this subset of patients.
  • Furthermore, recent insights into mechanisms of drug sensitivity should impact future clinical trial design.
  • [MeSH-major] Adenocarcinoma / drug therapy. Intracellular Signaling Peptides and Proteins / therapeutic use. Lung Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Erlotinib Hydrochloride. Humans. Protein-Tyrosine Kinases / antagonists & inhibitors. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638957.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Intracellular Signaling Peptides and Proteins; 0 / Quinazolines; 0 / protein kinase modulator; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Number-of-references] 38
  •  go-up   go-down


72. Maeda N, Palmarini M, Murgia C, Fan H: Direct transformation of rodent fibroblasts by jaagsiekte sheep retrovirus DNA. Proc Natl Acad Sci U S A; 2001 Apr 10;98(8):4449-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Jaagsiekte sheep retrovirus (JSRV) is the causative agent of ovine pulmonary carcinoma, a unique animal model for human bronchioalveolar carcinoma.
  • Thus JSRV is necessary and sufficient for the development of ovine pulmonary carcinoma, but no data are available on the mechanisms of transformation.
  • Inspection of the JSRV genome reveals standard retroviral genes, but no evidence for a viral oncogene.
  • However, an alternate ORF in pol (orf-x) might be a candidate for a transforming gene.
  • Transfection of a mutated version of pCMVJS21 in which the orf-x protein was terminated by two stop codons also gave transformed foci.
  • This is an unusual example of a native retroviral structural protein with transformation potential.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Sep;74(18):8444-51 [10954544.001]
  • [Cites] Virology. 2000 Oct 10;276(1):161-8 [11022004.001]
  • [Cites] Onderstepoort J Vet Res. 1980 Mar;47(1):13-8 [7454230.001]
  • [Cites] Onderstepoort J Vet Res. 1980 Dec;47(4):275-80 [6164973.001]
  • [Cites] Am Rev Respir Dis. 1983 Jul;128(1):195-209 [6346979.001]
  • [Cites] Arch Virol. 1983;78(1-2):89-95 [6197047.001]
  • [Cites] Nature. 1985 Sep 12-18;317(6033):169-71 [2993921.001]
  • [Cites] Cell. 1986 Dec 26;47(6):851-9 [3465451.001]
  • [Cites] Nature. 1990 Feb 22;343(6260):762-4 [2154701.001]
  • [Cites] Mol Carcinog. 1992;5(2):140-54 [1554413.001]
  • [Cites] J Virol. 1992 Aug;66(8):4930-9 [1629959.001]
  • [Cites] Oncogene. 1993 Jul;8(7):1721-9 [8390035.001]
  • [Cites] J Virol. 1996 Mar;70(3):1618-23 [8627682.001]
  • [Cites] J Gen Virol. 1996 Dec;77 ( Pt 12):2991-8 [9000089.001]
  • [Cites] Vet Clin North Am Food Anim Pract. 1997 Mar;13(1):55-70 [9071746.001]
  • [Cites] Leukemia. 1997 Apr;11 Suppl 3:432-4 [9209415.001]
  • [Cites] Trends Microbiol. 1997 Dec;5(12):478-83 [9447659.001]
  • [Cites] Virology. 1999 Jun 5;258(2):333-43 [10366570.001]
  • [Cites] J Virol. 1999 Dec;73(12):10070-8 [10559321.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1089-109 [10582341.001]
  • [Cites] Virus Res. 2000 Jan;66(1):109-16 [10653922.001]
  • [Cites] J Virol. 2000 Apr;74(7):3037-45 [10708418.001]
  • [Cites] J Virol. 2000 May;74(10):4698-704 [10775607.001]
  • [Cites] J Virol. 2000 Jul;74(13):5776-87 [10846056.001]
  • [Cites] J Virol. 2000 Sep;74(17):8065-76 [10933716.001]
  • [Cites] J Virol. 1999 Aug;73(8):6964-72 [10400795.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4285-7 [11296277.001]
  • (PMID = 11296288.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082564; United States / NCI NIH HHS / CA / R01CA82564
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC31855
  •  go-up   go-down


73. Jones AW: Evidence-based survey of the elimination rates of ethanol from blood with applications in forensic casework. Forensic Sci Int; 2010 Jul 15;200(1-3):1-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reliable information about the elimination rate of alcohol (ethanol) from blood is often needed in forensic science and legal medicine when alcohol-related crimes, such as drunken driving or drug-related sexual assault are investigated.
  • The courts usually want to know the suspect's blood-alcohol concentration (BAC) at some earlier time, such as the time of driving.
  • Making these back calculations or retrograde extrapolations of BAC in criminal cases has many proponents and critics.
  • Ethanol is an example of a drug for which the Michaelis-Menten pharmacokinetic model applies and the Michaelis constant (k(m)) for Class I ADH is at a BAC of 2-10mg/100mL.
  • This means that the enzyme is saturated with substrate after the first few drinks and that zero-order kinetics is adequate to describe the declining phase of the BAC profile in most forensic situations (BAC>20mg/100mL).
  • The slope of the BAC declining phase is slightly steeper in women compared with men, which seems to be related to gender differences in liver weight in relation to lean body mass.
  • [MeSH-major] Central Nervous System Depressants / pharmacokinetics. Ethanol / pharmacokinetics. Forensic Medicine
  • [MeSH-minor] Alcohol Dehydrogenase / genetics. Alcohol Dehydrogenase / metabolism. Aldehyde Dehydrogenase / genetics. Aldehyde Dehydrogenase / metabolism. Algorithms. Automobile Driving / legislation & jurisprudence. Cytochrome P-450 CYP2E1 / metabolism. Drug Interactions. Drug-Related Side Effects and Adverse Reactions. Female. Genetic Variation. Humans. Male. Sex Factors. Street Drugs / adverse effects. Substance Abuse Detection. Substance Withdrawal Syndrome. Tissue Distribution

  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20304569.001).
  • [ISSN] 1872-6283
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 0 / Street Drugs; 3K9958V90M / Ethanol; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


74. Dubois S, Bédard M, Weaver B: The association between opioid analgesics and unsafe driving actions preceding fatal crashes. Accid Anal Prev; 2010 Jan;42(1):30-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we examined the impact of opioid analgesics on drivers (all had a confirmed BAC=0) involved in fatal crashes (1993-2006) using a case-control design based on data from the Fatality Analysis Reporting System.
  • We calculated adjusted odds ratios (ORs) of any UDA by medication exposure after controlling for age, sex, other medications, and driving record.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887141.001).
  • [ISSN] 1879-2057
  • [Journal-full-title] Accident; analysis and prevention
  • [ISO-abbreviation] Accid Anal Prev
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


75. O'Kane CM, McKeown SW, Perkins GD, Bassford CR, Gao F, Thickett DR, McAuley DF: Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome. Crit Care Med; 2009 Jul;37(7):2242-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome.
  • OBJECTIVES: Acute respiratory distress syndrome (ARDS) is characterized by alveolar-capillary barrier damage.
  • In the Beta Agonists in Acute Lung Injury Trial, intravenous salbutamol reduced extravascular lung water (EVLW) in patients with ARDS at day 4 but not inflammatory cytokines or neutrophil recruitment.
  • METHODS: MMP-1/-2/-3/-7/-8/-9/-12/-13 was measured in supernatants of distal lung epithelial cells, type II alveolar cells, and bronchoalveolar lavage (BAL) fluid from patients in the Beta Agonists in Acute Lung Injury study by multiplex bead array and tissue inhibitors of metalloproteinases (TIMPs)-1/-2 by enzyme-linked immunosorbent assay.
  • Subjects with an increase in BAL fluid MMP-9 during the 4-day period had lower EVLW measurements than those in whom MMP-9 fell (10 vs. 17 mL/kg, p = 0.004): change in lung water correlated inversely with change in MMP-9, r = -.54, p = 0.0296.
  • Salbutamol up-regulated MMP-9 and down-regulated TIMP-1/-2 secretion in vitro by distal lung epithelial cells.
  • Inhibition of MMP-9 activity in cultures of type II alveolar epithelial cells reduced wound healing.
  • MMP-9 activity is required for alveolar epithelial wound healing in vitro.
  • Data suggest MMP-9 may have a previously unrecognized beneficial role in reducing pulmonary edema in ARDS by improving alveolar epithelial healing.
  • [MeSH-major] Adrenergic beta-Agonists / pharmacology. Albuterol / pharmacology. Metalloproteases / metabolism. Pulmonary Alveoli / drug effects. Respiratory Distress Syndrome, Adult / enzymology
  • [MeSH-minor] Bronchoalveolar Lavage Fluid / chemistry. Bronchoalveolar Lavage Fluid / cytology. Cell Culture Techniques. Epithelial Cells / drug effects. Extravascular Lung Water / drug effects. Extravascular Lung Water / enzymology. Humans. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Tissue Inhibitor of Metalloproteinase-2 / metabolism

  • Genetic Alliance. consumer health - Acute Respiratory Distress Syndrome.
  • Hazardous Substances Data Bank. ALBUTEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19487934.001).
  • [ISSN] 1530-0293
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / DHCS/06/06/101; United Kingdom / Department of Health / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.- / Metalloproteases; QF8SVZ843E / Albuterol
  •  go-up   go-down


76. Aleksandrova AE, Makarov VG, Kuznetsov AS, Vishnevetskaia TP, Dmitrieva OL, Kurenkova TIu, Makarova MN: [Effectiveness and mechanism of action of a new plant complex drug in nonspecific inflammatory processes in the bronchopulmonary system]. Patol Fiziol Eksp Ter; 2003 Apr-Jun;(2):15-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effectiveness and mechanism of action of a new plant complex drug in nonspecific inflammatory processes in the bronchopulmonary system].
  • It is a balanced compound, rich in biologically active substances including essential oils and flavonoids, possessing a wide spectrum of pharmacological activity.
  • Also, bronchofit demonstrated a prominent antioxidative activity, an antibacterial action in relation to Str. pyogenes and Bac. cereus.
  • By a total complex of the activities bronchofit is a promising medicine against bronchopulmonary inflammation.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Bronchopneumonia / drug therapy. Plant Extracts / pharmacology
  • [MeSH-minor] Animals. Anti-Infective Agents / pharmacology. Anura. Bronchoalveolar Lavage Fluid. Disease Models, Animal. Drug Evaluation, Preclinical / methods. Epithelium / drug effects. Glycosaminoglycans / metabolism. Histamine / metabolism. In Vitro Techniques. Male. Mice. Microbial Sensitivity Tests. Palate / cytology. Palate / drug effects. Rats

  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12838766.001).
  • [ISSN] 0031-2991
  • [Journal-full-title] Patologicheskaia fiziologiia i èksperimental'naia terapiia
  • [ISO-abbreviation] Patol Fiziol Eksp Ter
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Glycosaminoglycans; 0 / Plant Extracts; 820484N8I3 / Histamine
  •  go-up   go-down


77. Hamard P, Blondin C, Debbasch C, Warnet JM, Baudouin C, Brignole F: In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol; 2003 Dec;241(12):1037-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells.
  • BACKGROUND: The mechanisms of trabecular cell loss in glaucoma patients are poorly understood.
  • In order to determine whether drug-induced apoptosis could be one of the mechanisms by which trabecular cells die in glaucoma, we evaluated the effect of benzalkonium-preserved (BAC+) or preservative-free (BAC-) antiglaucoma medications on apoptotic marker expression by cultured human trabecular meshwork (HTM) cells.
  • METHODS: Normal and glaucomatous trabecular cell lines were treated for 15 min with antiglaucoma drugs (1/100 and 1/10 dilutions): timolol BAC+ or BAC-, betaxolol BAC+ or BAC-, latanoprost BAC+ or pure BAC.
  • RESULTS: Results obtained in the two cell lines were similar for all tested drugs and criteria.
  • In a 1/100 dilution, unpreserved beta-blockers had no apoptotic effect, preserved beta-blockers and latanoprost significantly increased Apo2.7 expression only, while BAC significantly increased all three apoptotic markers.
  • When tested in a 1/10 dilution, all drugs except unpreserved timolol triggered a 2- to 3.5-fold increase in apoptotic features, whereas up to 95% of the cells underwent apoptosis upon treatment with BAC (representing a 9-fold increase over the background level).
  • Benzalkonium-containing beta-blockers and prostaglandin analogue triggered mild expression of one out of three apoptotic markers, while the pro-apoptotic effect observed with BAC appeared to be largely hindered by active compounds in the preserved eyedrops.
  • [MeSH-major] Antihypertensive Agents / pharmacology. Apoptosis. Benzalkonium Compounds / pharmacology. Biomarkers / analysis. Preservatives, Pharmaceutical / pharmacology. Trabecular Meshwork / drug effects
  • [MeSH-minor] Adolescent. Aged. Annexin A5 / metabolism. Betaxolol / pharmacology. Cells, Cultured. DNA / metabolism. Humans. Male. Membrane Proteins / metabolism. Microscopy, Confocal. Prostaglandins F, Synthetic / pharmacology. Timolol / pharmacology

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • Hazardous Substances Data Bank. TIMOLOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2525-33 [11581193.001]
  • [Cites] Lens Eye Toxic Res. 1989;6(1-2):141-56 [2562166.001]
  • [Cites] Curr Eye Res. 1994 Jan;13(1):51-63 [8156826.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1091-8 [10752946.001]
  • [Cites] Exp Eye Res. 1998 Dec;67(6):687-97 [9990333.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Mar;35(3):144-9 [10476910.001]
  • [Cites] Leukemia. 1998 Jul;12(7):1013-25 [9665184.001]
  • [Cites] J Ocul Pharmacol. 1991 Fall;7(3):243-52 [1686051.001]
  • [Cites] Surv Ophthalmol. 2002 Aug;47 Suppl 1:S6-12 [12204697.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1991 Mar;32(3):520-2 [2001926.001]
  • [Cites] Ophthalmology. 1984 Jun;91(6):564-79 [6462622.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1983 Mar;24(3):320-5 [6832907.001]
  • [Cites] Exp Eye Res. 1993 Nov;57(5):557-65 [8282042.001]
  • [Cites] Exp Eye Res. 1993 Jun;56(6):683-92 [8595810.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1981 Nov;21(5):714-27 [7298275.001]
  • [Cites] Curr Eye Res. 2000 Feb;20(2):85-94 [10617908.001]
  • [Cites] J Immunol. 1996 Nov 1;157(9):3980-7 [8892631.001]
  • [Cites] Eye (Lond). 1987;1 ( Pt 2):204-10 [3653434.001]
  • [Cites] Curr Eye Res. 1989 Nov;8(11):1121-30 [2612200.001]
  • [Cites] Exp Eye Res. 1992 Jun;54(6):879-83 [1521580.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1995 Apr;36(5):787-95 [7706026.001]
  • [Cites] J Exp Med. 1995 Nov 1;182(5):1597-601 [7595231.001]
  • [Cites] Exp Eye Res. 2001 Jan;72(1):79-86 [11133185.001]
  • [Cites] Exp Eye Res. 1989 Jul;49(1):1-12 [2759185.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Mar;42(3):642-52 [11222522.001]
  • [Cites] Br J Ophthalmol. 2002 Sep;86(9):1046-52 [12185136.001]
  • [Cites] Exp Eye Res. 1998 May;66(5):521-9 [9628799.001]
  • [Cites] Ophthalmology. 1999 Mar;106(3):556-63 [10080214.001]
  • [Cites] Eye (Lond). 1987;1 ( Pt 1):15-28 [3556655.001]
  • [Cites] Exp Eye Res. 1989 Oct;49(4):645-63 [2806429.001]
  • (PMID = 14605906.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antihypertensive Agents; 0 / Benzalkonium Compounds; 0 / Biomarkers; 0 / Membrane Proteins; 0 / Preservatives, Pharmaceutical; 0 / Prostaglandins F, Synthetic; 0 / antigen 7A6; 6Z5B6HVF6O / latanoprost; 817W3C6175 / Timolol; 9007-49-2 / DNA; O0ZR1R6RZ2 / Betaxolol
  •  go-up   go-down


78. Martin-García E, Darbra S, Pallarès M: Intrahippocampal allopregnanolone decreases voluntary chronic alcohol consumption in non-selected rats. Prog Neuropsychopharmacol Biol Psychiatry; 2007 May 9;31(4):823-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blood alcohol concentrations (BAC) were assessed before testing the effects of injections on alcohol consumption.
  • [MeSH-major] Alcohol Drinking / drug therapy. Anesthetics / administration & dosage. Conditioning, Operant / drug effects. Pregnanolone / administration & dosage
  • [MeSH-minor] Alcohols / administration & dosage. Alcohols / blood. Animals. Behavior, Animal. Choice Behavior / drug effects. Dose-Response Relationship, Drug. Drinking Behavior / drug effects. Food Deprivation. Glucose / metabolism. Hippocampus / drug effects. Hippocampus / physiology. Linear Models. Male. Pregnenolone / administration & dosage. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Alcohol.
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329001.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alcohols; 0 / Anesthetics; 04Y4D91RG0 / pregnenolone sulfate; 73R90F7MQ8 / Pregnenolone; BXO86P3XXW / Pregnanolone; IY9XDZ35W2 / Glucose
  •  go-up   go-down


79. do Canto-Pereira LH, de P A David I, Machado-Pinheiro W, Ranvaud RD: Effects of acute alcohol intoxication on visuospatial attention. Hum Exp Toxicol; 2007 Apr;26(4):311-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the alcohol group, participants received an alcohol dose of 0.4 g/kg so as to produce a blood alcohol concentration (BAC) in the range of 0.08% during the experiments.
  • [MeSH-major] Alcoholic Intoxication / psychology. Attention / drug effects. Space Perception / drug effects. Visual Perception / drug effects
  • [MeSH-minor] Adult. Central Nervous System Depressants / blood. Data Interpretation, Statistical. Ethanol / blood. Female. Humans. Male. Reaction Time / drug effects. Visual Fields

  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Hum Exp Toxicol. 2007 Aug;26(8):671
  • (PMID = 17615112.001).
  • [ISSN] 0960-3271
  • [Journal-full-title] Human & experimental toxicology
  • [ISO-abbreviation] Hum Exp Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Central Nervous System Depressants; 3K9958V90M / Ethanol
  •  go-up   go-down


81. Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, Nakamura Y, Isogai E, Hirata T, Yoshida Y, Todo S, Kaneko Y, Albertson DG, Pinkel D, Feuerstein BG, Nakagawara A: Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene; 2008 Jan 17;27(4):441-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted microarray-based comparative genomic hybridization (array-CGH) with a DNA chip carrying 2464 BAC clones to examine genomic aberrations of 236 neuroblastomas and used in-house cDNA microarrays for gene-expression profiling.
  • Thus, combined genomic and molecular signatures may categorize novel risk groups and confer new clues for allowing tailored or even individualized medicine to patients with neuroblastoma.
  • [MeSH-major] Gene Expression Profiling. Neuroblastoma / diagnosis. Neuroblastoma / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Child. Child, Preschool. Chromosome Aberrations. Chromosomes, Human, Pair 17. Cluster Analysis. Gene Amplification. Humans. Infant. Infant, Newborn. Nuclear Proteins / genetics. Oncogene Proteins / genetics. Prognosis. Risk. Survival Analysis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637744.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins
  •  go-up   go-down


82. Garcia SB, Demarzo MM, Vinhadeli WS, Llorach-Velludo MA, Zoteli J, Herrero CF, Zucoloto S: No reduction with ageing of the number of myenteric neurons in benzalkonium chloride treated rats. Neurosci Lett; 2002 Oct 4;331(1):66-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The number of myenteric neurons may be reduced by topical serosal application of benzalkonium chloride (BAC).
  • We studied the effects of ageing in the population of neurons that survive after the application of BAC.
  • Ten treated and ten control animals were killed at intervals of 2, 6, 12 and 18 months after the surgery.
  • We performed myenteric neurons counting in serially cut histological preparations of the descending colon.
  • The control animals revealed a continuous loss of myenteric neurons number with increasing of age.
  • Interestingly, contrary to control animals, the BAC-treated rats presented no neuron loss with ageing at any experimental time.
  • [MeSH-major] Aging. Benzalkonium Compounds / pharmacology. Myenteric Plexus / drug effects. Neurons / cytology. Neurons / drug effects
  • [MeSH-minor] Animals. Cell Count. Colon, Sigmoid / drug effects. Colon, Sigmoid / innervation. Male. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12359325.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Benzalkonium Compounds
  •  go-up   go-down


83. De Saint Jean M, Debbasch C, Brignole F, Warnet JM, Baudouin C: Relationship between in vitro toxicity of benzalkonium chloride (BAC) and preservative-induced dry eye. Adv Exp Med Biol; 2002;506(Pt A):697-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between in vitro toxicity of benzalkonium chloride (BAC) and preservative-induced dry eye.
  • [MeSH-major] Benzalkonium Compounds / toxicity. Dry Eye Syndromes / chemically induced. Preservatives, Pharmaceutical / toxicity
  • [MeSH-minor] Cell Line. Cell Survival / drug effects. Conjunctiva / drug effects. Conjunctiva / pathology. Conjunctiva / physiopathology. Dose-Response Relationship, Drug. Flow Cytometry. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613979.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzalkonium Compounds; 0 / Preservatives, Pharmaceutical
  •  go-up   go-down


84. Breitmeier D, Seeland-Schulze I, Hecker H, Schneider U: The influence of blood alcohol concentrations of around 0.03% on neuropsychological functions--a double-blind, placebo-controlled investigation. Addict Biol; 2007 Jun;12(2):183-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is a general agreement that blood alcohol concentrations (BACs) of about 0.05% result in impairment of the ability to drive.
  • In addition, there are only a few studies to date investigating low BACs.
  • The present study aims to investigate the extent and quality of cognitive changes in low BACs of around 0.03%.
  • During the trials the BAC was regulated to about 0.03%.
  • As part of the study a record was made of the general level of intelligence, subjective impairments, possible depressive symptoms, general ability to perform, vigilance, divided attention, response times and performance of memory.
  • Verbal intelligence, general performance, vigilance (optical stimuli), divided attention, vigilance towards acoustic stimuli and the general response time to acoustic and visual-acoustic sequential stimuli, and memory were not impaired significantly by a BAC of around 0.03%.
  • The total response and motor response time to optical stimuli as well as decision time about sequential optical stimuli were, however, significantly changed for BACs of around 0.03%.
  • In conclusion, the present results show that already in BACs of around 0.03%, particular cognitive functions which rely on perception and processing of visual information, are significantly impaired.
  • This was evident in the more complex and urgent tasks.
  • [MeSH-minor] Adult. Attention / drug effects. Auditory Perception / drug effects. Automobile Driving / psychology. Cross-Over Studies. Dose-Response Relationship, Drug. Double-Blind Method. Humans. Infusions, Intravenous. Male. Reaction Time / drug effects. Visual Perception / drug effects

  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508991.001).
  • [ISSN] 1355-6215
  • [Journal-full-title] Addiction biology
  • [ISO-abbreviation] Addict Biol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


85. Zheng B, Tomita H, Inoue T, Ike Y: Isolation of VanB-type Enterococcus faecalis strains from nosocomial infections: first report of the isolation and identification of the pheromone-responsive plasmids pMG2200, Encoding VanB-type vancomycin resistance and a Bac41-type bacteriocin, and pMG2201, encoding erythromycin resistance and cytolysin (Hly/Bac). Antimicrob Agents Chemother; 2009 Feb;53(2):735-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of VanB-type Enterococcus faecalis strains from nosocomial infections: first report of the isolation and identification of the pheromone-responsive plasmids pMG2200, Encoding VanB-type vancomycin resistance and a Bac41-type bacteriocin, and pMG2201, encoding erythromycin resistance and cytolysin (Hly/Bac).
  • Eighteen identical VanB-type Enterococcus faecalis isolates that were obtained from different hospitalized patients were examined for their drug resistance and plasmid DNAs.
  • Of the 18 strains, 12 strains exhibited resistance to erythromycin (Em), gentamicin (Gm), kanamycin (Km), tetracycline (Tc), and vancomycin (Van) and produced cytolysin (Hly/Bac) and a bacteriocin (Bac) active against E. faecalis strains.
  • Em and Van resistance was transferred individually to E. faecalis FA2-2 strains at a frequency of about 10(-4) per donor cell by broth mating.
  • The complete DNA sequence of pMG2200 (106,527 bp) showed that the plasmid carried a Tn1549-like element encoding vanB2-type resistance and the Bac41-like bacteriocin genes of pheromone-responsive plasmid pYI14.
  • This is the first report of the isolation and characterization of a pheromone-responsive highly conjugative plasmid encoding vanB resistance.
  • [MeSH-major] Anti-Bacterial Agents / pharmacology. Bacterial Proteins / genetics. Bacteriocins / genetics. Cross Infection / genetics. Cross Infection / microbiology. Drug Resistance, Bacterial / genetics. Enterococcus faecalis / genetics. Erythromycin / pharmacology. Gram-Positive Bacterial Infections / genetics. Gram-Positive Bacterial Infections / microbiology. Perforin / genetics. Pheromones / pharmacology. Plasmids / drug effects. Plasmids / genetics. Vancomycin Resistance / genetics
  • [MeSH-minor] Amino Acid Sequence. Blotting, Southern. Conjugation, Genetic. Culture Media. DNA Nucleotidyltransferases / genetics. DNA, Bacterial / biosynthesis. DNA, Bacterial / genetics. Electrophoresis, Gel, Pulsed-Field. Humans. Microbial Sensitivity Tests. Molecular Sequence Data

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • REBASE - The Restriction Enzyme Database. gene/protein/disease-specific - REBASE ref# 17109 .
  • Hazardous Substances Data Bank. Erythromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 1988 Sep;170(9):4343-52 [2842316.001]
  • [Cites] Antimicrob Agents Chemother. 1989 Sep;33(9):1588-91 [2554802.001]
  • [Cites] J Bacteriol. 1990 Jan;172(1):155-63 [2152897.001]
  • [Cites] J Bacteriol. 1990 May;172(5):2633-41 [2158976.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Plasmid. 1991 Sep;26(2):131-5 [1749819.001]
  • [Cites] J Bacteriol. 1992 May;174(10):3152-60 [1315730.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9020-4 [1384040.001]
  • [Cites] J Bacteriol. 1992 Dec;174(24):8172-7 [1459967.001]
  • [Cites] J Bacteriol. 1993 Jan;175(1):117-27 [8380148.001]
  • [Cites] Eur J Biochem. 1993 May 15;214(1):333-8 [8508803.001]
  • [Cites] FEMS Microbiol Lett. 1994 Jun 15;119(3):359-63 [8050717.001]
  • [Cites] J Bacteriol. 1994 Dec;176(23):7335-44 [7961506.001]
  • [Cites] Trends Microbiol. 1995 Jun;3(6):229-36 [7648031.001]
  • [Cites] J Bacteriol. 1995 Oct;177(19):5574-81 [7559345.001]
  • [Cites] J Bacteriol. 1996 Mar;178(5):1302-9 [8631706.001]
  • [Cites] J Bacteriol. 1996 Jun;178(12):3585-93 [8655558.001]
  • [Cites] Antimicrob Agents Chemother. 1997 Mar;41(3):702-5 [9056018.001]
  • [Cites] Annu Rev Microbiol. 1997;51:527-64 [9343359.001]
  • [Cites] J Bacteriol. 1997 Dec;179(23):7468-75 [9393713.001]
  • [Cites] J Bacteriol. 1997 Dec;179(24):7843-55 [9401046.001]
  • [Cites] Soc Appl Bacteriol Symp Ser. 1997;26:89S-99S [9436321.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Jan;42(1):202-5 [9449290.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Apr;42(4):963-4 [9559822.001]
  • [Cites] Antimicrob Agents Chemother. 1998 Aug;42(8):2150 [9722470.001]
  • [Cites] J Bacteriol. 1998 Sep;180(17):4426-34 [9721279.001]
  • [Cites] Infect Control Hosp Epidemiol. 1998 Aug;19(8):539-45 [9758052.001]
  • [Cites] Antimicrob Agents Chemother. 1999 May;43(5):1105-10 [10223921.001]
  • [Cites] J Bacteriol. 2005 Feb;187(3):1044-54 [15659682.001]
  • [Cites] J Bacteriol. 2005 Nov;187(22):7727-37 [16267297.001]
  • [Cites] Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S25-34 [16323116.001]
  • [Cites] J Clin Microbiol. 2007 Sep;45(9):2813-8 [17634295.001]
  • [Cites] Plasmid. 2007 Nov;58(3):205-27 [17590438.001]
  • [Cites] J Bacteriol. 2008 Mar;190(6):2075-85 [18203826.001]
  • [Cites] J Bacteriol. 2000 Feb;182(4):1062-73 [10648533.001]
  • [Cites] Microbiology. 2000 Jun;146 ( Pt 6):1481-9 [10846226.001]
  • [Cites] J Bacteriol. 2000 Jul;182(13):3816-25 [10850999.001]
  • [Cites] Curr Microbiol. 2000 Oct;41(4):257-61 [10977892.001]
  • [Cites] Mol Microbiol. 2000 Sep;37(6):1327-41 [10998166.001]
  • [Cites] Clin Microbiol Rev. 2000 Oct;13(4):686-707 [11023964.001]
  • [Cites] Appl Environ Microbiol. 2001 Apr;67(4):1628-35 [11282615.001]
  • [Cites] Jpn J Infect Dis. 2001 Feb;54(1):17-22 [11326124.001]
  • [Cites] Plasmid. 2001 Sep;46(2):117-27 [11591137.001]
  • [Cites] Nature. 2002 Jan 3;415(6867):84-7 [11780122.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Feb;46(2):525-7 [11796369.001]
  • [Cites] J Bacteriol. 2002 Sep;184(18):5187-93 [12193637.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3326-33 [12202574.001]
  • [Cites] Appl Environ Microbiol. 2002 Dec;68(12):6457-61 [12450878.001]
  • [Cites] Science. 2003 Mar 28;299(5615):2071-4 [12663927.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2569-76 [12791882.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2641-3 [12791892.001]
  • [Cites] J Bacteriol. 2003 Dec;185(23):7024-8 [14617670.001]
  • [Cites] Clin Infect Dis. 2004 Jan 1;38(1):78-85 [14679451.001]
  • [Cites] FEMS Microbiol Rev. 2004 Feb;28(1):79-100 [14975531.001]
  • [Cites] J Bacteriol. 1975 Nov;124(2):784-90 [810482.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Jul;75(7):3479-83 [98769.001]
  • [Cites] Plasmid. 1979 Jul;2(3):454-65 [113798.001]
  • [Cites] J Bacteriol. 1980 Mar;141(3):1366-74 [6245068.001]
  • [Cites] J Bacteriol. 1981 Jan;145(1):494-502 [6257641.001]
  • [Cites] J Bacteriol. 1980 Aug;143(2):966-70 [6782083.001]
  • [Cites] Microbiol Rev. 1981 Sep;45(3):409-36 [6272080.001]
  • [Cites] J Bacteriol. 1982 Dec;152(3):1220-30 [6292164.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Sep;80(17):5369-73 [6412228.001]
  • [Cites] J Bacteriol. 1984 Jun;158(3):777-83 [6327637.001]
  • [Cites] Infect Immun. 1984 Aug;45(2):528-30 [6086531.001]
  • [Cites] J Bacteriol. 1986 Mar;165(3):831-6 [3005240.001]
  • [Cites] Plasmid. 1986 May;15(3):230-41 [3012615.001]
  • [Cites] J Bacteriol. 1987 Aug;169(8):3473-81 [3038841.001]
  • [Cites] J Clin Microbiol. 1987 Aug;25(8):1524-8 [3114322.001]
  • [Cites] Lancet. 1988 Jan 2-9;1(8575-6):57-8 [2891921.001]
  • [Cites] N Engl J Med. 1988 Jul 21;319(3):157-61 [2968517.001]
  • (PMID = 19029325.001).
  • [ISSN] 1098-6596
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Proteins; 0 / Bacteriocins; 0 / Culture Media; 0 / DNA, Bacterial; 0 / Pheromones; 0 / VanB protein, Enterococcus; 0 / bacteriocin 41, Enteroccus faecalis; 126465-35-8 / Perforin; 63937KV33D / Erythromycin; EC 2.7.7.- / DNA Nucleotidyltransferases; EC 2.7.7.- / DNA relaxase
  • [Other-IDs] NLM/ PMC2630599
  •  go-up   go-down


86. Argiris A, Mittal N: Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer; 2004 Mar;43(3):317-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
  • PURPOSE: To evaluate the efficacy of single-agent gefitinib (Iressa, ZD1839), an oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as first-line compassionate use therapy for advanced non-small-cell Lung cancer (NSCLC).
  • RESULTS: Four of 22 evaluable patients (18%), two with adenocarcinomas and two with bronchioloalveolar carcinomas, had an objective response and five patients (23%) had stable disease.
  • Duration of response or stable disease was 3.5-22+ months.
  • The partial response plus stable disease rate by Eastern Cooperative Oncology Group (ECOG) performance status (PS) was 4/5 for PS 0 patients; 3/6 for PS 1-2 patients; and 2/14 for PS 3-4 patients.
  • Of seven patients who received chemotherapy subsequent to gefitinib, one had a partial response, three had stable disease, two progressed, and one was non-evaluable for response.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Enzyme Inhibitors / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Administration, Oral. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Protein-Tyrosine Kinases / antagonists & inhibitors. Survival Rate


87. Jacks S, Giguère S, Gronwall PR, Brown MP, Merritt KA: Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals. Am J Vet Res; 2001 Dec;62(12):1870-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals.
  • OBJECTIVE: To determine the pharmacokinetics of azithromycin and its concentration in body fluids and bronchoalveolar lavage cells in foals.
  • ANIMALS: 6 healthy 6- to 10-week-old foals.
  • A microbiologic assay was used to measure azithromycin concentrations in serum, peritoneal fluid, synovial fluid, pulmonary epithelial lining fluid (PELF), and bronchoalveolar (BAL) cells.
  • Bronchoalveolar cell and PELF concentrations were 15- to 170-fold and 1- to 16-fold higher than concurrent serum concentrations, respectively.
  • CONCLUSIONS AND CLINICAL RELEVANCE: On the basis of pharmacokinetic values, minimum inhibitory concentrations of Rhodococcus equi isolates, and drug concentrations in PELF and bronchoalveolar cells, a single daily oral dose of 10 mg/kg may be appropriate for treatment of R. equi infections in foals.
  • Persistence of high azithromycin concentrations in PELF and bronchoalveolar cells 48 hours after discontinuation of administration suggests that after 5 daily doses, oral administration at 48-hour intervals may be adequate.
  • [MeSH-major] Anti-Bacterial Agents / pharmacokinetics. Azithromycin / pharmacokinetics. Horses / metabolism. Pulmonary Alveoli / metabolism
  • [MeSH-minor] Administration, Oral. Animals. Area Under Curve. Biological Availability. Body Fluids / metabolism. Cross-Over Studies. Female. Half-Life. Injections, Intravenous / veterinary. Male. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZITHROMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11763173.001).
  • [ISSN] 0002-9645
  • [Journal-full-title] American journal of veterinary research
  • [ISO-abbreviation] Am. J. Vet. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 83905-01-5 / Azithromycin
  •  go-up   go-down


88. Xu Y, Wang J, Bao Y, Jiang W, Zuo L, Song D, Hong B, Si S: Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model. Anal Biochem; 2010 May 15;400(2):207-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The functions of CD36 are complex and have been associated with atherosclerosis.
  • In the current study, we developed a high-throughput screening (HTS) assay to identify small molecule antagonists by expressing human CD36 using a Bac-to-Bac baculovirus expression system in Spodoptera frugiperda (Sf9) cells.
  • Furthermore, these two compounds inhibited lipid accumulation in RAW 264.7 murine macrophage cells in foam cell assays.
  • This HTS assay represents a potential method for identifying more effective macrophage scavenger receptor antagonists, which may serve as starting points for the development of novel anti-atherosclerotic agents.
  • [MeSH-minor] Animals. Baculoviridae. CHO Cells. Cricetinae. Cricetulus. Gene Expression. Humans. Ligands. Lipoproteins, HDL / metabolism. Lipoproteins, LDL / metabolism. Mice. Models, Chemical. Recombinant Proteins / antagonists & inhibitors. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Spodoptera / genetics. Spodoptera / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20152792.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2016481B compound; 0 / 2038751B compound; 0 / Antigens, CD36; 0 / Indoles; 0 / Ligands; 0 / Lipoproteins, HDL; 0 / Lipoproteins, LDL; 0 / Recombinant Proteins; 0 / acetyl-LDL; 0 / oxidized low density lipoprotein; 0I8Y3P32UF / Berberine
  •  go-up   go-down


89. National Toxicology Program: NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies). Natl Toxicol Program Tech Rep Ser; 2006 Apr;(521):4-232
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Structurally related compounds that bind to the AhR and exhibit biological actions similar to TCDD are commonly referred to as "dioxin-like compounds" (DLCs).
  • Since human exposure to DLCs always involves a complex mixture, the toxic equivalency factor (TEF) methodology has been developed as a mathematical tool to assess the health risk posed by complex mixtures of these compounds.
  • The TEF methodology is a relative potency scheme that ranks the dioxin-like activity of a compound relative to TCDD, which is the most potent congener.
  • This allows for the estimation of the potential dioxin-like activity of a mixture of chemicals based on a common mechanism of action involving an initial binding of DLCs to the AhR.
  • The toxic equivalency of DLCs was nominated for evaluation because of the widespread human exposure to DLCs and the lack of data on the adequacy of the TEF methodology for predicting relative potency for cancer risk.
  • The main sources of TCDD releases into the environment are from combustion and incineration; metal smelting, refining, and processing; chemical manufacturing and processing; biological and photochemical processes; and existing reservoir sources that reflect past releases.
  • TCDD (dioxin) was selected for study by the National Toxicology Program as a part of the dioxin TEF evaluation to assess the cancer risk posed by complex mixtures of polychlorinated dibenzodioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), and PCBs.
  • HEPATIC CELL PROLIFERATION DATA: To evaluate hepatocyte replication, analysis of labeling of replicating hepatocytes with 5-bromo-2'-deoxyuridine was conducted at the 14-, 31-, and 53-week interim evaluations.
  • DETERMINATIONS OF TCDD CONCENTRATIONS IN TISSUES: The tissue disposition of TCDD was analyzed in the liver, lung, fat, and blood of all animals in each group at the 14-, 31-, and 53-week interim evaluations and in 10 animals per group at the end of the 2-year study (105 weeks).
  • At 2 years, there was a significant increase in toxic hepatopathy characterized by increased incidences of numerous nonneoplastic liver lesions including hepatocyte hypertrophy, multinucleated hepatocytes, altered hepatocellular foci, inflammation, pigmentation, diffuse fatty change, necrosis, portal fibrosis, oval cell hyperplasia, bile duct hyperplasia, bile duct cysts, cholangiofibrosis, and nodular hyperplasia At 2 years, the incidence of hepatocellular adenoma was significantly increased in the 100 ng/kg core study group.
  • The highest incidence of cholangiocarcinoma was seen in the 100 ng/kg core study group and included a significant number of animals with multiple cholangiocarcinomas.
  • In the lung, the incidence of cystic keratinizing epithelioma of the lung was significantly increased at 2 years in the 100 ng/kg core study group.
  • Nonneoplastic effects in the lung included increased incidences of bronchiolar metaplasia.
  • The incidence of gingival squamous cell carcinoma of the oral mucosa was significantly increased in the 100 ng/kg core study group at 2 years and was accompanied by an increased incidence of gingival squamous hyperplasia.
  • At 2 years, the incidence of squamous cell carcinoma of the uterus in the 46 ng/kg group was significantly increased, and there were two squamous cell carcinomas in the 100 ng/kg stop-exposure group.
  • At 2 years, one acinar adenoma and two acinar cell carcinomas of the pancreas were seen in the 100 ng/kg core study group; one acinar carcinoma was seen in the 100 ng/kg stop-exposure group.
  • The incidences of acinar cell adenoma or carcinoma (combined) exceeded the historical vehicle control range.
  • Nonneoplastic effects in the lung included acinar cytoplasmic vacuolization, chronic active inflammation, acinar atrophy, and arterial chronic active inflammation. (ABSTRACT TRUNCATED)
  • [MeSH-minor] Animals. Body Weight / drug effects. Carcinogenicity Tests. Female. Mice. Neoplasms, Experimental / chemically induced. Organ Size / drug effects. Rats. Rats, Sprague-Dawley

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835633.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


90. Marx AH, Zielinski M, Kowitz CM, Dancau AM, Thieltges S, Simon R, Choschzick M, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Brümmendorf TH, Fiedler W, Bokemeyer C, Izbicki JR, Sauter G: Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. Histopathology; 2010 Sep;57(3):418-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.
  • AIMS: The epidermal growth factor receptor (EGFR) is a tyrosine kinase (TK) involved in the tumour progression of many cancer types and may serve as an important therapeutic target (erlotinib, cetuximab).
  • The aim of this study was performed to determine the potential impact of tumour heterogeneity on anti-EGFR therapy in Barrett's adenocarcinoma (BAC).
  • METHODS AND RESULTS: Tissue microarray (TMA) sections of 112 BAC and 45 lymph node metastases were analysed for EGFR amplification and expression using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).
  • EGFR amplification was seen in seven (6.25%) of 112 interpretable BAC and typically high-level with more than 10-20 EGFR copies per tumour cell (EGFR/centromere 7 ratio >3).
  • Moreover, FISH analysis of three to 16 large sections from all amplified BAC and corresponding lymph node metastases did not reveal any heterogeneity of EGFR amplification.
  • CONCLUSION: The high level and homogeneity of EGFR amplification in primary tumours and metastases suggests the potential therapeutic utility of anti-EGFR drugs in BAC.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Gene Amplification. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 20840671.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


91. Mutalithas K, Guillen C, Day C, Brightling CE, Pavord ID, Wardlaw AJ: CRTH2 expression on T cells in asthma. Clin Exp Immunol; 2010 Jul 01;161(1):34-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mast cell-derived prostaglandin D2 (PGD2) is the major prostanoid found within the airway of asthmatics immediately following allergen challenge.
  • PGD2 has been shown to have chemokinetic effects on eosinophils and T helper type 2 (Th2) cells in vitro.
  • Using flow cytometry we have studied the expression of CRTH2 on T cells in blood and bronchoalveolar lavage fluid in asthmatics and normal subjects.
  • There was a small population of CRTH2+ T cells in the bronchoalveolar lavage (BAL) of asthmatics (2.3%+/-0.6) and normal subjects (0.3%+/-0.1), and there was a significant difference between the two groups (P<0.05).
  • CRTH2 antagonism may not diminish T cell accumulation in the asthmatic lung.
  • [MeSH-major] Asthma / metabolism. Bronchoalveolar Lavage Fluid / cytology. Receptors, Immunologic / metabolism. Receptors, Prostaglandin / metabolism. T-Lymphocyte Subsets / metabolism. Th2 Cells / metabolism
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Anti-Asthmatic Agents / therapeutic use. Bronchoscopy. Female. Humans. Interleukin-13 / analysis. Interleukin-4 / analysis. Lymphocyte Count. Male. Middle Aged. Prostaglandin D2 / biosynthesis. Young Adult

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2000 Oct;30(10):2972-9 [11069080.001]
  • [Cites] Br J Pharmacol. 2008 Mar;153 Suppl 1:S191-9 [17965752.001]
  • [Cites] Br Med Bull. 2000;56(4):956-68 [11359631.001]
  • [Cites] J Allergy Clin Immunol. 2001 Dec;108(6):982-8 [11742277.001]
  • [Cites] J Allergy Clin Immunol. 2002 Dec;110(6):899-905 [12464957.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Apr;305(1):347-52 [12649388.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):169-77 [12895600.001]
  • [Cites] Hum Mol Genet. 2004 Nov 1;13(21):2691-7 [15345705.001]
  • [Cites] J Immunol. 1982 Oct;129(4):1627-31 [6809826.001]
  • [Cites] Chest. 1996 Feb;109(2):338-42 [8620702.001]
  • [Cites] J Immunol. 1999 Feb 1;162(3):1278-86 [9973380.001]
  • [Cites] FEBS Lett. 1999 Oct 8;459(2):195-9 [10518017.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Mar;312(3):954-60 [15528449.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3703-8 [15749909.001]
  • [Cites] Eur J Immunol. 2005 May;35(5):1491-500 [15816013.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2056-60 [16081770.001]
  • [Cites] J Allergy Clin Immunol. 2005 Sep;116(3):594-600 [16159629.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6531-6 [16272307.001]
  • [Cites] Immunology. 2006 Nov;119(3):362-8 [17067313.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):313-25 [17396136.001]
  • [Cites] J Exp Med. 2001 Jan 15;193(2):255-61 [11208866.001]
  • (PMID = 20491797.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 082265; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Asthmatic Agents; 0 / IL4 protein, human; 0 / Interleukin-13; 0 / Receptors, Immunologic; 0 / Receptors, Prostaglandin; 0 / prostaglandin D2 receptor; 207137-56-2 / Interleukin-4; RXY07S6CZ2 / Prostaglandin D2
  • [Other-IDs] NLM/ PMC2901512
  •  go-up   go-down


92. Juárez P, Walters ST, Daugherty M, Radi C: A randomized trial of motivational interviewing and feedback with heavy drinking college students. J Drug Educ; 2006;36(3):233-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At an eight-week follow-up, all groups reduced their consumption, peak BAC, consequences, and dependence symptoms.

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - College Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17345916.001).
  • [ISSN] 0047-2379
  • [Journal-full-title] Journal of drug education
  • [ISO-abbreviation] J Drug Educ
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / T32-AA07465
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


93. Yamaguchi Y, Miyagi Y, Baba H: Two-dimensional electrophoresis with cationic detergents: a powerful tool for the proteomic analysis of myelin proteins. Part 2: analytical aspects. J Neurosci Res; 2008 Mar;86(4):766-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-dimensional electrophoresis with cationic detergents: a powerful tool for the proteomic analysis of myelin proteins. Part 2: analytical aspects.
  • The ability to analyze proteins in developing and damaged myelin will be crucial to improve our understanding of the mechanisms of myelinogenesis, dysmyelination, and demyelination.
  • Comparative two-dimensional electrophoresis (2-DE) is a powerful approach to analyze these proteins.
  • In part 1 of this study (see accompanying paper), a method for the 2-DE analysis of myelin proteins using the cationic detergents benzyldimethyl-n-hexadecylammonium chloride (16-BAC) and hexadecyltrimethylammonium bromide (cetyltrimethylammonium bromide;.
  • We obtained improved separation and found that 16-BAC is the most effective agent for separation in 2-DE of myelin proteins and that CTAB is the most effective agent for solubilization of myelin proteins.
  • Here in part 2, major myelin proteins as well as membrane proteins with multitransmembrane domains were identified by mass spectrometry after 16-BAC/SDS-PAGE and CTAB/SDS-PAGE.
  • In addition, a high-molecular-weight protein enriched in myelin fraction was identified as unconventional myosin ID using 16-BAC/SDS-PAGE, which had previously not been detected using immobilized pH gradient isoelectric focusing (IPG)/SDS-PAGE.
  • From these results, we concluded that combinational analysis using IPG/SDS-PAGE, 16-BAC/SDS-PAGE, and CTAB/SDS-PAGE provides a powerful technique facilitating the proteomic analysis of myelin proteins in either developmental or pathological changes.
  • [MeSH-major] Cations. Detergents. Electrophoresis, Gel, Two-Dimensional / methods. Mass Spectrometry. Myelin Proteins / chemistry. Proteomics / methods
  • [MeSH-minor] Animals. Blotting, Western. Brain Chemistry. Male. Myelin Sheath / chemistry. Rats. Rats, Wistar

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17960831.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cations; 0 / Detergents; 0 / Myelin Proteins
  •  go-up   go-down


94. Hsiao EC, Yoshinaga Y, Nguyen TD, Musone SL, Kim JE, Swinton P, Espineda I, Manalac C, deJong PJ, Conklin BR: Marking embryonic stem cells with a 2A self-cleaving peptide: a NKX2-5 emerald GFP BAC reporter. PLoS One; 2008 Jul 02;3(7):e2532
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marking embryonic stem cells with a 2A self-cleaving peptide: a NKX2-5 emerald GFP BAC reporter.
  • BACKGROUND: Fluorescent reporters are useful for assaying gene expression in living cells and for identifying and isolating pure cell populations from heterogeneous cultures, including embryonic stem (ES) cells.
  • METHODOLOGY: Here, we describe a series of modular marker plasmids containing independent reporter, bacterial selection, and eukaryotic selection components, compatible with both Gateway recombination and lambda prophage bacterial artificial chromosome (BAC) recombineering techniques.
  • We use an emerald GFP marker cassette to create a human BAC reporter and ES cell reporter line for the early cardiac marker NKX2-5.
  • NKX2-5 expression was detected in differentiating mouse ES cells and ES cell-derived mice.
  • CONCLUSIONS: Our results describe a NKX2-5 ES cell reporter line for studying early events in cardiomyocyte formation.
  • The results also demonstrate that our modular marker plasmids could be used for generating reporters from unmodified BACs, potentially as part of an ES cell reporter library.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1985 Sep;42(2):519-26 [2992802.001]
  • [Cites] Gene. 1977;2(2):95-113 [344137.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Oct 23;227(3):707-11 [8885998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):352-7 [9419379.001]
  • [Cites] Annu Rev Biochem. 1998;67:509-44 [9759496.001]
  • [Cites] Development. 1999 Jan;126(1):75-84 [9834187.001]
  • [Cites] J Biol Chem. 1998 Dec 25;273(52):34970-5 [9857028.001]
  • [Cites] Dev Genes Evol. 1999 Jan;209(1):63-8 [9914420.001]
  • [Cites] Nat Biotechnol. 2004 Dec;22(12):1567-72 [15558047.001]
  • [Cites] Nat Biotechnol. 2005 May;23(5):584-90 [15834403.001]
  • [Cites] Nat Methods. 2005 Dec;2(12):905-9 [16299475.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1137-50 [17123591.001]
  • [Cites] Stem Cells. 2007 Jan;25(1):39-45 [16990587.001]
  • [Cites] Nat Biotechnol. 2007 Jan;25(1):91-9 [17187059.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):4777-8 [17360323.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10894-9 [17576928.001]
  • [Cites] Stem Cells. 2007 Jul;25(7):1707-12 [17395772.001]
  • [Cites] Cell. 2007 Jul 13;130(1):77-88 [17632057.001]
  • [Cites] Mol Ther. 2007 Sep;15(9):1630-9 [17609656.001]
  • [Cites] Stem Cells Dev. 2007 Aug;16(4):537-45 [17784828.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Methods Enzymol. 2000;328:592-615 [11075368.001]
  • [Cites] J Gen Virol. 2001 May;82(Pt 5):1013-25 [11297676.001]
  • [Cites] Genomics. 2001 Apr 1;73(1):56-65 [11352566.001]
  • [Cites] Curr Biol. 2001 Apr 3;11(7):514-8 [11413002.001]
  • [Cites] J Med Chem. 2001 Nov 22;44(24):4125-36 [11708915.001]
  • [Cites] Methods Mol Biol. 2002;185:127-56 [11768985.001]
  • [Cites] J Neurosci. 2002 Mar 1;22(5):1600-7 [11880490.001]
  • [Cites] Stem Cells. 2002;20(2):139-45 [11897870.001]
  • [Cites] Circ Res. 2002 Aug 9;91(3):189-201 [12169644.001]
  • [Cites] Res Microbiol. 2002 Jul-Aug;153(6):379-83 [12234013.001]
  • [Cites] Eukaryot Cell. 2002 Jun;1(3):401-13 [12455988.001]
  • [Cites] Genome Res. 2002 Dec;12(12):1992-8 [12466304.001]
  • [Cites] Genome Res. 2003 Mar;13(3):476-84 [12618378.001]
  • [Cites] Genesis. 2003 Apr;35(4):220-6 [12717733.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):917-25 [14586460.001]
  • [Cites] Nat Biotechnol. 2004 May;22(5):589-94 [15064769.001]
  • [Cites] Circ Res. 2004 Aug 20;95(4):389-97 [15242968.001]
  • [Cites] BMC Biotechnol. 2004 Jul 27;4:16 [15279677.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2919-28 [8474450.001]
  • (PMID = 18596956.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL66621; United States / NIDDK NIH HHS / DK / T32 DK007418; United States / NHLBI NIH HHS / HL / U01 HL066621; United States / NCRR NIH HHS / RR / RR18928-01; United States / NIAMS NIH HHS / AR / K08 AR056299; United States / NIDDK NIH HHS / DK / 2T32DK07418-26; United States / NHLBI NIH HHS / HL / R01 HL060664; United States / NHLBI NIH HHS / HL / HL60664; United States / NCRR NIH HHS / RR / C06 RR018928
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Homeodomain Proteins; 0 / NKX2-5 protein, human; 0 / Transcription Factors; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ PMC2430532
  •  go-up   go-down


95. Udiković Kolić N, Martin-Laurent F, Devers M, Petrić I, Begonja Kolar A, Hrsak D: Genetic potential, diversity and activity of an atrazine-degrading community enriched from a herbicide factory effluent. J Appl Microbiol; 2008 Nov;105(5):1334-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To characterize an atrazine-degrading bacterial community enriched from the wastewater of a herbicide factory.
  • Restriction analysis of amplified 16S rDNA revealed high diversity of bacterial populations forming the community, with Pseudomonas species dominating in the clone library.
  • CONCLUSIONS: The enriched community represents a complex bacterial association expressing substantial atrazine-mineralizing activity and a broad specificity towards a range of s-triazine compounds.
  • SIGNIFICANCE AND IMPACT OF THE STUDY: Our study is beginning to yield insights into the richness, genetic potential and density of functional atrazine-mineralizing community that could be a potential bioaugmentation agent for improving biotransformation processes in wastewaters bearing different s-triazine compounds.
  • [MeSH-minor] DNA, Bacterial / genetics. DNA, Bacterial / metabolism. Plasmids. Polymerase Chain Reaction. Pseudomonas / genetics. Pseudomonas / metabolism. RNA, Ribosomal, 16S / genetics. Triazines / metabolism

  • Hazardous Substances Data Bank. ATRAZINE .
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19146484.001).
  • [ISSN] 1365-2672
  • [Journal-full-title] Journal of applied microbiology
  • [ISO-abbreviation] J. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / Herbicides; 0 / Industrial Waste; 0 / RNA, Ribosomal, 16S; 0 / Triazines; QJA9M5H4IM / Atrazine
  •  go-up   go-down


96. Kilburn BA, Chiang PJ, Wang J, Flentke GR, Smith SM, Armant DR: Rapid induction of apoptosis in gastrulating mouse embryos by ethanol and its prevention by HB-EGF. Alcohol Clin Exp Res; 2006 Jan;30(1):127-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ethanol exposure during gastrulation and early neurulation induces apoptosis within certain embryonic cell populations, leading to craniofacial and neurological defects.
  • Ethanol alters intracellular signaling, leading to cell death in chick embryos, suggesting that apoptosis could occur rapidly and that signaling pathways activated by survival factors might reduce apoptosis.
  • Control animals received maltose/dextran.
  • Blood alcohol concentrations (BAC) were determined by gas chromatography.
  • Apoptosis was quantified using fluorescence microscopy to detect annexin V binding and DNA fragmentation [terminal deoxynucleotidyl transferase-mediated dUTP-X nick end labeling (TUNEL)] in whole-mount or sectioned embryos.
  • Apoptosis increased (p < 0.05) in all germ cell layers.
  • Mice treated with 4 g/kg sustained BAC of 400 mg% for nearly 3 hours, significantly increasing apoptosis within the first hour.

  • MedlinePlus Health Information. consumer health - Fetal Alcohol Spectrum Disorders.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Alcohol Clin Exp Res. 1995 Dec;19(6):1454-62 [8749810.001]
  • [Cites] Alcohol Clin Exp Res. 1995 Apr;19(2):378-86 [7625573.001]
  • [Cites] Neurotoxicol Teratol. 1997 Mar-Apr;19(2):141-6 [9136130.001]
  • [Cites] Alcohol. 1996 Nov-Dec;13(6):589-95 [8949954.001]
  • [Cites] Dev Genet. 1997;21(1):102-8 [9291586.001]
  • [Cites] Alcohol Clin Exp Res. 1997 Sep;21(6):1108-20 [9309325.001]
  • [Cites] Bioessays. 1998 Jan;20(1):41-8 [9504046.001]
  • [Cites] Dev Neurosci. 1999;21(1):68-75 [10077704.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jun;31(6):637-43 [10404636.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3355-63 [10487711.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):913-9 [15562026.001]
  • [Cites] Alcohol Health Res World. 1997;21(4):287-97 [15706739.001]
  • [Cites] Alcohol Clin Exp Res. 2005 Jul;29(7):1237-46 [16046880.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):884-8 [10622253.001]
  • [Cites] Science. 2000 Feb 11;287(5455):1056-60 [10669420.001]
  • [Cites] Brain Res Dev Brain Res. 2000 Feb 7;119(2):209-16 [10675770.001]
  • [Cites] Alcohol Clin Exp Res. 2000 Mar;24(3):307-14 [10776667.001]
  • [Cites] Alcohol Clin Exp Res. 2000 May;24(5):716-26 [10832914.001]
  • [Cites] Semin Neonatol. 2000 Aug;5(3):243-54 [10956449.001]
  • [Cites] Life Sci. 2001 Jan 26;68(10):1095-105 [11228094.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1931-9 [11296226.001]
  • [Cites] J Pharmacol Exp Ther. 2001 May;297(2):774-9 [11303069.001]
  • [Cites] FASEB J. 2001 Jul;15(9):1649-51 [11427515.001]
  • [Cites] Alcohol Clin Exp Res. 2001 Oct;25(10):1523-35 [11696674.001]
  • [Cites] Methods Mol Biol. 2002;203:69-77 [12073455.001]
  • [Cites] Brain Res Dev Brain Res. 2003 Jan 10;140(1):15-28 [12524173.001]
  • [Cites] Alcohol Clin Exp Res. 2003 Mar;27(3):515-23 [12658119.001]
  • [Cites] Cell Death Differ. 2003 May;10(5):508-15 [12728249.001]
  • [Cites] Cell Biochem Biophys. 2003;39(1):13-22 [12835526.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8543-8 [12808140.001]
  • [Cites] Antioxid Redox Signal. 2003 Dec;5(6):741-9 [14588147.001]
  • [Cites] J Neurosci Res. 2003 Nov 15;74(4):577-88 [14598302.001]
  • [Cites] Semin Pediatr Surg. 2004 Feb;13(1):2-10 [14765365.001]
  • [Cites] Lancet. 1973 Nov 3;302(7836):999-1001 [4127281.001]
  • [Cites] N Engl J Med. 1978 May 11;298(19):1063-7 [347295.001]
  • [Cites] Science. 1981 Nov 20;214(4523):936-8 [6795717.001]
  • [Cites] J Pediatr. 1982 Aug;101(2):232-4 [7097418.001]
  • [Cites] J Pediatr. 1982 Nov;101(5):819-24 [7131170.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jan;156(1):33-9 [3799767.001]
  • [Cites] Int J Dev Neurosci. 1992 Aug;10(4):273-9 [1414440.001]
  • [Cites] Am J Med Genet. 1992 Sep 15;44(2):168-76 [1456286.001]
  • [Cites] Teratology. 1993 Jan;47(1):57-64 [8475458.001]
  • [Cites] Alcohol Clin Exp Res. 1993 Apr;17(2):359-65 [8488980.001]
  • [Cites] Development. 1993 Aug;118(4):1255-66 [8269852.001]
  • [Cites] Development. 1994 May;120(5):1071-83 [8026321.001]
  • [Cites] Alcohol. 1994 Sep-Oct;11(5):385-7 [7818796.001]
  • [Cites] J Pharmacol Toxicol Methods. 1997 Jun;37(4):215-28 [9279777.001]
  • (PMID = 16433740.001).
  • [ISSN] 0145-6008
  • [Journal-full-title] Alcoholism, clinical and experimental research
  • [ISO-abbreviation] Alcohol. Clin. Exp. Res.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA011085; United States / NIAAA NIH HHS / AA / AA12057; United States / NIAAA NIH HHS / AA / R01 AA012057; United States / NIAAA NIH HHS / AA / AA11085; United States / NIAAA NIH HHS / AA / R29 AA011085; United States / NIAAA NIH HHS / AA / R37 AA011085; United States / NIEHS NIH HHS / ES / P30 ES009090; United States / NIEHS NIH HHS / ES / ES09090
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HBEGF protein, human; 0 / Hbegf protein, mouse; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Receptors, Peptide; 0 / annexin V receptor; 3K9958V90M / Ethanol; 62229-50-9 / Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS13845; NLM/ PMC1679959
  •  go-up   go-down


97. Lin J, Zhang W, Xie B, Li L, Zhang L, Zheng J, Wang X: [Clinical investigation of IRESSA in the treatment of patients with advanced refractory non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi; 2006 Oct 20;9(5):455-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical investigation of IRESSA in the treatment of patients with advanced refractory non-small cell lung cancer].
  • BACKGROUND: Chemotherapy is a main method for patients with advanced non-small cell lung cancer (NSCLC).
  • NSCLC is usually a drug-resistant neoplasm.
  • Innate or acquired drug-resis-tance contributes to the chief cause for bad effect in the treatment of patients with NSCLC.
  • To search for a new anti-cancer drug becomes a goal of clinical oncologists.
  • RESULTS: Totally 33 patients enrolled in this study and all were stage IV.
  • The disease-control rate was 65.6% (21/32).
  • The curative effect was correlated with the pathological type, in sequence of alveolar cell carcinoma, adenocarcinoma and squamous cell carcinoma.
  • No electrocardiogram abnormality was found.
  • CONCLUSIONS: IRESSA takes better effect on the advanced drug-resistant patients with NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176471.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


98. Owczarek-Lipska M, Denis C, Eggen A, Leeb T, Posthaus H, Dolf G, Braunschweig MH: The bovine dilated cardiomyopathy locus maps to a 1.0-Mb interval on chromosome 18. Mamm Genome; 2009 Mar;20(3):187-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In human medicine, cardiomyopathies frequently warrant heart transplantation in children and adults.
  • Bovine dilated cardiomyopathy (BDCMP) is a heart muscle disorder that has been observed during the last 30 years in cattle of Holstein-Friesian origin.
  • The common symptoms in affected animals are subacute subcutaneous edema, congestion of the jugular veins, and tachycardia with gallop rhythm.
  • Recently, the disease locus was mapped to a 6.7-Mb interval MSBDCMP06-BMS2785 on bovine Chr 18 (BTA18).
  • A BAC contig of 2.9 Mb encompassing the crucial interval was constructed to establish the correct marker order on BTA18.
  • We show that the disease locus is located in a gene-rich interval of 1.0 Mb and is flanked by the microsatellite markers DIK3006 and MSBDCMP51.
  • [MeSH-minor] Animals. Cattle. Female. Genotype. Male. Microsatellite Repeats

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuromuscul Disord. 2005 May;15(5):372-6 [15833432.001]
  • [Cites] Zentralbl Veterinarmed A. 1993 Nov-Dec;40(9-10):690-6 [8135075.001]
  • [Cites] Schweiz Arch Tierheilkd. 1985 Aug;127(8):479-503 [4048922.001]
  • [Cites] J Vet Med A Physiol Pathol Clin Med. 2004 Sep-Oct;51(7-8):332-5 [15533113.001]
  • [Cites] Tierarztl Prax. 1992 Jun;20(3):254-8 [1386692.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2471-81 [12933343.001]
  • [Cites] Dtsch Tierarztl Wochenschr. 1985 Oct 8;92(10):363-6 [3908053.001]
  • [Cites] Schweiz Arch Tierheilkd. 1982 Feb;124(2):69-82 [7089512.001]
  • [Cites] Circulation. 1996 Mar 1;93(5):841-2 [8598070.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Genet Sel Evol. 2001 Sep-Oct;33(5):543-8 [11712974.001]
  • [Cites] Anim Genet. 2007 Jun;38(3):265-9 [17433012.001]
  • [Cites] Aust Vet J. 1990 Feb;67(2):75-6 [2344340.001]
  • [Cites] Schweiz Arch Tierheilkd. 1990;132(3):105-16 [2343288.001]
  • [Cites] J Anim Sci. 1998 Jul;76(7):1824-9 [9690637.001]
  • [Cites] J Comp Pathol. 1991 Jan;104(1):101-12 [2019669.001]
  • (PMID = 19219501.001).
  • [ISSN] 1432-1777
  • [Journal-full-title] Mammalian genome : official journal of the International Mammalian Genome Society
  • [ISO-abbreviation] Mamm. Genome
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Harder SD, Soukup JM, Ghio AJ, Devlin RB, Becker S: Inhalation of PM2.5 does not modulate host defense or immune parameters in blood or lung of normal human subjects. Environ Health Perspect; 2001 Aug;109 Suppl 4:599-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhalation of PM2.5 does not modulate host defense or immune parameters in blood or lung of normal human subjects.
  • We tested the hypothesis that exposure of healthy volunteers to concentrated ambient air particles (CAPS) between 0.1 and 2.5 microm in diameter is associated with modulation of human alveolar macrophage (AM) function, cytokine production, and immune phenotype in both blood and lung.
  • Eighteen hours after exposure, analysis of cells obtained by bronchoalveolar lavage (BAL) showed a mild increase in neutrophils in both the bronchial (8.4 +/- 2%) and alveolar fractions (4.2 +/- 1.7%) in subjects exposed to the highest concentration of CAPS compared to neutrophils in the fluids of those exposed to filtered air (bronchial fraction 2.7 +/- 0.6%; alveolar fraction 0.8 +/- 0.3%).
  • [MeSH-major] Air Pollutants / pharmacology. Lung / immunology. Macrophages, Alveolar / drug effects. Neutrophils / immunology
  • [MeSH-minor] Administration, Inhalation. Adolescent. Adult. Aerosols / pharmacology. Bronchoalveolar Lavage Fluid / cytology. Bronchoalveolar Lavage Fluid / immunology. Cytokines / biosynthesis. Female. Humans. Lymphocyte Subsets / drug effects. Lymphocyte Subsets / immunology. Male. Particle Size. Reference Values

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 2000 Jan;11(1):6-10 [10615836.001]
  • [Cites] Ann Allergy Asthma Immunol. 1999 Dec;83(6 Pt 2):624-9 [10619333.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Feb 15;171(1):20-6 [11181108.001]
  • [Cites] Can J Public Health. 1983 Mar-Apr;74(2):117-22 [6850488.001]
  • [Cites] Am Rev Respir Dis. 1989 Mar;139(3):587-94 [2923355.001]
  • [Cites] Am J Public Health. 1989 May;79(5):623-8 [2495741.001]
  • [Cites] Environ Health Perspect. 1998 Mar;106(3):127-32 [9441960.001]
  • [Cites] J Allergy Clin Immunol. 1995 Jan;95(1 Pt 1):103-15 [7529782.001]
  • [Cites] J Air Waste Manag Assoc. 1996 Oct;46(10):927-39 [8875828.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Mar;155(3):1021-6 [9116981.001]
  • [Cites] J Toxicol Environ Health A. 1998 Dec 11;55(7):455-77 [9860321.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Mar;159(3):702-9 [10051240.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Mar 15;155(3):245-52 [10079210.001]
  • [Cites] Am J Respir Cell Mol Biol. 1991 Jan;4(1):72-81 [1846079.001]
  • (PMID = 11544170.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Air Pollutants; 0 / Cytokines
  • [Other-IDs] NLM/ PMC1240588
  •  go-up   go-down


100. Hubicka B, Källmén H, Hiltunen A, Bergman H: Personality traits and mental health of severe drunk drivers in Sweden. Soc Psychiatry Psychiatr Epidemiol; 2010 Jul;45(7):723-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More specifically the aim was to investigate the personality traits as assessed by The NEO personality inventory (NEO-PI-R) and aspects of mental health as assessed by the symptom checklist (SCL-90) as compared to the general population.
  • The subjects were 162 severe DUI offenders (with the BAC >0.099%) with an age range of 18-88 years, 143 males and 19 females.
  • The differences between the DUI group and the general population on the on SCL-90 scales were all significant except on the Hostility scale.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Alcoholism / diagnosis. Alcoholism / psychology. Checklist. Comorbidity. Ethanol / blood. Female. Humans. Male. Middle Aged. Severity of Illness Index. Sex Factors. Sweden / epidemiology